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A-134974   (N7-[(1´R,2´S,3´R,4´S)-2´,3´-dihydroxy-4´-aminocyclopentyl]-amino-5-
iodopyrrolopyrimidine)  
ABT-702   4-amino-5-(3-bromophenyl)-7-(6-morpholino-pyridin-3-yl)pyrido[2,3-d] 
pyrimidine) 
ACV   acyclovir 
ACVMP   acyclovir monophosphate 
ADA   adenosine deaminase 
ADME   Absorption, distribution, metabolism, excretion 
Ado, ADO   adenosine 
ADP   adenosine-5’-diphosphate 
AK   adenosine kinase 
AMP   adenosine-5’-monophosphate 
Ap4A   diadenosinetetraphosphate 
ARL67156   N6-Diethyl-β,γ-dibromomethylene-ATP 
AR(s) 
ATP   
adenosine receptor(s) 
adenosine-5’-triphosphate 
AU   absorption units 
AUC   area under the curve 
AZT   azidothymidine 
BVDU   (E-5-(2-bromovinyl))-2'-deoxyuridine 
cAMP   cyclic adenosine-3’,5’-monophosphate 
CE   capillary electrophoresis 
CHO   Chinese hamster ovary 
CITP   transient capillary isotachophoresis 
CMC   critical micelle concentration 
CZE    capillary zone electrophoresis 
DAD   diode array detector 
Dulbecco’s modified eagle’s medium DMEM 
DMSO dimethylsulfoxide 
DNA deoxyribonucleic acid 
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EMMA electrophoretically mediated microanalysis 
E-NTPDase   ecto-nucleoside 5‘-triphosphate diphosphohydrolase 
EOF electroosmotic flow 
FC fused silica capillary  
GCV   ganciclovir 
GMP guanosine-5’-monophosphate 
Hepes N-[2-hydroxyethyl]piperazine-N’-2-ethansulfonic acid 
HPLC high performance liquid chromatography 
HSV 1   herpes simplex virus type 1 
I.D.   internal diameter 
I.S.   internal standard 
kD kilodalton 
KM Michaelis-Menten constant 
LIF laser-induced fluorescence 
LOD limit of detection 
LOQ   limit of quantification 
MECC   micellar electrokinetic capillary chromatography 
(m, µ, n) M; µm   (milli-, micro-, nano-) molar; micro meter 
NC neutral capillary 
NG108-15 neuroblastoma x gliomahybrid cell line 
5’-NT 5’-nucleotidase 
NTPDase nucleoside triphosphate diphosphohydrolase 
O.D.   outer diameter 
p.s.i   pound per square inch; 1 p.s.i. = 0,069 bar = 6,895 kPa 
PC personal computer 
PCV penciclovir 
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Pi 
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RB2 
RSD 
Reactive blue 2 
relative standard deviation (%) 
SAR structure-activity relationship 
SD standard deviation 
SDS sodium dodecyl sulphate  
SDS-PAGE   SDS-polyacrylamide gel electrophoresis 
TEMED tetramethylethylenediamine 
TK 1   cytosolic thymidine kinase 
TK 2   mitochondrial thymidine kinase 
TK thymidine kinase 
TMP thymidine -5’-monophosphate 
Tris tris(hydroxymethyl)aminomethane 
UDP uridine-5’-diphosphate 
UMP uridine-5’-monophosphate 
UTP uridine-5’-triphosphate 
UV ultraviolet 
5-IT  5'-iodotubercidin 
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Summary 
 
Aim of study 
The aim of the present work was to develop and optimise capillary electrophoresis-based 
methods for the assaying of nucleoside and nucleotide metabolizing enzymes. 
 
More specifically the aim included: 
 
¾ Developing and optimizing a micellar electrokinetic capillary chromatographic 
method for the separation of nucleotides and nucleosides. 
¾ Developing, optimizing and validating a capillary zone electrophoresis method 
for the separation of nucleotides and their enzymatic degradation products and 
application of the method to study nucleotide metabolism. 
¾ Developing and validating an electrophoretically mediated microanalysis with 
partial-filling technique for the in-line monitoring of adenosine kinase 
reactions. 
¾ Developing, optimizing and validating at-capillary-inlet enzymatic 
microreaction methods for the characterization of ecto-nucleoside triphosphate 
diphosphohydrolases and automation of the analytical process. 
¾ Developing and validating an at-capillary-inlet reaction method to study the 
extracellular nucleotide metabolism of living cells. 
 
Analysis of nucleotides and nucleosides by micellar electrokinetic capillary 
chromatography  
A method for the analysis of nucleotides (AMP, ADP, ATP and UMP) and the nucleoside 
adenosine using capillary electrophoresis has been developed. A fused-silica capillary, 100 
mM SDS, 20 mM phosphate buffer, pH 7.4, was used, which produced reproducible 
separations of all nucleotides and the nucleoside within 17 min. Linear relationships between 
peak areas and sample concentrations, an average minimum detectable concentration in the 
range of 3 to 6 µM, and an average minimum detectable quantity in the range of 2 to 4 µM 
was obtained. The developed method allowed the qualitative and quantitative analysis of 
nucleotides and nucleosides in enzymatic reactions. 
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Adenosine kinase assay 
Adenosine kinase catalyzes the transfer of phosphate from nucleoside triphosphates to 
adenosine. The development of specific adenosine kinase inhibitors represents a promising 
strategy for the rational development of clinically useful drugs.  
In the present study, a fast and convenient capillary electrophoresis method was developed for 
the screening of adenosine kinase inhibitors and substrates. Efficient separation conditions 
were achieved using a 20 mM sodium phosphate buffer (pH 7.5 or pH 8.5)  and a constant 
current of 95 µA. Normal polarity mode was applied for the separations. The samples were 
injected by pressure and detected by their UV absorbance at 260 nm. The validity of the 
newly developed method was confirmed by the determination of Ki values of standard 
antagonists. Dose response curves and calculated Ki values were in excellent agreement with 
data obtained by the standard radioactive assay. 
Based on the off-line method, an in-line CE method was developed by a methodology known 
as electrophoretically mediated microanalysis (EMMA). A single plug of assay buffer 
containing adenosine kinase enzyme was injected by hydrodynamic injection into the 
capillary, followed by a pulg of assay buffer containing substrate with or without inhibitor. 
These two plugs were sandwiched by two assay buffer plugs. Then the reaction was started by 
the application of 5 kV separation voltage (negative polarity) for 0.20 min. After the reaction, 
a constant current of –60 µA with reverse polarity was applied to separate the reaction 
products. 
 By in-capillary reaction, the scale of the enzymatic reaction was radically reduced to the 
nano-scale (nL) as compared to off-line analysis of the reaction carried out in a 
microcentrifuge tube. Moreover, since the capillary is used as a reaction vessel, all the assay 
steps (mixing, reaction, separation, and quantitation) were combined in a fully automated 
nanoscale activity assay. The Ki values for standard antagonists obtained by EMMA were in 
good agreement with those obtained using the off-line CE assay. 
 
Thymidine kinase assay 
Thymidine kinase (TK) is a key enzyme in the salvage pathway of nucleotide metabolism 
catalyzing the transfer of the terminal phosphate group of ATP to the 5’-hydroxyl group of 
thymidine and thus yielding thymidine monophosphate. Herpes simplex virus type 1 
thymidine kinase exhibits an extensive substrate promiscuity, accepting a variety of different 
nucleobases and sugar moieties, in contrast to other TKs. This substrate diversity is the crucial 
molecular basis of selective antiviral therapy. HSV-1 thymidine kinase in not required for the 
Summary 
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efficient replication of viruses in dividing cells but may be important in reactivation of virus 
from the latent state. A strategy for the control of herpetic recurrences would be to interfere 
with the reactivation process by applying inhibitors of the virus-encoded TK. 
A simple and rapid capillary electrophoresis method was developed for the determination of 
substrates of HSV-1 TK. The method was optimized with two different types of capillaries, 
fused-silica and a neutral polyacrylamide-coated one. In case of the fused-silica capillary the 
separations were carried out using 20 mM sodium phosphate as a running buffer and samples 
were hydrodynamically injected. Due to sample adsorption and low sensitivity with the fused-
silica capillary, a method was developed using a polyacrylamide-coated capillary with 
electrokinetic injection. With this method, good separation was achieved using a short 
capillary of 20 cm effective length, and 50 mM phosphate as a running buffer, within less 
than 7 min.  
This CE method is also very useful for the investigation of novel potential inhibitors of HSV-
1 TK. Determination of Km and Kcat values by the new capillary electrophoresis method has 
multiple advantages such as no need for expensive radiolabeled substrates and a minimal use 
of reagents.  
 
Ectonucleotidase assay 
Nucleotides, such as ATP, ADP, UTP and UDP act as physiological agonists at so-called P2 
(nucleotide) membrane receptors. The nucleotides are quickly degraded by an arsenal of ecto-
enzymes to limit the nucleotides’ effects. Inhibitors of nucleotide degradation would act as 
site- and event-specific indirect P2 receptor agonists by increasing the concentration of the 
nucleotides. 
The ecto-nucleoside triphosphate diphosphohydrolases (EC 3.6.1.5) represent a major family 
of ecto-nucleotidases. They catalyze the sequential hydrolysis of the γ- and β-phosphate 
residues of nucleoside tri- and diphosphates, producing the corresponding nucleoside di- 
and/or monophosphate derivatives. 
 A CE method for the characterization of recombinant NTPDases and for assaying NTPDase 
inhibitors has been developed performing the enzymatic reaction within the capillary. After 
hydrodynamic injection of plugs of substrate solution with or without inhibitor, followed by a 
plug of enzyme, and subsequent injection of another plug of substrate solution with or without 
inhibitor, the reaction took place for 5 min at the capillary inlet. The method employing a 
polyacrylamide-coated capillary and reverse polarity mode provided baseline resolution of 
substrates and products within a short separation time of less than 7 min. A 50 mM phosphate 
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buffer (pH 6.5) was used for the separations and the products were detected by their UV 
absorbance at 210 nm.  The Michaelis-Menten constants (Km) for the recombinant rat 
NTPDases1-3 obtained with this method were consistent with previously reported data 
obtained by other methods. The new method was fast and accurate, it required only tiny 
amounts of material (nanoliter scale), no sample pretreatment and can be fully automated. 
With this newly developed in-capillary electrophoresis method we tested a series of suramin 
and reactive blue 2 analogs as potential inhibitors. Compound 5.2.10 was identified as a 
selective inhibitor of NTPDase3 with a Ki value of 1.5 µM, while being inactive at NTPDase1 
and 2. This compound is the first selective NTPDase3 inhibitor described to date and may be 
a useful pharmacological tool. 
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o react for different time intervals. Then, a constant current of –60 µA 
 was applied to separate the reaction products. Subsequently, after 
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electrophoretic separation, the concentrations of nucleoside tri-, di-, and monophosphates 
were determined. 
The method worked well. However, some problems related to the stability of the cells inside 
the capillary at longer incubation times of 30 minutes or more were observed. Also the rate of 
degradation of nucleotides was different in different batches of the cells. However, the 
method was successful to study the metabolism of nucleotides. The method can be further 
improved for high-throughput screening of inhibitors of nucleotide metabolism in living cells, 
on which a combination of degrading enzymes are active. 
 
Ester hydrolysis assay 
A CE-based micellar electrokinetic chromatography method was developed for the 
determination of the chemical and enzymatic stability of 5'-deoxy-5'-methylthioadenosine-
2',3'-diester a novel natural product isolated from ascidians, which exhibited affinity for A1 
and A3 adenosine receptors. A constant current (95 µA) was applied, and a sodium tetraborate 
buffer containing 100 mM SDS, pH 8.5 was used for the separations. The compound was 
stable by heating at 99 °C for 10 min and in the presence of rat brain cortex after incubation at 
37 °C for 90 min, while it showed slow hydrolysis by incubation with carboxylesterase. 
 
Purity determination of an A2B receptor antagonist 
A micellar electrokinetic chromatographic method was developed for determining the purity 
of a newly synthesized antagonist radioligand for A2B adenosine receptors [3H]PSB-298. A 
fused-silica capillary of 30 cm of effective length and a positive voltage of 10 kV in 150 mM 
Tris-HCl buffer containing 100 mM SDS, pH 9.1, was used for the separations. The CE 
method was validated with respect to linearity, limit of quantitation, limit of detection and 
accuracy. 
 
Conclusions 
The present work demonstrated that capillary electrophoresis could be used to study enzyme 
kinetics, and to search for inhibitors and substrates of the enzymes, specifically of nucleotide- 
and nucleoside-metabolizing enzymes. It requires short analysis times and only tiny amounts 
(nanoliter) of samples. Compared with HPLC and spectrophotometric methods, capillary 
electrophoresis is an alternative and simple method for the determination of nucleosides and 
nucleotides in complex biological samples. It has been proven that CE indeed could and 
should further be developed into a routine method for on-line monitoring of enzymatic 
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processes. Moreover, this nano-scale analysis technique can be used in the areas of inhibitor 
screening and drug development. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 1. Capillary electrophoresis  
 
Capillary electrophoresis (CE) was evolved from electrophoresis, a method for separating 
charged molecules. In CE, a sample is separated into its individual components as it migrates 
through a capillary (Figure 1.1.). Due to its sensitivity and versatility, CE has moved to the fore- 
 
 
 
Figure 1.1. Illustration of the electroosmotic flow in a capillary.  An open-ended capillary 
extends between two buffer reservoirs, across which a high voltage is applied. 
 
 
front of analytical methodology. Its applicability is enhanced by the development of facile and 
rapid methods, including the automation of processes, high resolution, short separation times, and 
a very small amount of analyte sample requirement 1.  
Electrophoresis is based on the migration of analytes within an electrolyte solution under the 
influence of an electric field. The propelling forces of the electric field and the retarding effects 
of the viscosity of the solution govern the movement of ions in solution. The mobility of an ion 
under the influence of an electric field can be summarized in the form: 
µe =  q/ 6πη  rv 
The values µe, q, r, v and η are electrophoretic mobility (µe), charge (q), radius (r), velocity (v) 
of ion and viscosity of solution (η), respectively. The electric field is given as a function of the 
applied voltage and the capillary length (in volts/cm). As seen from the equation the mobility of 
 1
an ion is dependent upon its size and charge; analytes with different charge-to-mass ratios move 
at different velocities under the same conditions2. In order to get a complete separation in CE, 
high separation efficiency is required. There are several parameters (Table 1.1) which are 
responsible for the separation efficiency, diffusion, adsorption at the capillary wall, the length of 
the injected plug, and, more important, electrodispersive effects due to the ionic strength within 
the sample zone and joule heating3. 
 
Table 1.1. Factors affecting separation efficiency (plate numbers, N) in CE and means to reduce 
their contribution 
 
Factor Means to decrease its contribution 
Diffusion  
 
Joule heating  
 
 
 
Electrophoretic dispersion 
Analyte-wall interactions  
 
Injection plug length 
Detection width 
increasing applied potential, increasing viscosity, decreasing 
temperature, increasing hydrodynamic size of the analyte 
active cooling, lowering the applied potential, increasing area- 
to-volume ratio of capillary, increasing viscosity of the 
background electrolyte, reducing the ionic strength of the 
solution 
lowering analyte/electrolyte concentration ratio 
optimizing the electrolyte pH or ionic strength, dynamic or 
permanent capillary coating 
decreasing the injection plug length  
decreasing detection width 
 
 
1.1. Electroosmotic flow  
 
Electroosmotic flow (EOF) is the most striking feature and a fundamental constituent of CE. 
Separation is usually performed in 10 to 100 cm long capillaries made from fused silica. The 
negatively charged silanol groups present in this material give rise to a surface negative charge or 
zeta (ζ) potential, which causes the flow of electrolyte from the anode (where the sample is 
applied) to the cathode (where the sample is analyzed). This flow of electrolyte through the 
capillary is called electroosmotic flow. EOF drives positively charged, neutral, and negatively 
charged analytes through the capillary to the detector. A second force, electrophoresis, which 
drives cations toward the cathode and anions toward the anode, enhances EOF for cations and 
opposes EOF for anions, resulting in their further separation (Figure 1.2.). The magnitude of EOF 
is highly dependent on the pH of the running buffer; below pH 4, the ionization is small and the 
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EOF flow rate is not significant, at this pH the capillary wall loses its charge. At pH ~9 the 
silanol groups on the inner wall of the silica capillary are ionized, giving the wall a negative  
 
                           
                           Cations               µobs (+)    =   µEOF + µe(+) 
                           Neutral species    µEOF        =  mobility of neutral species 
                           Anions                µobs (-)     =  µEOF + µe(-) 
 
                      Figure 1.2. Effect of EOF on electrophoretic mobility 
 
charge and resulting in an EOF. Some important parameters, which are used to control the EOF 
experimentally, are listed in table 1.2. In HPLC the pump systems give a laminar flow, by the 
slower velocity of the solution at the column walls as compared to the centre. Laminar flow gives 
broad peaks as the solution travels along the column. Whereas in CE sharp peaks are produced 
due to the EOF. Due to their chemical nature, the charged molecules may interact with the ionic 
capillary wall through several different mechanisms such as ionic interactions, electrostatic 
interactions, van der Waals interactions, and hydrogen bonding. If these interactions are strong, 
they can adversely affect resolution and EOF. In order to minimize or eliminate surface charge, it 
is possible to chemically modify or coat the inner surface of capillaries2,3. 
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 Table 1.2. Methods to control electroosmotic mobility 
 
 
Variable Result Comment 
 
Ionic strength 
or buffer 
concentration 
 
Reducing the double-
layer thickness  
• High ionic strength generates high currents     
and Joule heating 
• Low ionic strengths may result in sample  
adsorption 
• May distort peak shape if conductivity 
different from sample conductivity 
• Limits sample stacking if reduced 
Organic 
modifier 
 
Changing the 
viscosity of the buffer 
• Complex changes, effects need to be 
determined experimentally 
• May alter selectivity 
Surfactant Adsorbs to capillary 
wall via hydrophobic 
and/or ionic 
interactions 
• Anionic surfactants can increase EOF 
• Cationic can reverse or decrease EOF 
• Can significantly alter selectivity 
 
Multivalent 
ions 
Change the surface 
charge density 
• Can reverse the EOF direction 
• Cations can potentially bind to the analyte 
and change its net charge and electrophoretic 
mobility 
Covalent 
coating 
Chemical bonding to 
capillary wall 
• Many modifications possible 
• Stability often problematic 
Buffer pH EOF decreased at low 
pH, increased at high 
pH 
• Best method to change EOF 
• May change charge or structure of solute 
Neutral 
hydrophilic 
polymer 
Adsorbs to capillary 
wall via hydrophobic 
interactions 
• Decreases EOF by shielding surface charge 
and increasing viscosity 
 
Temperature  Changes viscosity, 
surface charge density 
and thickness of 
double layer 
• Often useful as temperature is controlled 
instrumentally 
 
 
 
1.2. Capillary zone electrophoresis  
 
Capillary zone electrophoresis (CZE) is the most common mode; here the capillary is filled with 
background electrolyte that consists of an aqueous buffer solution. The separations are based on 
the relative migration of the negatively charged analytes to the positively charged anode and the 
attraction of the ions in the buffer for the negatively charged cathode. The overall mobility of the 
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electroosmotic flow must be greater than that of the analytes, or the analyte cannot be detected. 
The selectivity of analyte separations by CZE is based on buffer pH and composition. Buffer pH 
is important as it determines the ionic charge on each analyte species2. Transient capillary 
isotachophoresis (CITP)-capillary zone electrophoresis (CZE) in the presence of electroosmotic 
flow (EOF) can be used to increase sensitivity. Using CITP-CZE products of the adenosine 
deaminase reaction, inosine and hypoxanthine, were detected with a limit of detection as low as 
28 nM4. The proteolytic activity of elastases from different sources was investigated with CZE5. 
The Michaelis constant of the irreversible deamination of adenosine to inosine by adenosine 
deaminase, using capillary zone electrophoresis employing electrophoretically mediated 
microanalysis (EMMA), was investigated6. CZE was used for the detection and assay of protein 
kinase and phosphatase activities in complex biological mixtures. By means of the capillary zone 
electrophoresis methodology, the phosphorylated and dephosphorylated forms of the peptide 
Kemptide, a 46-amino-acid fragment from protein phosphatase inhibitor-1 and a peptide 
fragment corresponding to the RII subunit of cAMP-dependent protein kinase (PKA), were 
resolved. It was found that CZE might prove to be extremely useful for the analysis of peptides 
that are phosphorylated at multiple sites in vivo7. In one review article the theory and 
methodological developments of sample stacking developed for charged analytes in CZE and 
also in electrokinetic chromatography have been described8. Furthermore, on-line concentration 
methods for charged species, namely sample self-stacking, acetonitrile stacking, sweeping, cation 
selective exhaustive injection sweeping, and use of a pH junction, have been discussed8. 
 
1.3. Micellar electrokinetic capillary chromatography  
 
If separation in CE is not possible by simply varying the buffer pH, or if neutral compounds are 
to be analyzed, then micellar electrokinetic capillary chromatography (MECC) is a powerful tool 
for separation. Here high separation efficiency of CE can be combined with a partition 
chromatography3. Partition chromatography in its simplest form consists of a stationary phase 
and a mobile phase where the separation of molecules is based on different affinities of the 
analytes for the two phases. When surfactants are added to a buffer in concentrations above their 
critical micellar concentration (CMC), micelles are formed. Micelles are ordered aggregates of 
surfactants with structures that hide their hydrophobic tails from water and orient their polar head 
groups toward the water.  The micelles in MECC are the equivalent of the stationary phase in 
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HPLC. Because micelles are not stationary, they are subject to both EOF and electromotive 
forces. Separations are based on the partitioning of molecules between the differently migrating 
micellar and running buffer phases3. A number of pharmaceuticals (e.g. acetaminophen 
(paracetamol), salicylic acid, sulfamethoxazole, theophylline, tolbutamide and trimethoprim) 
have been determined in human plasma by micellar electrokinetic chromatography (MECC), 
without sample pre-treatment, using underivatized fused-silica capillaries9. Electrophoretically 
mediated microanalysis (EMMA) combined with micellar electrokinetic capillary 
chromatography (MECC) was used to perform an on-capillary enzymatic reaction of bovine 
plasma amine oxidase with benzylamine as substrate10. MECC, employing reversed 
electroosmotic flow by cationic surfactant and reversed-polarity mode was used to study the in 
situ measurement of the kinetics of ATP metabolic transformation by MgATPase in the fast-
twitch gastrocnemius muscle11. Micellar electrokinetic chromatography with laser-induced 
fluorescence (MECC-LIF) detection has been used to determine the phosphorylation activity of 
the substrate peptide kemptide using cAMP-dependent protein kinase (PKA). Kemptide and 
phosphorylated kemptide could be reacted with 7-fluoro-4-nitrobenzo-2-oxa-1,3-diazole (NBD-
F) as a fluorophor. It was found that the MECC-LIF is very useful for protein kinase assays and 
can be applied to the testing of inhibitors12. The metabolism of extracellular nucleotides (ATP, 
ADP, AMP, UTP, UDP, and UMP) in NG108-15 cells, a neuroblastoma x glioma hybrid cell 
line, was studied by means of capillary zone electrophoresis (CZE) and micellar electrokinetic 
capillary chromatography (MECC) in the presence of ecto-nucleotidases and ectophosphatases in 
a previous Ph.D. thesis in our group13.  
 
1.4. Coating of the fused-silica capillary surface 
 
The capillary wall in CE may be coated to overcome nonreproducible EOF due to the adsorption 
of analytes to the capillary wall.  The EOF can be suppressed or controlled at a certain pH, and 
analyte-wall interactions can be reduced or eliminated, by coating the active sites on the inner 
surface of the fused-silica capillary. The active sites comprise inert siloxane bridges, hydrogen 
bonding sites and ionizable vicinal, geminal and isolated silanol groups14. The coating of the 
capillary wall reduces or eliminates analyte-wall interactions, by changing the electroosmotic 
flow to effect more rapid separations, improved reproducibility, or resolution of difficult 
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separation problems. Dynamic and permanent coatings of the fused-silica capillary inner surface 
have been studied extensively14-17. 
 
1.4.1. Dynamic coating 
In dynamic wall coating, additives are added to the background electrolyte to quench analyte 
adsorption on the capillary wall, in addition to the rinsing of the capillary with a solution 
containing a coating agent that is either a polymer or a small molecular-mass compound. There 
are three main classes of modifiers added to the background electrolyte: (i) amines or 
oligoamines; (ii) neutral polymers, and (iii) nonionic and zwitterionic surfactants15. The main 
advantages of dynamic coating are the simplicity and the renewable character. The dynamic 
coating is also easily removed from the capillary wall by rinsing. Some additives are only useful 
in a specific pH range, due to their pH-dependent dissociation. But on the other hand, covalently 
bonded capillaries still exhibit longer lifetimes and require less maintenance than dynamically 
coated capillaries17. 
 
1.4.2. Permanent coating 
A permanent wall coating is an attractive way to eliminate EOF and wall-analyte interaction in 
the separation capillary. Based on the separation performance, acrylamide-coated capillaries are 
superior to any other type of coating and cannot be prepared by adsorptive methods. Preparation 
of a permanent wall coating consists of three steps: capillary pre-treatment, introduction of 
double bonds to the capillary wall, and binding of a polymer to this intermediate layer17. Various 
types of coating layers can be generated either by silanization of the SiOH as anchor groups for 
the fixation of polar, neutral or ionic small and larger oligomers or by multipoint adsorption of 
neutral and charged polymers that can be cross-linked14. At present, different permanently coated 
CE capillaries with reproducible properties have become available, with either hydrophobic 
(alkylpolysiloxane) or hydrophilic (poly(ethyleneglycol) and poly(vinylalcohol) coatings and also 
charged coatings that are fixed by covalent bonding or by strong adsorption and cross-linking of 
polymeric layers14. 
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Chapter 2. Development of capillary electrophoresis methods for 
high-resolution separation and quantitation of nucleosides and 
nucleotides 
 
2.1. Separation and quantitation of adenosine, AMP, ADP, ATP and UMP by capillary 
electrophoresis using micellar electrokinetic capillary chromatography  
 
2.1.1. Introduction 
Extracellular purines (adenosine, ADP, and ATP) and pyrimidines (UDP and UTP) are important 
signalling molecules that mediate diverse biological effects via cell-surface receptors termed 
purine receptors. There are two main families of purine receptors, adenosine or P1 receptors, and 
P2 receptors, recognizing nucleotides, such as ATP, ADP, UTP, and UDP. P1 receptors have 
been further subdivided, according to convergent molecular, biochemical, and pharmacological 
evidence into four subtypes, A1, A2A, A2B, and A3, all of which couple to G proteins. Based on 
differences in molecular structure and signal transduction mechanisms, P2 receptors divide 
naturally into two families of ligand-gated ion channels and G protein-coupled receptors termed 
P2X and P2Y receptors, respectively; to date seven mammalian P2X receptors (P2X1-7) and eight 
mammalian P2Y receptors (P2Y1, P2Y2, P2Y4, P2Y6, P2Y11, P2Y12, P2Y13, P2Y14) have been 
cloned, characterized, and accepted as valid members of the P2 receptor family. Extracellular 
purines and pyrimidines have important and diverse effects on many biological processes 
including smooth muscle contraction, neurotransmission, exocrine and endocrine secretion, the 
immune response, inflammation, platelet aggregation, pain, and modulation of cardiac function18.  
The pharmacological characterization of P2 purinoceptors is hampered due to the absence of 
selective and potent antagonists. Morever, ATP, as well as other nucleotide agonists for the P2 
receptors, are subject to degradation by ecto-nucleotidases. Breakdown of ATP is the first step 
towards complete dephosphorylation of ATP yielding adenosine19. Consequently, a selective 
``ecto-ATPase`` inhibitor  would be an important pharmacological tool to study structure-activity 
relationships of ATP and its analogs at P2 purinoceptors20. The effect of ATP in tissues such as 
rabbit ear artery21 and guinea-pig vas deferens22 is enhanced in the presence of an inhibitor of 
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ecto-ATPase, ecto-ATPase may serve a physiological role of terminating the effect of released 
ATP and thereby limit stimulation of nucleotide receptors23. 
Enzymes are excellent drug targets as they have blockable catalytic sites and are governed by a 
number of well understood properties. These properties allow mechanistic enzymologists and 
medicinal chemists to rationally design and synthesize inhibitors of enzymes. In some cases, an 
enzyme may be a member of a family of related enzymes, e.g NTPDases (several isoforms are 
known), each with similar but not identical structure and function. Within enzyme families, a 
specific isoform or a group of isoforms may be responsible for disease while other family 
members may be associated with normal cell function. In such cases it is important to design 
isoform-selective enzyme inhibitors.  
Capillary electrophoresis is a useful tool for the analysis of nucleotides. Due to easy quantitation 
of separated peaks and the possibility of automation, CE continues to play a more and more 
important role in analytical biochemistry24-27. The kinetic study of metabolic processes is of 
prime importance in biological sciences and biomedicine. The adenine nucleotide adenosine 5’-
triphosphate (ATP) is the primary source of cellular energy and essential for the maintenance of 
cellular energy homeostasis. The measurement and kinetic analysis of the tissue metabolites 
associated with the cellular energetic state have a special significance in biology11,28,29. Several 
enzymes catalyze reactions involving nucleosides and/or nucleotides as substrates, and the 
resulting products (also nucleotides) have been characterized by capillary electrophoresis6,13,30-32. 
Nucleotides are easily analyzed by CE methods because they are negatively charged in a pH 
range from 2-12. Both the structures and the net charges on the molecule play a part in the 
separation of the compound. Above pH 6, each phosphate group adds an additional negative 
charge to the nucleotide; thus a nucleoside triphosphate such as adenosine triphosphate, ATP, has 
a higher charge than its mono- or diphosphorylated forms2. MECC was originally developed to 
separate neutral compounds by CE, it has also been found useful in the separation of charged 
compounds. The addition of a surfactant, sodium dodecyl sulphate (SDS), to the buffer creates 
micelles within the buffer, which act as a chromatographic stationary phase. MECC has 
previously been used in the separation of nucleotides and nucleosides by CE13. 
The aim of this project was to develop a simple and robust method for the separation of 
nucleosides, nucleosides mono-, di- and triphosphates, which would be used to study enzymatic 
reactions. 
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2.1.2. Experimental 
2.1.2.1. Materials and methods 
2.1.2.1.1. Capillary electrophoresis instrumentation 
High-performance capillary electrophoresis was performed on a P/PACE System 5500 (Beckman 
Coulter Instruments, Fullerton, CA, USA) equipped with a photodiode array (PDA) detection 
system. The instrument was controlled by P/ACE Station software (Beckman instruments). The 
runs were performed under the following conditions: T = 25 0C, λ = 210 nm, V = 10 kV, 20 mM 
potassium hydrogen phosphate, 100 mM SDS, pH 7.4. The electrophoretic separations were 
carried out using an eCAP fused silica capillary (75.0 µm diameter (I.D.) x 375 µm outside 
diameter (O.D.), 37.0 cm length (30 cm to the detector). The capillary was washed with 0.1 N 
NaOH for 2 min, deionized water for 1 min, and 20 mM potassium hydrogen phosphate, 100 mM 
SDS, pH 7.4 for 1 min before each injection. Injections were made by applying a slight pressure 
to the sample solution for 5 s delivering approximately 5 nL and finally the buffer to be used for 
the subsequent separations. 
 
2.1.2.1.2. Chemicals 
Adenosine-5’-triphosphate (A 2383), adenosine-5’-diphosphate (A 2754), adenosine-5’-
monophosphate (A 1752), adenosine (A 9251), uridine-5’-monophosphate (U 6375) and sodium 
dodecyl sulphate (SDS) were from Sigma (Taufkirchen, Germany). Dipotassium hydrogen 
phosphate for the CE-buffer was obtained from Fluka (Neu-Ulm, Germany). 
 
2.1.2.1.3. Preparation of standard solutions  
The nucleotides and the nucleoside were dissolved in deionized water to obtain 10 mM stock 
solutions and were further diluted to get 1.0 mM stock solutions. The 1.0 mM stock solutions 
were further diluted for the standard calibration curves. For validating the method of the ATP, 
ADP, and adenosine determination, 20 µM of AMP was used as an internal standard. For the 
AMP determination, 20 µM of UMP was used as an internal standard. 
 
2.2. Results and discussion  
2.2.1. Separation of nucleotides  
High-performance liquid chromatography has been used to quantify nucleotides and nucleosides 
details can be found in a review article33, but it has its limitations. The columns are expensive, 
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and large amounts of mobile phase are needed for the analysis. The sample volume required is 
relatively large, often between 10-100 µl. Column equilibration in the ion exchange and ion-
pairing modes can be time-consuming. While CE analyses are generally faster than comparable 
HPLC analyses, the solvents used are inexpensive, and smaller quantities of both buffer and 
sample are required. It is a flexible technique with several separation and detection modes. CE 
has been used extensively for the determination of nucleotides and nucleosides2,11,13,24,25,27-30,34-38. 
The selectivities achieved in CE separations are mainly determined by the differences in 
electrophoretic mobilities of solutes, which are mainly influenced by buffer composition and 
buffer pH. The resolution in CE separations is also significantly affected by electroosmotic flow, 
which refers to the bulk buffer flow caused by the electrical double layer on the capillary inner 
surface and the applied voltage25. Phosphate buffer has been used as a separation buffer due to its 
good buffer capacity. It gives better peak efficiency and higher resolution than other buffers for 
acidic compounds. A separation buffer of pH 7.4 was chosen because the nucleotides were 
relatively stable at a low pH, but readily hydrolyzed at a high pH value. At this pH value the 
nucleotides were negatively charged and moved from the cathode to the anode. Alkaline buffers 
provide a stable EOF and if the capillary is already preconditioned in an alkaline environment, 
capillary equilibration time after NaOH rinse is short2. In a fused silica capillary a strong EOF 
exists with direction from the anode to the cathode. MECC with SDS was used to control the 
EOF and enhance the separation of the ribonucleotides along with the separation of neutral 
nucleoside (adenosine) and charged nucleotides simultaneously. Our goal was to determine the 
nucleotides and nucleosides after enzymatic reactions in a short time and to improve the detection 
limits. 
 
2.2.2. Development of a capillary electrophoresis method for the determination of 
nucleotides 
 
2.2.2.1. Method validation 
The method for the determination of nucleotides was validated with respect to specificity, linea-
rity, and limits of quantitation, detection and precision. A known concentration of UMP was used 
as an internal standard (I.S.) to quantify AMP. AMP was used as an internal standard for the 
validation of the determination of adenosine, ATP and ADP. The use of internal standard has 
been generally accepted to be crucial for reproducibility in CE to compensate for injection errors 
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and minor fluctuations of the migration times. AMP and UMP were selected as I.S. due to their 
structural similarities with the other nucleotides. In this case charged analytes move towards the 
cathodic side with the EOF, and separation is achieved on the basis of size and charge of the 
analytes. Adenosine being neutral in charge was separated from the EOF by the addition of SDS. 
After that, AMP followed by ADP, and at last ATP came out of the capillary, in the order of 
increasing charge (AMP < ADP < ATP) and molecular size (AMP < ADP < ATP). 
 
2.2.2.2. Limit of detection and quantitation 
For the determination of linearity and the limit of detection and quantitation, calibration curves of 
standard solutions were obtained from 7 to 8 different concentrations of adenosine, AMP and 
ATP (2.0, 5.0, 10.0, 15.0, 20.0, 30.0, 40.0 and 50.0 µM) and UMP and ADP (5.0, 10.0, 15.0, 
20.0, 30.0, 40.0 and 50.0 µM). The limit of detection (LOD) calculated at a signal-to-noise ratio 
equal to 3 was found to be between 3.69 and 2.16 µM for the various nucleotides and adenosine 
(see Table 2.1). Good linearity was found in the range from the compounds' lowest measured 
concentration within the linear range to the highest concentration at 40 µM or 50 µM. The limit 
of quantitation (LOQ) calculated at a signal-to-noise ratio equal to 10  was found in the range of 
3.8 to 6.1 µM. (see Table 2.1). 
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Table 2.1. Method validation parameters for nucleotide and nucleoside determination 
Compound  
 
AMP ADP ATP UMP ADO 
Limit of detection (µM) ± SD 
Limit of quantification (µM) ± SD 
% recovery rate ± SD 
RSD (%) of recovery rate 
R2 of recovery rate 
Coefficient of correlation; R2 
Mean value of migration time 
(min) ±  SD (n= 6) 
RSD of migration time (%) 
3.30 ± 0.60 
4.94 ± 0.60 
98.5 ± 0.59 
3.85 
0.999 
0.998 
7.61 ± 0.07 
 
0.92 
3.69 ± 0.66 
5.88 ± 0.66 
99.5 ± 0.63 
3.00 
0.999 
0.999 
10.79 ± 0.18 
 
1.67 
3.70 ± 0.70 
6.06 ± 0.70 
99.2 ± 0.68 
3.58 
0.999 
0.982 
17.14 ± 0.21  
 
1.23 
2.16 ± 0.38 
3.77 ± 0.38 
99.3 ± 0.30 
1.40 
0.999 
0.998 
8.10 ± 0.03 
 
0.37 
2.30 ± 0.48 
3.50 ± 0.48 
98.7 ± 0.30 
1.40 
0.999 
0.999 
4.73 ± 0.03 
 
0.63 
 
 
2.2.2.3. Precision of migration time 
The precision of the assay was investigated with respect to repeatability. Each standard was run 6 
times. Standard deviation and variation coefficients of migration times were determined. There 
was less difference in migration times of adenosine, AMP and UMP while relatively more differ-
ence was observed in migration times of ATP and ADP. The relative standard deviation of 
migration times for AMP and UMP and adenosine was low, 0.92, 0.37 and 0.63 %, respectively, 
while it was only slightly higher for ADP and ATP, 1.67 and 1.23 %, respectively. The results are 
summarized in Table 2.1. 
 
2.2.2.4. Linearity of calibration curve and recovery 
To determine the linearity of calibration curve and recovery rates, standard solutions of 2.0 to 
50.0 µM concentrations of nucleotides were run, and linear relationships with regression 
coefficients (R2) of 0.999 were found by plotting corrected peak areas against concentrations for 
all nucleotides. The found concentrations were calculated from the obtained linear regression 
curves and plotted against the concentrations originally present in the standard solutions to obtain 
the recovery equations. Recovery rates were found to be high 98.5-99.5% for all nucleotides 
(Table 2.1). 
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2.3. Summary  
An improved method for the analysis of nucleotides (AMP, ADP, ATP and UMP) and the 
nucleoside adenosine using micellar capillary electrophoresis was developed. All these analytes 
were separated in a fused-silica capillary (30 cm to the detector, I.D. 75 µm) and normal polarity 
mode at constant voltage of 10 kV in a 20 mM phosphate, 100 mM SDS, buffer (pH 7.4), which 
produced reproducible separations. The peaks of the analytes were detected by their respective 
UV absorbances at 210 nm. In the presence of phosphate buffer, the migration order of 
nucleoside and nucleotides based on charge-to-molecular mass ratios is adenosine followed by 
AMP (monophosphate), followed by ADP (diphosphate) and finally ATP (triphosphate). Linear 
relationships between peak areas and sample concentrations were found at the calibration range. 
This method allowed reproducible and reliable qualitative and quantitative analysis of AMP, 
ADP, ATP and UMP and adenosine. Uhrova et al. performed the separation of eleven nucleotides 
on a fused silica capillary using 20 mM phosphate-borate buffer (pH 8.0-9.0). The detection 
limits achieved for the nucleotides ranged between 0.62 and 3.8 µg/mL. The analysis time was 
about 14-16 min24. Huang et al. used a polyacrylamide-coated capillary and a Tris-HCl 
phosphate-mixed buffer for the separation and quantitation of 14 ribonucleotides in 50 min with 
5.4 µM minimum detectable concentration and 0.08 pmol minimum detectable quantity25. 
O’Neill et al. developed a method for the separation and quantitation of nucleotides in cell 
extracts using Tris-HCl and phosphate buffer, (pH 5-6), and a coated fused silica capillary37. 
They performed the separation of 15 nucleotides within 45 min and minimum detctable 
concentration of 2-8 µM. In the present study baseline separation was achieved for the nucleoside 
and nucleotides in less than 18 min with high separation efficiencies. The compounds can be 
detected with linear response over the concentration range of 2 µM to 50 µM, and detection 
limits from 2 µM to less than 4 µM. The developed separation method for nucleotides and 
nucleosides can now be applied to biological studies such as enzymatic assays.  
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Chapter 3. Capillary electrophoresis assays of adenosine kinase 
 
3.1. Introduction 
Adenosine kinase (AK; EC 2.7.120) is the key cytosolic enzyme that catalyzes the 
phosphorylation of adenosine (ADO) to AMP and is one of two enzymes responsible for ADO 
metabolism. ADO deaminase (ADA, adenosine aminohydrolase, EC 3.5.4.4) also contributes to 
ADO conversion, but AK appears to predominate under physiologic conditions39,40. AK has been 
purified from a variety of tissues from different species, including humans41,42 and the AK gene 
has been cloned from rat and human tissue43-46. ATP is generally considered to be the preferred 
phosphate source for the reaction catalysed by AK. Magnesium is also required for AK activity 
and the true AK co-substrate is the MgATP2- complex45.  AK was found to contain two binding 
sites, a catalytic site with high affinity for ADO and a low affinity regulatory site that may be the 
MgATP2- binding site. The predominant ADO-specific transport system operates as a non-
concentrative, bi-directional, facilitated diffusion transport47. The AK enzyme is a monomer with 
a molecular weight in the range of 38-56 kDa, whose structure consists of one large α/β domain 
with nine β-strands, eight α-helices, and one small α/β-domain with five β-strands and two α-
helices. The active site is formed along the edge of the β-sheet in the large domain while the 
small domain acts as a lid to cover the upper face of the active site (Figure 3.1.1). One adenosine 
molecule is located in a site that matches the ribose site in ribokinase and probably represents the 
binding site for the nucleoside undergoing phosphorylation. As seen in Figure 3.1.1, a Mg2+ ion 
binding site is observed in a trough between the two adenosine sites. The structure of the active 
site is consistent with the observed substrate specificity. The active-site model suggests that 
Asp300 is an important catalytic residue involved in the deprotonation of the 5'-hydroxyl during 
the phosphate transfer. The second adenosine site probably represents the ATP/ADP binding 
site48.  
The endogenous purine nucleoside adenosine (ADO) functions as an extracellular signalling 
molecule by interacting with specific extracellular receptors (P1 receptors). The prototypic 
endogenous inhibitory neuromodulator adenosine (ADO) is one component of a purinergic 
cascade (Figure 3.1.2) that results from the metabolic inactivation of ATP. The availability of 
these purines (ADO, AMP, ADP, and ATP) is under metabolic control in the extracellular milieu 
and each has distinct, receptor-mediated activities. There is abundant evidence that ADO affects a 
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variety of physiological processes, all potentially therapeutically useful47,49,50. The search for 
compounds that modulate ADO receptor function as potential therapeutic entities has focused-  
 
              
adenosine 
                                                   β                          α 
 
Figure 3.1.1. Crystal structure of human adenosine kinase bound with two molecules of 
adenosine.  
 
largely on direct-acting ADO receptor agonists and antagonists. ADO receptor agonists are 
effective in animal models, but their therapeutic utility has been limited by side effects, in 
particular hypotension, renal anti-diuresis and bradycardia, a result of their non-tissue specific 
interaction with ADO receptor subtypes throughout the body49. Adenosine kinase inhibitors are 
of considerable interest as novel site- and event-specific indirect adenosine receptors agonists and 
more powerful in situations where more adenosine is released. They exhibit potent 
antinociceptive, anticonvulsive and antiinflammatory activity without the limiting cardiovascular  
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Figure 3.1.2. The purinergic cascade. ATP, ADP, AMP and, ADO are released from nerves or 
cells into the extracellular space. These purines are readily metabolized by enzymes that are 
located both intra- and extracellularly. The phosphorylation of ADO to AMP is mediated 
primarily by the action of AK. 
 
side effects exhibited by direct adenosine receptor agonists51,52. Furthermore, the adenosine 
kinase of the protozoa Toxoplasma gondii, which is pathogenic in immunocompromised 
individuals such as patients suffering from AIDS, has been identified as a novel potential 
chemotherapeutic drug target53,54. Because inhibition of AK can significantly increase levels of 
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endogenous ADO, the development of specific AK inhibitors represents a promising strategy for 
the rational development of clinically useful purinergic drugs47. 
ADO has a half-life in the order of seconds in physiological fluids, and its beneficial actions are, 
therefore, restricted to the tissue and cellular site where it is released. Reuptake of ADO into the 
cell, followed by its intracellular metabolism is responsible for the rapid disappearance of ADO 
from the extracellular space  (Figure 3.1.3.). Since ADO has been shown to effectively limit 
pathophysiological processes resulting from tissue trauma and injury, the identification of ligands 
that mimic or potentiate the beneficial actions of ADO has been the subject of substantial drug 
discovery efforts50,49,39. 
 
ATP 
ADO (P1) - R 
ADO (P1) - R NT 
AK 
ADA
InosineADO
  ATP                      AMP 
ADO
 
Figure 3.1.3. ADO is released from cells to function as a local homeostatic modulator of cellular 
function by activating specific extracellular P1 receptors. Reuptake of adenosine (ADO), and its 
intracellular metabolism by adenosine kinase (AK), are key factors regulating local extracellular 
ADO levels at P1 receptors sites. AK inhibitors potentiate the local concentrations and, 
therefore, the actions of endogenously released extracellular ADO. Adenosine deaminase (ADA), 
nucleotidase (NT). 
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3.1.1. Structures and activities of adenosine kinase inhibitors 
AK phosphorylates ADO utilizing ATP as a phosphate donor, which might suggest that AK 
inhibitors could be designed as ATP mimics. However, due to their anionic nature, with multiple 
charged atoms, nucleoside triphosphate analogs are likely to have very poor ADME (Absorption, 
Distribution, Metabolism, and Excretion) properties, and therefore have not received serious 
consideration. To date, AK inhibitors have been designed to bind to the substrate ADO site, and 
these inhibitors have been demonstrated to competitively displace ADO. Many of these 
molecules are small, and have at most a single charge47. Novel nucleoside and nonnucleoside 
inhibitors of AK have recently been reported that show a high degree of selectivity for the AK 
enzyme and have in vivo effects consistent with the augmentation of the actions of endogenous 
ADO in animal models of pain, inflammation, and seizure activity55,56. 
 
3.1.2. Nucleoside inhibitors of adenosine kinase  
Miller and coworkers have tested 119 different nucleosides for their ability to inhibit the purified 
AK from rabbit liver44. Tubercidin and analogs with a pyrrolo[2,3-d]pyrimidine ring structure 
have binding affinity for AK (Figure 3.1.4). Although 5-Iodotubercidin (5-IT) is a competitive 
inhibitor of the binding of ADO to AK, it is a alternative substrate for the enzyme by virtue of 
having a hydroxy group at the 5'-position57,58. Other closely related nucleosides, 5'-deoxy-5-
iodotubercidin (5'd-5IT) and 5'-Amino-5'-deoxy58 analogues of 5-bromo- (A-285601) and 5-
iodotubercidin (A-134974) were found to be the most potent AK inhibitors reported to date (IC50 
< 0.001 µM) with anticonvulsant activity in the rat maximal electric shock (MES) induced 
seizure assay57. 5-Iodotubercidin has the potential to undergo in vivo 5'-O-phosphorylation and 
therefore produce cytotoxicity; therefore, to eliminate toxicity l-lyxofuranosyl analogues of 
tubercidin had benn synthesized59. The lead compound was GP790 (IC50 0.47 nM)59. Similarly 
substitution of the tubercidin molecule with aromatic rings at the N4- and the C5-positions yield 
N4-arylamino-5-arylpyrrolo[2,3-d]pyrimidine analogs, a modification which not only retains AK 
inhibitor potency but also improves in vivo activity60. Combining the beneficial effects of having 
the 5'-amino group and the 5-iodo group yielding 4-amino-5-iodo-7-(5'-deoxy-5'-amino-β-D-
ribofuranosyl)pyrrolo[2,3-d]pyrimidine (3.1) and 4-amino-1-(5'-amino-5'-deoxy-1-β-D-
ribofuranosyl)-3-bromo-pyrazol[3,4-d] pyrimidine (GP 515) (Figure 3.1.4) resulted in potent and 
selective AK inhibitors with in vivo activity as antiinflammatory agents61,62. The most potent AK 
inhibitor A-134974 (IC50 = 60 pM) was obtained by removing the 5'-methylene group to give the 
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4'-aminocarbocyclic analog of 5-IT. This compound, A-134974, has shown antihyperalgesic 
activity in rats53. Recently, 6,8-disubstituted purine nucleosides, e.g. 3.4 were found as adenosine 
kinase inhibitors. Among the series of 6,8-bisarylamine-N,N'-diylpurine nucleosides such as 8-
aniline(N-yl-6-indolin-N-yl-9-(β-D-ribofuranosyl)purine (3.4) (Figure 3.1.4) was found to be a 
potent AK inhibitor with an IC50 value of 0.019 µM63. 
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Figure 3.1.4. Structures of nucleoside adenosine kinase inhibitors39,47,50 
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3.1.3. Non-nucleoside inhibitors of adenosine kinase 
There are a number of non-nucleoside AK inhibitors that have been disclosed, many of them 
obtained through modification of compound 3.5 (see Figure 3.1.5) that had been discovered by 
high throughput screening64. The more recently generated AK inhibitors were also found through 
a high throughput screening approach and are generally more potent than the natural product 5-
bromopyrrolopyrrolidine, the first compound recognized in this class. By optimizing this series, 
the pyridopyrimidine ABT-702 was produced exhibiting exceptional potency (ED50 = 0.7 
µmol/kg) in the mouse against thermal hyperalgesia55,64. The 5-position of the pyridopyrimidine 
ring in ABT-702 has also been modified, and in the case of the 5-benzyl-substituted compound 
3.7, the in vitro potency was increased 12-fold over that of ABT-702, but without an increase in  
the in vivo potency. Solubility was not improved with most of the 5- modified analogs, with the 
exception of the highly soluble 3.9, which reduced hyperalgesia but was inactive after oral 
administration65. A different type of modification, the incorporation of a nitrogen atom at the 5-
position of the pyridopyrimidine ring in 3.12 increased water solubility while retaining the in 
vitro potency as well as in vivo activity in a rat inflammatory hyperalgesia model66. Novel non-
nucleoside AK inhibitors based on 4-amino-6-alkynylpyrimidines, 4-Amino-5-[(2-
chlorobenzyl)methylamino]-6-[6-(4-morpholinyl)-3-pyridinylethynyl]pyrimidine 3.13 (IC50 = 15 
nM), 4-Amino-5-(benzylmethylaminomethyl)-6-[6-(4-morpholinyl)-3- pyridinylethynyl]pyrimid-
ine 3.14 (IC50 = 2 nM) as well as similar analogs in the series were prepared, for which high 
potency was demonstrated in vitro, and they effectively reduced pain and inflammation in animal 
models40. The more recently described 2-pyridyloxazolo-pyrimidine derivative 3.15 was 
synthesized by high throughput derivatization of the oxazolo-pyrimidine resulting in a ≤ 10 
nanomolar IC50 value67. Recently by the modification of existing pyridopyrimidines  
pyrazolopyrimidine 3.16 was produced with an IC50 value of 7.5 nM68. 
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Figure 3.1.5. Structures of non-nucleoside adenosine kinase inhibitors  
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Structure-activity relationships of nucleoside inhibitors of adenosine kinase 
Structure-activity relationships have been established for both substrates and inhibitors of AK, 
the majority of which have nucleoside-like structures50 (Figure 3.1.4).  The initial reports of the 
structure-activity relationships for nucleoside-like compounds as inhibitors and substrates of AK 
were reported by Miller et al44. For nucleoside-like compounds trans-hydroxy groups with respect 
to the base portion are necessary for substrate or inhibitor activity42. Substitutions, deletion, 
replacement or inversion of the hydroxyl groups at the 2'- or 3'- positions eliminates ligand 
recognition by the enzyme39,47,50. Replacing the ribofuranosyl ring oxygen with a methylene 
group (aristeromycin) results in AK inhibitory actvity39. Removal or substitution of the 5'-
hydroxyl phosphorylation site would be expected to eliminate substrate activity. But substitution 
of the 5'-hydroxyl group gives potent activity as inhibitors, such as in 5'-deoxyadenosine. A 
particularly interesting observation is that additional substitution of an amino group at the 5'-
position enhances potency still further as shown by 5'-amino-5'-deoxyadenosine (IC50 = 9 nM). 
Inversion of the stereochemical configuration of the 5'-hydroxymethylene group results in a 
potent AK inhibitor39. The 1-aza and the 3-aza nitrogen atoms in the adenine ring are necessary, 
and their replacement leads to a loss of activity49. Replacement of the N7 nitrogen of the adenine 
ring with carbon leads to tubercidin, which shows reduced activity compared with the parent 
adenosine. However, very potent pyrrolopyrimidine analogs can be created by appending 
lipophilic aryl or halogen moieties on the C5 of the heterocyclic ring of tubercidin (e.g. 5'-deoxy-
5-iodotubercidin, IC50 = 1 nM). A related synthetic analog (5-IT, 17 nM) (Figure 3.1.4) was 
prepared69. Substitution at C6 (e.g. methoxy, mercapto) retains activity while substitution at C2 
eliminates actvity47. Potency can further be enhanced by substitution of lipophilic moieties at the 
4- and 5- position of tubercidin by combining this modification with the aforementioned 
favorable 5'-amino group to give a family of AK inhibitors, most prominently GP-515 and GP-
683, along with the related α-lyxofuranosyl analog GP-947 (see Figure 3.1.4)39. One of the most 
potent in vitro inhibitor is compound 3.2, illustrating the beneficial effect of combining the 
potency-enhancing 5'-amino moiety and the iodotubercidin structure. Henderson and coworkers70 
found many of the purine nucleoside analogs as inhibitors of AK, but all the pyrimidine 
nucleosides tested were inactive. Among the inhibitors of AK, 5-IT (Figure 3.1.4) showed 
activity in the micromolar range70. Replacement of the ribose ring with a cyclopentane 
carbocyclic ring gives more potent inhibitors71. Replacement of the adenine ring of 
noraristeromycin with a 5-iodopyrrolidine gave the even more potent compound 3.3 (IC50 = 13 
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nM) and combining the 4'-amino-truncated carbocyclic moiety with a heterocyclic ring gave very 
high potency (A-134974, IC50 = 0.06 nM) (Figure 3.1.4)39. 
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Figure 3.1.6. General structure-activity relationships for nucleoside-analogs as AK inhibitors. 
 
A novel family of non-nucleoside inhibitors of AK has been recently reported71 (Figure 
3.1.5)66,72,73 that show a high degree of selectivity and have in vivo effects consistent with the 
augmentation of the actions of endogenous ADO in animal models of pain, inflammation and 
seizure activity55,56. Most of the compounds were obtained through modification of a compound 
(3.5) which was discovered by high throughput screening64. A number of analogs were examined, 
and it was found that replacement of the 5-aza atom with a carbon, when coupled with lipophilic 
substitution at the 5-position, gave compounds potent in vitro, e.g. compound 3.6 (IC50 = 5 nM). 
To improve the water solubility of 7-dimethylaminophenyl-substituted compounds, the 7-phenyl 
moiety of compound 3.6 was substituted with a 7-morpholine (or replaced by a 2-pyridyl) moiety 
as seen in ABT-702 which increased water solubility as well as antinociceptive actions in 
vivo55,56. An examination of the SAR of many analogs showed that compounds bearing a wide 
variety of lipophilic C5-substituents displayed potent in vitro inhibitory activity; compounds 3.7 
and 3.10 have subnanomolar potency to inhibit AK. Compounds ABT-702 and 3.8 exhibited in a 
carageenan-induced thermal hyperalgesia assay ED50 values of 5-10 µmol/kg in rate47,56. 
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3.2. Development of off-line and in-line capillary electrophoresis methods for 
the screening and characterization of adenosine kinase inhibitors and 
substrates 
 
3.2.1. Project  
Adenosine kinase (AK; EC 2.7.120) catalyzes the phosphorylation of adenosine to AMP74 (see 
Figure 3.2.1).  
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Several methods including radioisotopic69, thin-layer chromatographic (TLC)75 and HPLC-UV 
methods44,46, have been devised to monitor the adenosine kinase reaction and associated kinetics, 
but all of the currently known methods have serious drawbacks. The radioisotopic method 
requires the use of radioactive materials, which is neither economic nor environmentally friendly. 
It is limited to radiolabeled substrates (e.g. [3H]adenosine or [14C]adenosine); alternative 
substrates that are not available in radiolabeled form cannot be investigated. Therefore, the 
radioactive method is useful for testing inhibitors, but less suitable for investigating substrates. 
On the other hand, TLC is not suitable for the determination of minute enzymatic activity in 
complex biological medium, because it shows low resolution, is time-consuming and not 
sensitive enough. HPLC is also used for enzyme assays; however, it suffers from the requirement 
of large quantities of solvents, relatively high prices for columns, and frequently long retention 
times. 
Capillary electrophoresis (CE) has recently emerged as a powerful tool for enzyme analysis5,76,77, 
including the determination of Michaelis-Menten constants78-81, and for enzyme inhibition 
assays79-83 exhibiting a number of advantages over conventional methods. These include rapid 
separation, the ability to simultaneously discriminate between and identify multiple components 
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of similar structure with high resolution1, ultra-low sample volume requirements, and high 
throughput by automation. CE is particularly useful for investigating enzymatic reactions 
involving charged substrates or products, e.g. for the monitoring of phosphorylation or 
dephosphorylation reactions. Phosphorylated and nonphosphorylated products and substrates 
have significantly different electrophoretic mobility, and therefore can readily be separated and 
quantified84.  
Electrophoretically mediated microanalysis (EMMA), first described by Bao and Regnier85 has 
been successfully used for in-line enzyme assays86. In this technique the capillary is used as a 
microbioreactor as well as for the separation of substrate and products. There are two major types 
of EMMA methods. In the first continuous format85, the capillary is filled with an appropriate 
substrate solution and upon injection of a zone of enzyme; the product will continuously form 
during the electrophoretic mixing of enzyme and substrate. One drawback of this method is that 
the separation buffer has to allow the enzymatic reaction to proceed. 
In the second technique87, substrate and enzyme are introduced into the capillary as distinct 
plugs. Upon application of an electric potential, these zones mix with each other due to 
differences in their electrophoretic mobilities. The reaction proceeds during the mixing process. 
The resultant product is transported to the detector separately from enzyme and educts under the 
influence of an applied voltage, where they are individually detected. Recently, Van Dyck et al.10 
introduced the combination of the EMMA methodology with a partial filling technique. Using 
this method part of the capillary is filled with the buffer optimized for the enzymatic reaction 
whereas the rest of the capillary is filled with the background electrolyte optimal for the 
separation of substrate and product. EMMA with partially filled capillary has been used for the 
inhibition studies of haloalkane dehalogenase86 and for the determination of Michaelis-Menten 
constants of bovine plasma amine oxidase and haloalkane dehalogenase10,87. 
CE enzymatic assays can be categorized into three formats depending on the step when the 
enzymatic reaction takes place: pre-column, on-column and post-column. In the first pre-column 
CE-enzymatic assay format, the substrate is mixed with enzyme and the mixture is incubated for 
a specified amount of time. The products of the enzymatic reaction are then injected into the CE 
column, electrophoretically separated, and quantified. In the second type of CE-enzymatic assays 
all the steps of the assay take place within the capillary (including mixing, separation and 
detection). EMMA consists of three steps; during the first (pre-reaction step) the zones of the 
enzyme and the substrate are brought into contact by hydrodynamic injection inside the capillary. 
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During the second step the enzymatic reaction is allowed to occur in the presence or absence of 
an electric field. During the third (post-reaction) step the product is electrophoretically 
transported to a detector.                       
In the present study, methods for analyzing the enzymatic reactions of adenosine kinase have 
been developed. These methods allow to measure substrates and potential inhibitors for 
adenosine kinase within a few minutes with high accuracy and reproducibility by means of 
capillary electrophoresis. These are suitable for the high-throughput screening of test compounds. 
CE-based adenosine kinase studies are extremely fast and require only very small amounts of 
sample. This is of particular advantage when the enzyme, substrate or test compounds (potential 
substrates or inhibitors) are very expensive.  
 
3.2.2. Materials and methods  
3.2.2.1. Reagents and chemicals 
N´-linked 5´-AMP-Sepharose 4B was purchased from Amersham Pharmacia Biotech (Steinheim, 
Germany). Sodium acetate and phenylmethylsulfonyl fluoride (PMSF) were obtained from Fluka 
Biochemika (Neu-Ulm, Germany). CM-cellulose, DEAE-sephacel, adenosine, adenosine-5´-
triphosphate, magnesium chloride hexahydrate, adenosine-5´-triphosphate, adenosine, 
magnesium chloride hexahydrate, adenosine-5´-triphosphate, thymidine-5´-monophosphate, 
sucrose, ethlylenediamine tetraacetic acid (EDTA) disodium salt, 
tris(hydroxymethyl)aminomethane (Trizma Base), ABT-702 (4-amino-5-(3-bromophenyl)-7-(6-
morpholino-pyridin-3-yl)pyrido[2,3-d]pyrimidine), A-134974 (N7-[(1´R,2´S,3´R,4´S)-2´,3´-
dihydroxy-4´-aminocyclopentyl]-4-amino-5-iodopyrrolopyrimidine) and 5-iodotubercidin were 
from Sigma (Taufkirchen, Germany). Fresh bovine liver was obtained from a local 
slaughterhouse in Cologne, Germany. [2,8-3H]Adenosine (33.10 Ci/mmol) was obtained from 
Perkin-Elmer Life Sciences, Rodgau-Jügesheim, Germany. 2-Substituted adenosine derivatives 
3.2.2–3.2.8 (see Table 3.1) were synthesized in analogy to published procedures51.  
 
3.2.2.2. Adenosine kinase purification  
Adenosine kinase was purified from bovine liver by a modification of the procedure described by 
Anders and Fox41. All procedures were carried out at 4 °C, unless otherwise noted. Bovine liver 
(140 g) was freed of fat and connective tissue and cut into small pieces, placed in a small beaker 
and homogenized with an Ultra Turrax homogenizer at full speed for one minute in the isolation 
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buffer (280 ml, 0.25 M sucrose, 1 mM EDTA, 10 mM Tris-HCl, pH 7.1 and 0.1 mM of the 
proteinase inhibitor phenylmethylsulfonyl fluoride). The homogenate was transferred to a Teflon 
glass homogenizer and further homogenized for 30 s, then transferred to centrifuge tubes and 
centrifuged at 30,000 g for 1 hr at 4 °C. The clear supernatant was decanted and brought to pH 
6.0 with 1 N HCl. It was then mixed with an equal volume of settled CM-cellulose previously 
equilibrated with 10 mM sodium acetate buffer pH 6.0. After shaking the mixture for 90 min, the 
sample was filtered through a Büchner funnel, and washed once with 10 mM sodium acetate, pH 
6.0. It was mixed with a volume of settled DEAE-sephacel equal to the initial volume of bovine 
liver supernatant previously equilibrated with 10 mM sodium acetate, pH 6.0. The mixture was 
stirred for 2.5 hr, then filtered, and washed as before. The filtrate was centrifuged again at 30,000 
g for 30 min at 4 °C to remove the suspended particles. The supernatant was loaded on a 5'-AMP-
Sepharose 4B column (XK 2.6 ✕ 30 cm; 30 ml), which was pre-equilibrated with 10 mM sodium 
acetate buffer pH 6.0 and eluted at a flow rate of 4.0 ml/min.  
The column was washed with the same buffer (150 ml of sodium acetate buffer, pH 6.0) to re-
move non-specifically bound protein, and then, in turn, with 100 ml of 10 mM Tris-HCl buffer 
pH 7.4 containing 1M KCl, 68 ml of 0.1 M Tris-HCl buffer pH 7.4 containing 5 mM ATP and fi-
nally with 90 ml of 0.1 M Tris-HCl buffer pH 7.4 containing 5 mM ATP-Mg and 5 mM adeno-
sine. Adenosine kinase was eluted with the final wash, at a flow rate of 4.0 ml/min, with collec-
tion of 5 ml fractions. The final preparation was concentrated with Centriplus YM-10 (Amicon) 
centrifugal filter devices. Adenosine kinase was freed from salts, adenosine and ATP by dialysis 
for 24 hours in 10 mM Tris-HCl buffer pH 7.4. Capillary electrophoresis analysis of adenosine 
kinase was done to confirm that adenosine kinase was free from adenosine and ATP. Protein 
concentration of the finally purified enzyme was determined by the method of Lowry et al.88 
Using bovine serum albumin as a standard. The enzyme was stored at –85 °C in 0.5 µg/ml bovine 
serum albumin and 10 mM Tris-HCl buffer pH 7.4. The Km and specific activity of purified 
adenosine kinase preparation were found to be 1.03 µM and 3.1 mM AMP/min/mg protein, 
respectively as determined by standard methods89. 
 
3.2.2.3. Polyacrylamide gel electrophoresis 
SDS-polyacrylamide gel electrophoresis was performed according to the method of Lämmli90 
with 10% cross-linked gel. Electrophoresis was done in 0.025 M Tris-HCl and 0.192 M glycine 
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buffer, pH 8.8 under denaturating conditions (addition of 1% SDS). Bromophenol blue was used 
as the tracking dye, while staining was done with Coomassie Blue. 
 
3.2.2.4. Determination of Km and Vmax values of adenosine kinase by radioactive method 
The standard radiochemical assay was performed as described earlier with modifications89 in a 
final volume of 100 µl containing 20 mM Tris-HCl, 0.2 mM MgCl2, 5 mM K2HPO4, 1 mM ATP 
and 10 µl of different concentrations of [3H]adenosine (0.1, 0.5, 1.0, 2.0, 2.5, 5.0, 10.0, 20.0, 25.0 
and 50.0 µM). The reaction was initiated by the addition of 10 µl of suitably diluted adenosine 
kinase enzyme (39 ng of protein). Incubation was performed for 5 minutes at 37 °C and then the 
reaction was stopped by the addition of 1.0 ml of cold 0.1 M aqueous lanthanum chloride 
solution in order to precipitate the radiolabeled AMP formed through the enzymatic reaction. The 
sample was kept on ice for at least 3 hours, and then filtered through GF/C glass fiber filters 
using a cell harvester (Brandel, purchased through Adi Hassel, München, Germany) in order to 
separate the precipitated labeled [3H]AMP from soluble [3H]adenosine. The filter papers were 
washed twice with 20-25 ml of cold water and then transferred to scintillation vials. Three ml of 
scintillation cocktail Ultima Gold (Canberra Packard, Dreieich, Germany) was added to each 
sample vial and radioactivity was counted in a scintillation counter (Tri-Carb 2100 TR, Canberra 
Packard).  
 
3.2.2.5. Effects of Mg2+ on the activity of adenosine kinase 
Effects of different concentrations of Mg2+ (10 to 300 µM) on the enzyme activity were moni-
tored. The reaction mixture contained 1 mM ATP, 200 µM adenosine, 64 mM Tris-HCl buffer, 
pH 7.5, and different concentrations of MgCl2. The reaction was started by adding 10 µl of 
suitably diluted adenosine kinase and the mixture (final volume 100 µl) was incubated at 37 °C 
for 10 min, then stopped by heating at 99 °C for 5 minutes. The AMP formed was measured in 
duplicate by capillary electrophoresis. Each analysis was repeated three times in two separate 
experiments. 
 
3.2.2.6. Effects of phosphate on the activity of adenosine kinase 
Effects of different concentrations of phosphate were investigated by adding 0, 1, 5 and 25 mM 
of dipotassium hydrogen phosphate to the reaction mixture which had the following composition: 
80 µM adenosine, 20 mM Tris-HCl buffer, pH 7.5, 1.0 mM ATP, 0.2 mM MgCl2. The reaction 
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was started by adding 10 µl of adenosine kinase (0.078 µg). The reaction was carried out at 37 °C 
for 35 min and was stopped by heating at 99 °C for 2 minutes. An aliquot (50 µl) of the reaction 
mixture was added to a small CE vial containing 20 µl of UMP solution with final a 
concentration of 20 µM as an internal standard and 30 µl of deionized water. 
 
3.2.2.7. Adenosine kinase inhibition assay by radioactive method  
The standard radiochemical inhibition assay was performed as previously described89 with minor 
modifications. In a final volume of 100 µl containing 20 mM Tris-HCl, 0.2 mM MgCl2, 5 mM 
K2HPO4, 1 mM ATP, 1 µM [3H]adenosine and different concentrations of the inhibitor, the 
reaction was initiated by the addition of 10 µl of adenosine kinase enzyme (ca. 39 ng of protein). 
Incubation was performed for 5 minutes at 37 °C and the reaction was stopped by the addition of 
1.0 ml of cold 0.1 M aqueous lanthanum chloride solution in order to precipitate the radiolabeled 
AMP formed. The sample was kept on ice for at least 3 hours, and then filtered through GF/C 
glass fiber filters using a cell harvester (Brandel). The filter papers were washed twice with 20-25 
ml of cold water and then transferred to scintillation vials. Three ml of scintillation cocktail 
Ultima Gold (Canberra Packard, Dreieich, Germany) was added to each sample vial and 
radioactivity was counted in a scintillation counter (Tri-Carb 2100 TR, Canberra Packard).  
 
3.2.3. Capillary electrophoresis method 
3.2.3.1. Off-capillary enzymatic reaction: Method A 
CE separations were carried out using a P/PACE system (Beckman Coulter Instruments, 
Fullerton, CA, USA) equipped with a DAD detection system. The electrophoretic separations 
were carried out using an eCAP fused-silica capillary [40 cm (30 cm effective length) ✕ 75 µm 
internal diameter (I.D) ✕ 375 µm outside diameter (O.D) obtained from Beckman Coulter]. On-
line UV detection was performed in the range of 190-350 nm. The runs were performed under the 
following conditions: T = 25 0C, λmax = 260 nm, current = 95 µA, running buffer 20 mM sodium 
phosphate buffer, pH 7.5. The capillary was washed with 0.1 N NaOH for 2 min, deionized water 
for 1 min, and running buffer for 1 min before each injection. Injections were made by applying 
0.1 psi of pressure to the sample solution for 25 s, and 20 mM sodium phosphate buffer, pH 7.5, 
or pH 8.5, respectively, were used for the separations in adenosine kinase inhibition assays, while 
100 mM SDS, 30 mM borate buffer, pH 9.5 was used for substrate assays. 
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 The CE instrument was fully controlled through a personal computer, which operated with the 
analysis software 32 KARAT obtained from Beckman Coulter. The evaluation of the elec-
tropherograms was done using the same software. The temperature was kept constant at 25 °C in 
the capillary as well as in the sample storing unit. 
 
3.2.3.2. In-capillary adenosine kinase inhibition studies by EMMA with partial filling 
technique: Method B 
The electrophoretic separations were carried out using an eCAP polyacrylamide-coated fused-
silica capillary [(30 cm (20 cm effective length) x 50 µm internal diameter (I.D.) x 360 µm 
outside diameter (O.D.), obtained from CS-Chromatographie (Langerwehe, Germany)]. 96-Well 
plates were obtained from Beckman Coulter. The separation was performed using an applied 
current of -60 µA. Analytes were detected using direct UV absorbance at 210 nm, it was used to 
get high sensitivity as compared to 260 nm. The capillary was conditioned by rinsing with water 
for 2 min and subsequently with buffer (phosphate 50 mM, pH 6.5) for 1 min. Sample injections 
were made at the cathodic side of the capillary. The capillary temperature was kept constant at 37 
°C. The temperature of the sample storing unit was adjusted to 10 °C. 
 
3.2.3.3. Preparation of standard solutions of AMP and nucleosides for method validation 
Nucleosides (2-substituted adenosine derivatives) were dissolved in DMSO to obtain 10 mM 
stock solutions and AMP was dissolved in enzyme assay buffer (20 mM Tris-HCl, 0.2 mM 
MgCl2, 5 mM K2HPO4 and appropriately diluted enzyme). AMP and nucleosides were further 
diluted in enzyme assay buffer to get 1.0 mM stock solutions. The 1 mM stock solutions were 
further diluted for the standard calibration curves. For validating the method of AMP and 
nucleoside determination, 20 µM of TMP was used as an internal standard. A fused silica 
capillary was used for the separation and quantitation of AMP and the nucleosides according to 
method A. 
 
3.2.4. Biological assays 
3.2.4.1. Off-capillary adenosine kinase substrate assay: Method A 
Adenosine kinase substrate specificity assays were performed similarly as adenosine kinase 
inhibition assays, but different nucleosides were used instead of adenosine. The assays were 
carried out at 37 °C in a final volume of 100 µl. The reaction mixture contained 20 mM Tris-HCl, 
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0.2 mM MgCl2, 5 mM K2HPO4, 1 mM ATP and 200 µM of test compound (nucleoside) in 1 % 
DMSO and 20 µM of TMP was used as an internal standard. The separation conditions were 100 
mM SDS, 30 mM borate buffer, and pH 9.5. Calculating the percent  phosphorylation of 
substrates requires a calibration curve to convert the product peak areas of the reaction to the 
product concentration. Due to the unavailability of isolated reaction products, we could not obtain 
a product calibration curve directly. However, the percent  phosphorylation of substrates were 
calculated using the calibration curves of nucleosides. Because the phosphate group has not 
significant difference in UV absorption as compared to the substrates. 
 
3.2.4.2. Adenosine kinase inhibition assay by capillary electrophoresis, off-line enzymatic 
reaction: Method A  
Enzyme inhibition assays were carried out at 37 °C in a final volume of 100 µl. The reaction 
mixture contained 20 mM Tris-HCl, 0.2 mM MgCl2, 5 mM K2HPO4, 1 mM ATP and 100 µM 
adenosine without internal standard. A-134974 was again tested by using 20 µM UMP as an 
internal standard, whereas the other assay conditions were the same as without internal standard. 
10 µl of different concentrations of adenosine kinase inhibitors or test compounds were added 
and the reaction was initiated by the addition of 10 µl of the appropriately diluted enzyme. The 
mixture (final volume 100 µl) was incubated for 15 min and terminated by heating at 99 °C for 2 
min. The reaction mixture was then transferred to mini CE vials (aliquot of 50 µl) and injected 
into the CE instrument under the conditions described above. Inhibition of adenosine kinase was 
tested over a range of 7 to 8 concentrations of antagonist spanning 3 orders of magnitude to 
determine Ki values of standard compounds, while new test compounds were screened at 30 and 
3 µM concentrations, and in some cases also at 100 µM. Each analysis was repeated three times 
in two separate experiments. The Cheng-Prusoff equation91 and a KD value of 1 µM for 
adenosine was used to calculate the Ki values from the IC50 values, determined by the non-linear 
curve fitting program PRISM (GraphPad, San Diego, California, USA).  
 
             Ki   = 
                       IC50 
 
                      [Adenosine] 
      1  +      
                 Km (Adenosine) 
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3.2.4.3. Development of a high throughput screening method on 96-well plates using 
EMMA: Method B 
Before use, a new capillary was washed with deionized water for 10 minutes. Prior to analysis, 
the capillary was conditioned by a wash cycle at 40 p.s.i (1 p.s.i = 6894.76 Pa) starting with 
deionized water for 2 min, followed by a 1 min rinse with CE running buffer (K2HPO4, 50 mM, 
pH 6.5) for 1 min. After each analysis the capillary was rinsed in the same way with CE running 
buffer followed by deionized water for 2 min and 1 min, respectively. After each injection, the 
capillary ends (and electrodes) were dipped into water to prevent carry over of sample.  
 
3.2.4.4. Automation of analytical process 
Due to the 96-well plate, pressure injection was not used, because it has no lids/stoppers and it is 
not possible to use pressure for injection of sample to the capillary. Therefore vacuum injection 
was used to inject the substrate, inhibitor and enzyme assay buffer in to the capillary. 
The automation cycle consists of (i) washing with water for 2 min (40 p.s.i) (ii) equilibration with 
the CE running buffer dipotassium hydrogen phosphate 50 mM, pH 6.5 for 1 minute (40 p.s.i), 
(iii) injection of a plug of solution containing 20 mM Tris-HCl, and 0.2 mM MgCl2, pH 7.4 (iv) a 
plug of suitably diluted enzyme (v) injection of a plug of solution containing 20 mM Tris-HCl, 
pH 7.4, 0.2 mM MgCl2, 1 mM ATP, 100 µM adenosine, 20 µM UMP as an internal standard and 
various concentrations of inhibitor in the same solution. (vi) injection of a plug of solution 
containing 20 mM Tris-HCl, and 0.2 mM MgCl2, pH 7.4. The reaction was initiated by the 
application of 5 kV separation voltage (negative polarity) for 0.20 min to let the two plugs 
interpenetrate. The voltage was turned off for 5 min (zero-potential amplification) and again 
turned on at constant current –60 µA, to elute the products formed. The capillary was washed 
with deionized water 40 psi for 2 minutes and 50 mM phosphate buffer pH 6.5 as a background 
electrolyte for 1 minute before each run. 
The enzyme and substrate along with inhibitor were placed in the sample storage unit and its 
temperature was kept constant at 10 °C. At this temperature, enzyme activity remained unaffected 
for at least 24 h, therefore, there was no loss of enzymatic activity during the required time for 
collecting a series of data. Substrate and buffers used in the enzyme reaction were kept at 10 °C 
in the 96-well plate at the autosampler reservoir.  
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3.3. Results and discussion 
Extracellular levels of adenosine can be increased by blocking the phosphorylation of adenosine 
to AMP by adenosine kinase92. Adenosine kinase inhibitors have been shown to be potent 
analgesic72,73 antinociceptive and antiinflammatory agents in animal models39. Substrates for 
adenosine kinase of the protozoa Toxoplasma gondii, which is pathogenic in 
immunocompromised individuals such as patients suffering from AIDS can be used for the 
treatment of toxoplasmosis. Subversive substrates of Toxoplasma gondii, but not the human, 
adenosine kinase are preferentially metabolized to their monophosphorylated forms and become 
selectively toxic to the parasites but not their host, such as 6-benzylthioinosine53,93. Similarly 8-
aminoadenosine is a potential therapeutic agent for the treatment of multiple myeloma, for 8-
aminoadenosine is phosphorylated to its triphosphate form, which is cytotoxic for multiple 
myeloma94.  
In the present study, a capillary electrophoresis method was developed and validated for the 
separation and quantification of AMP and base-modified AMP derivatives in biological samples, 
and subsequently a rapid, convenient method for adenosine kinase assays was developed. 
Adenosine kinase isolated from bovine liver was used in inhibition and substrate assays.  
 
3.3.1. Development of a CE-based adenosine kinase assay  Method A: Off-line enzymatic 
reaction 
3.3.1.1. Method validation 
Capillary electrophoresis based methods for the quantitative determination of nucleosides and 
nucleotides25,34-38 and for monitoring their metabolism30 were previously developed in a number 
of laboratories including ours. Our previously developed methods were not suitable for the 
determination of the current series of alternative substrates for adenosine kinase because of the 
substituents at the 2-position of the nucleosides, which increased the migration times of most of 
the derivatives with respect to adenosine. Therefore, we optimized the separation buffer 
concentration and pH, which decreased the migration time. For the nucleosides a 30 mM borate 
buffer in the presence of 100 mM SDS, pH 9.5, was found suitable for the substrate assay. This 
buffer decreased the migration time and improved the resolutions of the peaks. For the 
quantitative determination of the reaction products of adenosine kinase, a fused-silica capillary 
was used. In this case the products of the enzymatic reaction (nucleotides: AMP, ADP and excess 
of ATP along with adenosine) move towards the cathodic side. In case of inhibition assays, for 
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high resolution and fine peak shape 20 mM potassium phosphate buffer, pH 7.4, was used for 
AMP method validation, later on, UMP was used as an internal standard to quantify the 
enzymatic product (AMP), and the method was further improved by increasing the pH of the 
running buffer from 7.4 to 8.5, which increased the negative charge on the capillary surface and 
hence decreased the migration times.  
The method for the determination of nucleosides was validated with respect to specificity, linea-
rity, and limits of quantitation, detection and precision. A known concentration of TMP was used 
as an internal standard (I.S.) for nucleosides because UMP as an internal standard co-migrated 
with ADP when borate buffer was used for the separation. Therefore, TMP was employed as an 
internal standard for substrate assays.  
 
3.3.1.2. Limit of detection, quantitation and precision of migration time 
The determination of Ki values of adenosine kinase inhibitors was achieved by measuring the 
corrected peak area of AMP formed during the enzymatic reaction, while the percentage of 
phosphorylation of nucleosides was calculated by measuring the corrected peak area of 
nucleotides. For substrate assays we did not have the phosphorylated products as standards to 
generate calibration curves for the measurement of phosphorylated product of the enzymatic 
reaction. Therefore, we determined the calibration curves using the nucleosides and from 
calibration curves of nucleosides the amount of nucleotides were determined because phosphate 
groups neither have any effect on the maximum absorption wavelength nor the molar absorption 
coefficient.  
For the determination of linearity and the limit of detection and quantitation, calibration curves of 
standard solutions were obtained from 5 to 6 different concentrations of AMP (2.0, 5.0, 10.0, 
20.0, 30.0, and 40.0 µM) and nucleosides (2.0, 5.0, 10.0, 20.0, and 40.0 µM). The limit of 
detection (LOD) calculated at a signal-to-noise ratio equal to 3 was found to be between 4.7 and 
1.4 µM for the various nucleosides, and for AMP it was 1.6 µM (see Table 3.1). Good linearity 
was found in the range from the compounds' lowest measured concentration within the linear 
range to the highest concentration at 40 µM. The limit of quantitation (LOQ) calculated at a 
signal-to-noise ratio equal to 10 was found in the range of 5.2 to 15.3 µM (see Table 3.1). The 
precision of the migration time was investigated with respect to repeatability. Each standard was 
run 5 times. Standard deviation and variation coefficients of migration times were determined. 
There was less difference in migration times of fast migrating nucleosides while relatively more 
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difference was observed in migration times for slower migrating nucleosides. The relative 
standard deviation of migration times for AMP and compounds 3.2.4 and 3.2.6 was low, 1.7, 1.3, 
and 1.2 %, respectively, while it was only slightly higher for compounds 3.2.2, 3.2.3 and 3.2.8, 
being 3.5, 2.9, and 3.0 %, respectively. The results are summarized in Table 3.1. 
 
3.3.1.3. Linearity of calibration curve and recovery 
To determine the linearity of calibration curve and recovery rates, standard solutions of 2.0, 5.0, 
10.0, 20.0, and 40.0 µM concentrations of AMP and nucleosides were run, and linear 
relationships with regression coefficients (R2) in the range of 0.994 to 0.999 were found by 
plotting corrected peak areas against concentrations for AMP and all nucleosides. The found con-
centrations were calculated from the obtained linear regression curves and plotted against the 
concentrations originally present in the standard solutions to obtain the recovery equations. Re-
covery rates were found to be high, 98.8-99.9% for AMP and all nucleosides (Table 3.1). 
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Table 3.1. Method validation parameters for AMP and adenosine derivatives (nucleosides) using 20 µM TMP as an internal standard for 
nucleosides and 20 µM UMP for AMP. 
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2-(4-Benzylpiperazin-1-yl)-
adenosine
2-(Pyrrolidin-1-yl)-
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adenosine
3.2.1 3.2.2 3.2.3 3.2.4
3.2.6 3.2.7 3.2.8
2-Benzylamino-
adenosine
3.2.5
 
Compound  
 
AMP        3.2.2 3.2.3 3.2.4 3.2.5 3.2.6 3.2.7 3.2.8
Limit of detection (µM) ± SD 1.6 ± 0.2 3.4 ± 0.2 2.4 ± 0.2 4.7 ± 0.2 4.1 ± 0.2 1.7 ± 0.1 1.8 ± 0.2 1.4 ± 0.1 
Limit of quantification (µM) ± 
SD 
5.9 ± 0.4 13.0 ± 0.3 9.1 ± 0.4 7.3 ± 0.3 15.3 ± 0.5 6.4 ± 0.2 6.7 ± 0.3 5.2 ± 0.2 
% Recovery rate ± SD 99.3 ± 0.52 98.2 ± 0.51 99.1 ± 0.54 97.3 ± 0.42 96.7 ± 0.64 95.6 ± 0.60 98.5 ± 0.31 99.5 ± 0.21 
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RSD (%) of Recovery rate 3.11 7.2 5.2 8.5 8.1 8.5 5.4 5.5 
R2 of Recovery rate 0.998 0.974 0.997 0.988 0.991 0.992 0.998 0.999 
Coefficient of correlation; R2 0.999        0.990 0.998 0.994 0.995 0.996 0.999 0.999
Mean value of migration time 
(min) ±  SD (n= 6) 
9.50 ± 0.14 8.60 ± 0.30 10.4 ± 0.3 7.60 ± 0.1 19.73 ± 0.34 6.90 ± 0.08 5.68 ± 0.08 12.16 ± 0.36 
RSD of migration time (%) 1.5 3.5 2.9 1.3 1.7 1.2 1.4 3.0 
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3.3.2. Purification and characterization of adenosine kinase from bovine liver  
Adenosine kinase was purified from bovine liver using ion exchange and affinity chromatogra-
phy, and subsequent concentration was achieved with Amicon centrifugal filter devices. During 
ion exchange chromatography, positively and negatively charged contaminating proteins bind to 
CM-cellulose and DEAE-cellulose, respectively, while adenosine kinase does not bind under 
these conditions. Ion exchange chromatography removed most of the contaminating proteins. 
Subsequent affinity chromatography played the crucial role in purifying adenosine kinase by 
binding the enzyme to the 5-AMP-sepharose column material whereas the other proteins were 
eluted. Adenosine kinase was finally eluted with a buffer containing 5 mM ATP-Mg and 5 mM 
adenosine. The molecular weight of the enzyme was estimated as 38 kDa by SDS-
polyacrylamide gel electrophoresis. This value was similar to published values for the enzyme 
from bovine liver89, human liver95, human placenta41, rat brain96, Leishmania donovani46 and 
mycobacterium tuberculosis97, but slightly different from that found in bovine adrenal medulla 
(40 kDa), determined by the same method.  
Km and Vmax values of the isolated enzyme were determined by the standard radioactive method 
using constant concentrations of 0.2 mM MgCl2 and 1 mM ATP. The Km and Vmax values of the 
adenosine kinase preparation were found to be 1.03 µM and 3.1 mM AMP/min/mg protein, 
respectively, at pH 7.4 (Figure 3.2.2). The Km value for adenosine, determined in this study was 
very similar to the literature value for adenosine kinase from the same source89.  
The activity of adenosine kinase as a function of various concentrations of MgCl2 had been 
examined in previous studies69,45,95. Mg2+ was found as a co-substrate of this enzyme. In our 
studies, adenosine kinase from bovine liver showed maximal activity at a concentration of 0.2 
mM of MgCl2. After increasing the concentration of MgCl2 above this limit, there was no further 
increase in the activity of adenosine kinase, whereas lower concentrations of MgCl2 had reduced 
enzymatic activity (Figure 3.2.3). Adenosine kinase did not show any activity in the absence of 
magnesium, it showed an absolute requirement for magnesium. The dependence of the AK 
activity on Mg2+ and ATP suggests that the ATP-Mg complex is the true substrate for the 
enzyme. In a previous study98, an excess of free Mg2+ and ATP4- both have been shown to 
produce strong inhibition of AK. We did not find any inhibition by Mg2+ up to concentrations of 
0.3 mM. Higher concentrations of Mg2+ were not tried due to separation problems by CE.  
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Figure 3.2.2. Plot of initial adenosine concentration with respect to the reaction velocity (mM of 
AMP produced in one minute per mg of enzyme) for the determination of Km and Vmax  values by 
the standard radioactive method. Enzyme activity was determined at pH 7.5 using 1 mM ATP, 0.2 
mM MgCl2 and various concentrations of [3H]adenosine. Km was 1.03 µM, Vmax  was 3.1 mM 
AMP/min/mg protein. 
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Figure 3.2.3. Effects of different MgCl2 concentrations on the activity of bovine liver adenosine 
kinase at a fixed concentration of ATP, determined by capillary electrophoresis. Km was 
determined at pH 7.5 using 1 mM ATP, 200 µM adenosine and various concentrations of MgCl2. 
The separation conditions were 20 mM phosphate buffer, pH 7.41, a fused silica capillary, 40 cm 
length (30 cm to the detector), 75 µm I.D.; 95 µA; 25 °C; detection at 260 nm; pressure injection. 
 
Previous studies showed that the catalytic activity of adenosine kinase could be greately affected 
by the presence of inorganic phosphate74. Thus, we investigated the effects of increasing 
phosphate concentrations (from 1 to 25 mM) at pH 7.5 on adenosine kinase from bovine liver. 
We did not find any change in the activity of adenosine kinase with increased concentrations of 
phosphate (data not shown). In previous reports69,74,89 it was found that phosphate markedly 
influenced the activity of adenosine kinase from Chinese hamster ovary (CHO) cells, bovine 
liver, yeast and Leishmania donovani. It was suggested that inorganic phosphate enhanced the 
reaction rate along with an improved affinity of the enzyme for adenosine by formation or 
stabilization of an enzyme-adenosine-ATP transition state complex. The catalytic activity of 
Escherichia coli recombinant and bovine liver AK was almost completely dependent on the 
presence of inorganic phosphate at pH 6.2. However, at pH 7.4, the activity of AK was not 
completely dependent on the presence of inorganic phosphate, but Vmax was doubled in the 
presence of 20 mM inorganic phosphate74. Similar studies were conducted with AK from various 
rat tissues99, which did not show any effect of inorganic phosphate on Km and Vmax at pH 6.0 and 
pH 7.4 in the presence of various concentrations of Mg2+ and ATP. We used 80 µM of adenosine 
to investigate the effects of phosphate on bovine liver adenosine kinase, a concentration of 
adenosine much higher than its Km value. It is possible that at lower concentrations of adenosine, 
phosphate would show an effect.  
 
3.3.3. Investigation of alternative substrates 
A series of nucleosides (2-substituted adenosine derivatives, Table 3.1) were tested as potential 
substrates of bovine liver adenosine kinase. The nucleosides were used at a concentration of 200 
µM in the presence of 0.2 mM MgCl2 and 1 mM ATP. Several of these adenosine derivatives 
were phosphorylated to the corresponding monophosphates by the enzyme (Table 3.2). All of the 
2-substituted 2-aminoadenosine derivatives were poorer substrates of adenosine kinase than the 
natural substrate adenosine. 
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A pyrrolidinyl- and an isopropylamino-substitution were best tolerated by adenosine kinase; 
while smaller (ethylamino) or larger 2-substituents (benzylamino, cyclohexylamino, 4-
benzylpiperazinyl) resulted in a lower degree of phosphorylation. The best substrate of the 
present small series of 2-substituted adenosine derivatives was a 2,N6-disubstituted adenosine 
derivative, 2-isopropylamino-N6-isopropyladenosine 3.2.4, exhibiting 81% of phosphorylation in 
comparison with adenosine (set at 100%, see Figure 3.2.5). The phosphorylation of adenosine 
analogs, including 2-chloroadenosine, N6-cyclohexyladenosine, and N6-R-
phenylisopropyladenosine had been studied; it was observed that these adenosine derivatives are 
phosphorylated and thus would likely be incorporated into nucleic acids100. 
With this newly developed method it is easy to determine the phosphorylated products 
(nucleotides). Electrophoretic mobility of the nucleoside analogs changed after phosphorylation 
by adenosine kinase and product peaks appeared in the electropherogram with similar migration 
time as that of AMP.  
 
 
 
 
 
 
Figure 3.2.5. Typical electropherogram of AK enzyme substrate assay with 20 µM TMP as an 
internal standard in enzyme assay buffer. Concentration of adenosine derivative 3.2.4 was 200 
µM in 1 % DMSO, incubation time 10 min, concentration of AK 0.078 µg. The separation 
conditions were 100 mM SDS, 30 mM borate buffer, pH 9.5, fused silica capillary, 40 cm length 
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(30 cm to the detector), 75 µm I.D.; 95 µA; 25 °C; detection at 260 nm; pressure injection (3.2.4 
= 2-Isopropylamino-N6-isopropyadenosine, 3.2.4-MP = 2-Isopropylamino-N6-
isopropyadenosine-5'-monophosphate). 
 
Table 3.2. Percent phosphorylation of 2-substituted 2-aminoadenosine derivatives by adenosine 
kinase in comparison with the physiological substrate  
 
No. Compound Phosphorylation (%)a 
(n = 3) 
1 
  
Adenosine 
 
 
100 ± 2 
2 2-Ethylaminoadenosine 3 ± 1 
3 2-Isopropylaminoadenosine 4 ± 0 
4 2-Isopropylamino-N6-isopropyladenosine 81 ± 3 
5 2-Benzylaminoadenosine 4 ± 0  
6 2-Cyclohexylaminoadenosine  3 ± 0  
7 
 
2-(Pyrrolidin-1-yl)adenosine 
 
53 ± 2  
 
8 
 
2-(4-Benzylpiperazin-1-yl)adenosine 
 
 3 ± 0  
 
 
a Percentage of phosphorylated product obtained with respect to the natural substrate adenosine 
set at 100%. Quantitative determination was achieved by standard calibration curves of 
corresponding nucleosides. For reaction conditions see Figure 3.2.5. 
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3.3.4. Investigation of adenosine kinase inhibitors by off-capillary method 
Inhibition of adenosine kinase was determined by a range of concentrations of inhibitors, in the 
presence of a fixed amount of adenosine (100 µM). The Ki values of the standard inhibitors tested 
in this study were very close to the Ki values obtained by the standard radiometric method (Table 
3.3).  
ABT-702 is a non-nucleoside adenosine kinase inhibitor, 5-iodotubericidin (5-IT) and A-134974 
are adenosine analogs (for structures see Table 3.3). ABT-702 is an orally active antinociceptive 
agent and more potent than 5-IT55. A-134974 was the most potent compound among all 
adenosine kinase inhibitors tested. Using bovine liver adenosine kinase and the newly developed  
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Figure 3.2.6. Concentration-dependent inhibition of AK by the standard inhibitors A-134974 (▼,), 
ABT-702 (■) and 5-iodotubercidin (▲) determined by incubation of the reaction mixture outside 
the capillary by capillary electrophoresis at pH 7.5 using 1 mM ATP, 0.2 mM MgCl2 and various 
concentrations of inhibitor. The separation conditions were 20 mM phosphate, pH 7.41, fused 
silica capillary, 40 cm length (30 cm to the detector), 75 µm I.D.; 95 µA; 25 °C; detection at 260 
nm; pressure injection. 
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CE method, concentration-dependent inhibition of adenosine kinase by the standard inhibitors 
was observed (Figure 3.2.6). All three standard inhibitors were tested without internal standard, 
but later on A-134974 was also tested in the presence of an internal standard. The use of internal 
standard did not result in significantly different Ki value, it only let to a moderate improvement of 
the relative standard deviation (see Table 3.3). 
 
Table 3.3. Comparison of Ki values for standard AK inhibitors obtained with the new capillary 
electrophoresis (CE) methods and with the classical radioactive method. All values are means ± 
S.E.M of three separate experiments. 
  
 
 
 
 
 
 
Ki [nM] ± SEM Inhibitor 
CE method  
bovine liver 
AK 
Radioactive 
method bovine 
liver AK 
Radioactive 
method human  
AK 
Radioactive method 
rat brain cytosolic 
AK 
ABT-702   
 
5-Iodotubercidin  
  (5-IT) 
A-134974 
1.4 ± 0.04a 
1.7 ± 0.07b 
30.6 ± 1.7a 
 
0.090 ± 0.006a,d 
0.097 ± 0.004a,e 
0.060 ± 0.031b  
3.40 ± 0.03 
 
29.0 ± 6.1 
 
0.070 ± 0.006 
3.0 ± 0.855  
 
4061, 26 ± 6101 
 
0.06 ± 0.0753  
1.7 ± 0.555 
 
9.3 ± 1.555 
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ABT-702 5-IT A-134974
a) Off-line method 
b) EMMA 
c) N.D = not determined 
d) Without I.S. 
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e) With I.S. 
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Figure 3.2.7 A. Typical electropherogram of AK enzyme control assay (without inhibitor). 
Concentration of adenosine was 100 µM and 20 µM UMP was used as an internal standard. The 
separation conditions were 20 mM phosphate, pH 7.5, fused silica capillary, 40 cm length (30 cm 
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to the detector), 75 µm I.D.; 95 µA; 25 °C; detection at 260 nm; pressure injection; normal 
polarity. 
  
B. Typical electropherogram of adenosine kinase enzyme inhibition assay. Concentration of A-
134974 was 1.0 µM, same separation conditions as A. The concentration of the inhibitor A-
134974 was below the detection limit of CE, therefore, the peak for A-134974 did not appear in 
the electropherogram.  
 
A typical electropherogram from the adenosine kinase control assay is shown in Figure 3.2.7A in 
which 100 µM of adenosine was used without inhibitor. The percentage conversion of substrate 
into product was in the range of 15-20 %. It showed a larger peak of AMP, while the second 
electropherogram of a typical adenosine kinase inhibition experiment is shown in Figure 3.2.7B, 
in which 1.0 µM of A-134974 was present. In that electropherogram the peak size for AMP is 
significantly smaller compared to the control assay. The product peak (AMP) eluted within less 
than 8 minutes using a fused silica capillary and sodium phosphate buffer, pH 7.5, while the 
neutral molecule adenosine migrated with the EOF or slightly later depending on the conditioning 
of the capillary. In the normal polarity mode AMP comes frist than the UMP. Later on, the 
method was made even faster by increasing the pH value of the sodium phosphate buffer from 
7.5 to 8.5. With an increase in pH of the running buffer, the surface of the silica capillary is 
deprotonated to a larger extent leading to a decreased migration time of the nucleotides. 
 
3.3.5. Electrophoretically mediated microanalysis with the partial-filling technique 
In the EMMA method, the capillary was first filled with a given background electrolyte. 
Subsequently, plugs of Tris-HCl buffer, pH 7.5, enzyme solution, substrate solution, Tris-HCl 
buffer, pH 7.5, and of the background electrolyte were injected into the capillary. For schematic 
illustration of the combination of EMMA with a partial filling technique see Figure 3.2.8. The 
slowly moving enzyme was injected first followed by the faster moving substrate. Small buffer 
plugs were injected before the enzyme and after the substrate to shield the enzymatic reaction 
from the background electrolyte. These buffer plugs contained Mg2+ ions which are necessary for 
the enzymatic reaction to proceed. Initially, the classical EMMA arrangement was tried out 
without partially filling the capillary but the enzymatic product was too little to be measured. 
Upon the application of the 5 kV potential, the two plugs will interpenetrate and after 0.20 min 
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the voltage was turned off to allow the reaction to continue in the absence of an electric field. 
This zero-potential amplification was necessary to accumulate enough product to detect it 
spectrophotometrically. Internal standard (I.S.) was used to compensate for minor variability in 
injection volumes, because nanoliter volume plugs of substrate and inhibitor were used. In the 
EMMA method a neutral capillary was used to prevent the adsorption of enzyme onto the  
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Separation buffer Plug of assay buffer   
Detector 
 III
 II
 I
 
Figure 3.2.8. Schematic illustration of the different steps of the in-capillary reaction assay. (I) a 
plug of assay buffer followed by a plug of enzyme and a plug of substrate, and again a plug of 
assay buffer are introduced hydrodynamically into the capillary; (II) the voltage is turned on and 
the fast migrating substrate plug penetrates the slow migrating enzyme plug. When the two plugs 
have merged, the voltage is turned off (zero-potential amplification) and incubation starts; (III) 
product is generated during the reaction and the compounds are swept towards the detector upon 
the subsequent application of the voltage. 
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capillary wall because in a fused silica capillary the proteins can adsorb onto the capillary 
surface, which may lead to an increase in migration time and to current breakdown. A typical 
electropherogram of the in-capillary enzymatic reaction, using 50 mM phosphate buffer, pH 6.5 
as a background electrolyte is shown in Figure 3.2.9. By using a coated capillary and reverse 
polarity mode the elution order of the nucleotides becomes reversed. UMP comes first, then 
AMP. The standard adenosine kinase inhibitors ABT-702 and A-134974 were tested by this 
method, and Ki values of the inhibitors were found to be very close to the Ki values obtained by 
the standard radiometric method and the off-capillary enzymatic reaction method (Table 3.3).  
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paration conditions as A.  
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3.4. Summary  
A fast and convenient capillary electrophoresis (CE) assay was developed for the screening of 
adenosine kinase inhibitors and substrates. The method employing a fused-silica capillary and 
normal polarity mode provided good resolution of substrates and products of the enzymatic 
reaction and a short analysis time of less than 15 min. After stopping the enzymatic reaction by 
heating, the samples were injected by pressure and detected by their UV absorbance at 260 nm. 
Constant current (95 µA) was applied, and a phosphate buffer (pH 7.5 or pH 8.5) was used for 
the separations. Adenosine kinase isolated from bovine liver was used for these experiments. 
Dose response curves and calculated Ki values for standard antagonists obtained by CE were in 
excellent agreement with data obtained by the standard radioactive assay. In contrast to the 
radiometric assay, the CE assay can easily be used for investigating adenosine kinase substrates 
as well. A 2,N6-disubstituted adenosine derivative, 2-isopropylamino-N6-isopropyladenosine, was 
found to be a good substrate (81 % of phosphorylation with respect to adenosine = 100 %), while 
2-(ar)alkyl-substituted 2-aminoadenosine derivatives without an additional N6-substituent were 
poorer substrates, e.g. 2-ethylamino-, 2-benzylamino-, and 2-cyclohexylaminoadenosine showed 
only less than 5 % phosphorylation with respect to adenosine (100 %). Capillary electrophoresis-
based enzyme assays can be used for high throughput screening of potential adenosine kinase 
inhibitors and substrates. They may prove to be useful not only for adenosine kinase, but for 
kinase assays in general.  
Based on the off-line assay, an in-line adenosine kinase inhibition assay was developed by a 
methodology known as electrophoretically mediated microanalysis (EMMA). All the different 
steps (i.e. mixing, incubation, separation and in-line quantitation) are combined in the capillary, 
which is used as a microreactor for the enzymatic reaction. In EMMA after hydrodynamic 
injection of a plug of solution containing 20 mM Tris-HCl, and 0.2 mM MgCl2, pH 7.4, a plug of 
suitably diluted enzyme was injected, followed by a plug of solution containing 20 mM Tris-HCl, 
pH 7.4, 0.2 mM MgCl2, 1 mM ATP, 100 µM adenosine, and 20 µM UMP as an internal standard 
along with various concentrations of inhibitor in the same solution. The reaction was initiated by 
the application of 5 kV separation voltage (negative polarity) for 0.20 min to let the two plugs 
interpenetrate. The voltage was then turned off for 5 min (zero-potential amplification) and again 
turned on at a constant current of –60 µA, to elute the products formed. The method employing a 
polyacrylamide-coated capillary of 20 cm effective length and reverse polarity mode provided 
good resolution of substrates and products within a short separation time of less than 7 min. A 50 
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mM phosphate buffer (pH 6.5) was used for the separations and the products were detected by 
their UV absorbance at 210 nm. By in-capillary reaction, the scale of the enzymatic reaction was 
radically reduced to the nL scale as compared to off-line analysis of the reaction carried out in a 
microcentrifuge tube. Moreover, since the capillary is used as a reaction vessel, all the assay steps 
(mixing, reaction, separation, and quantitation) are combined in a fully automated nanoscale 
activity assay. This process was carried out automatically using a temperature-controlled 
autosampler in order to eliminate routine handling and to speed-up the process. The Ki values for 
standard antagonists obtained by EMMA were in good agreement with those obtained using an 
off-line CE assay.  
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Chapter 4. Capillary electrophoresis assays of thymidine kinase  
  
4.1. Introduction 
Thymidine kinase (TK) is a key enzyme in the salvage pathway of nucleotide metabolism 
catalyzing the transfer of the terminal phosphate group of ATP to the 5’-hydroxyl group of 
thymidine (dT) and thus yielding thymidine monophosphate (dTMP). The product dTMP is 
subsequently phosphorylatad by nucleoside kinases to dTTP, which is used for the synthesis of 
DNA102-104. In mammalian cells the total TK activity is expressed by two genetically 
distinguishable isoenzymes: TK-1 and TK-2. TK-1 is cytosolic and is expressed only in S-phase 
cells and TK-2 is considered to be localized in mitochondria105,106. Of the two isoenzymes TK-1 
is the most studied and the one generally referred to when talking about TK activity. As cytosolic 
activity (TK-1), which increases with cellular DNA synthesis, whereas the mitochondrial activity 
(TK-2) remains relatively constant during various phases of the cell cycle107, it is assumed that 
TK-1 plays a role in the replication of DNA. In a variety of cancer and virus-infected cells the 
expression of TK-1 differs from the expression in normal cells. Generally, the level of TK 
activity is increased. Cancer cells with a changed ratio of TK-1 and TK-2, e.g. expression of TK-l 
in quiescent malignant cells and/or expression of TK enzymes with biochemical properties 
different from the normal counterparts have been observed108. In contrast to the cellular enzyme, 
the viral thymidine kinase from Herpes simplex virus (HSV) type 1 differs condiderably from the 
human host cell isoenzyme109 and exhibits a broad range of acceptance for nucleosides110,111. 
HSV1 TK is a homodimer with 376 residues per subunit. The constituent subunits display the 
general α/β folding pattern. A central five-stranded parallel β-sheet is flanked on either side by 
helices. The central five-β-strand domain is referred to as the CORE domain. The LID domain of 
HSV1 TK consists of only eight residues, reminiscent of other small variants of nucleoside 
monophosphate (NMP) kinases112 (Figure 4.1). Nucleoside analogs are modified nucleosides that, 
when phosphorylated by nucleoside kinases inhibit further DNA synthesis either by incorporation 
into DNA or by inhibition of DNA polymerases113,114. A very efficient application of nucleoside 
analogs is seen in the treatment of Herpes Simplex Virus type 1 infections. Herpes Simplex virus 
encodes for its own TK, which can phosphorylate the nucleoside analog acyclovir, an acyclic 
guanosine analog, while the human host TK cannot. Only cells infected with Herpes simplex 
virus will be affected – and killed - from the treatment with acyclovir and analogs. 
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ADP 
ADP 
TMP 
 
Figure 4.1. Ribbon representation of the symmetric HSV1 TK dimer with bound ADP and dTMP. 
The CORE domain is depicted in blue, the TMP-binding domain in red, and the LID domain in 
yellow. The additional residues (250-322) are shown in green. Substrate and cofactor are 
depicted as cyan ball and stick models.  
 
4.1.1. Mechanism of action of antiviral drugs 
More than 8 known viruses exist within the herpes virus family, the most important pathogenic 
being HSV-1 and -2115. Antiviral drug design could, in principle, be targeted at either viral 
proteins or cellular proteins. The viral approach is likely to yield more specific, less toxic 
compounds, with a narrow spectrum of antiviral activity and a higher likelihood of virus drug-
resistance development, whereas the second approach might afford antiviral compounds with a 
broader activity spectrum and less chance of resistance development, but higher likelihood of 
toxicity. Both routes are worth exploring, the preferred route being dictated by both the nature of 
the virus and the targets that the virus or its host cell has to offer116. Despite the impressive safety 
record and efficacy of nucleoside analogs in general, and acyclovir in particular, for the treatment 
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of diseases caused by herpes viruses, a number of problems are associated with their use. As 
nucleoside analogs are incorporated into DNA and are chain terminators, they are potentially 
mutagenic. However, acyclovir is not mutagenic115. The treatment of choice for diseases caused 
by herpes viruses is acyclovir (ACV), which is a nucleoside analog of deoxyguanosine that has to 
be phosphorylated three times. The first phosphorylation is completed by the virally encoded 
thymidine kinase (TK) protein which allows ACV to become active only in virus-infected cells. 
The second and third phosphorylations are achieved by cellular thymidylate kinases.  
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Figure 4.2. Mechanism of action of antiviral drugs active against HSV 
 
4.1.2. Nucleoside analogs as substrates of thymidine kinase 
Thymidine kinase catalyzes the phosphate transfer from ATP to thymidine (dT) in the presence of 
Mg2+ thus yielding thymidine monophosphate (dTMP) and ADP. Herpes simplex virus type 1 
encodes for its own multifunctional TK. Unlike the very specific human cytosolic TK (TK1), it is 
able to phosphorylate pyrimidine as well as purine analogs117. At present, all the antiviral agents 
that are available for the treatment of herpes virus infections are nucleoside analogs: either 
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acyclic guanosine analogs (aciclovir (ACV), penciclovir (PCV), ganciclovir (GCV),) or their oral 
prodrug forms (valaciclovir (VACV), famciclovir (FCV) and valganciclovir) or thymidine 
analogs such as brivudin (E-5-(2-bromovinyl)-2'-deoxyuridine (BVDU), all being substrates of 
herpes virus TK116,118. Aciclovir is the drug of choice against HSV infections. All of these 
compounds target the viral DNA polymerase, and before they can interact with viral DNA 
synthesis, however, they need to be phosphorylated intracellularly to the triphosphate form114. 
 
4.1.3. Non-nucleoside analog inhibitors of herpes simplex virus 1 thymidine kinase 
Nucleoside analogs can successfully cure the peripheral manifestations of viral infections, but are 
unable to prevent the initial viral infection or eradicate latent viral foci in neuronal cells. 
Aciclovir has a good potency as an antiherpetic drug, although it has rather poor efficacy, being a 
weak substrate for TK, its triphosphate exhibits a strong chain-terminating effect. As part of the 
search for novel TK inhibitors, which could be useful chemotherapeutic agents to prevent 
recurrent herpes infections, a group of compounds based on N-phenyl derivatives of guanine have 
been developed, including (N2-[m-(trifluoromethyl)phenyl]guanine (mCF3-PG))119-121. Some of 
these compounds display good competitive inhibition. The most potent inhibitor of HSV1 TK 
among the 9-substituted derivatives, 9-(4-hydroxybutyl)-N2-phenylguanine (HBPG), was a 
competitive inhibitor with respect to the substrate thymidine but was not a substrate for the 
enzyme121. The nucleoside analogs 5-substituted-6-aza-2'-deoxyuridines inhibit the 
phosphorylation of thymidine by HSV-1 TK but have no effect on the corresponding human 
enzyme122. The 5'-O-Trityl derivative of thymidine has been found to be a non-substrate inhibitor 
of HSV-1 TK123. Acyclovir (ACV) targets viral DNA herpes virus (HSV) polymerases. Before it 
can interact with viral DNA synthesis, it needs to be phosphorylated intracellularly, in three steps, 
into the triphosphate form. The first phosphorylation step is ensured by the HSV-encoded 
thymidine kinase (TK), and is therefore confined to virus-infected cells. 
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Figure 4.2. Examples of antiviral nucleoside analogs acting by a chain termination 
mechanism116.  
 
Cidofovir, (S-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine; HPMPC); Adefovir (9-(2-
phosphonylmethoxyethyl)adenine; PMEA); AZT, azidothymidine; DP, diphosphate; dThd, 
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thymidine; MP, monophosphate; NDP, nucleoside 5'-diphosphate; PR, 5-phosphoribose; PRPP, 
5-phosphoribosyl-1-pyrophosphate; TP, triphosphate. 
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4.2. Development and validation of a capillary electrophoresis method for the 
characterization of herpes simplex virus type 1 thymidine kinase, its antiviral 
substrates and inhibitors 
 
4.2.1. Introduction 
Thymidine kinase (EC 2.7.121) is the key enzyme in the pyrimidine salvage pathway catalyzing 
the transfer of the γ-phosphate from ATP to thymidine to produce thymidine 5´-monophosphate 
in the presence of Mg2+ (see Figure 4.3)107.  
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Figure 4.3. Enzymatic reaction of thymidine kinase  
 
Herpes simplex virus type 1 encodes for an own thymidine kinase (HSV-1 TK), which has a very 
broad substrate specificity; it phosphorylates a wide range of substrates, including 
acycloguanosines (e.g. acyclovir, ganciclovir, penciclovir) and uracil derivatives (e.g. 2'-fluoro-2'-
deoxy-1-arabinofuranosyl-5-iodouracil (FIAU))102,124,125. Nucleoside analogs are phosphorylated 
in three steps in HSV-1 infected cells. The first phosphorylation is completed by the virally 
encoded thymidine kinase, while the second and third phosphorylations to the corresponding di- 
and tri-phosphates are achieved by cellular kinases. Antiviral nucleoside triphosphate analogs act 
by competitive inhibition of viral DNA polymerase and they may act as DNA chain 
terminators126. In animal tumour models HSV-1 TK has been used extensively in gene therapy. 
Improvements in sensitivity of the HSV1-tk reporter gene imaging assay can be achieved either 
(i) by identifying substrates that exhibit higher Vmax/Km for HSV1-TK or (ii) by engineering TK 
enzyme(s) with improved Vmax/Km for a particular reporter substrate. Decreased Vmax/Km of 
HSV1-TK for thymidine (an endogenous competitor) also should improve HSV1-tk reporter gene 
assay sensitivity. It has been reported that mutant HSV1-TK enzymes that exhibit greater 
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cytotoxicity, due to increased substrate Vmax/Km, could also be better reporter genes for in vivo 
imaging of gene expression, in combination with positron-labeled acycloguanosines127. 
The compounds among the antiherpetic drugs that have demonstrated efficacy in the treatment of 
herpes virus infections in animals and humans are 9-[(2-hydroxyethoxy)methyl]guanine 
(acyclovir, ACV), 9-[(1,3-dihydroxy-2-propoxy-methylguanine (DHPG, ganciclovir), (E)-5-(2-
bromovinyl)-2’-deoxuridine (BVDU), and 1-(2-deoxy-2-fluoro-β-D-arabinofuranosyl)-5-
methyluracil (FMAU)112,118,124. These nucleoside analogs have been identified as substrates of the 
herpes simplex virus type 1 encoded thymidine kinase (HSV-1 TK), but are not recognized as 
substrates by cellular kinases128. Endogenous thymidine within the cell competes with the 
nucleoside analogs for the active site. The rate of phosphorylation by thymidine kinase at a 
specific concentration of substrate can be determined by two ways, Km (binding affinity) and Vmax 
(maximum velocity). At low concentrations (equal to Km) of substrate, the binding affinity plays 
a key role, but at higher concentrations, Vmax is the key factor in determinig the 
phosphorylation129. 
For HSV-1 TK determination of specificity (Kcat/Km) of prodrug toward natural substrate 
thymidine had been performed by several methods, including radioisotopic130-132, HPLC103,104,133 
and spectrophotometric134 assays. Unfortunately, these methods are not suitable for the 
determination of thymidine kinase in complex biological samples. Radiometric assays require 
tedious procedures and the use of radiolabeled substrates125. As the reaction proceeds, aliquots 
are removed and measured by liquid scintillation counting103,135 and also there are risks of 
contamination and radiation exposure. In addition to the requirement for radioisotopes, the above 
method requires sampling and analysis of multiple single points per assay, therefore, these are 
complicated and hence difficult to use for kinetic studies of the substrates of the enzyme. High 
performance liquid chromatography among the separation techniques has been used for the 
characterization of new antiviral lead compounds but this technique suffers from relatively high 
prices of its consumables and also biological matrices which have a tendency to shorten the 
column life time. Spectrophotometric methods134 are also employed for the determination of Kcat 
values of HSV-1 TK substrates. These are not suitable because of the use of two enzymes which 
require their isolation and purification. It is a time-consuming method and not enough sensitive. 
It also requires high amounts of materials and is prone to interference from other biological 
matrices. 
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Capillary electrophoresis (CE) is an excellent and easy analytical technique offering the 
advantage of high resolution, shorter separation times and consumes extremely small amounts 
(nanoliters) of sample; in addition, there is no need of radiolabeled substrate. CE offers a high 
capability of automatization and easily to adopt in high-throughput screening (HTS) assays. CE 
assays are highly advantageous when the antiviral lead compounds are not availabe in 
radiolabeled form. It has previously been successfully used for the determination of Kcat, Km and 
Vmax of UDP-N-acetylglucosamine-2-epimerase/N-acetylmannosamine kinase136.  
In the present study, we have developed a capillary electrophoresis method that allows to 
measure substrates and potential inhibitors for thymidine kinase within a few minutes with high 
accuracy and reproducibility. The new method is suitable for the high-throughput screening of 
test compounds. 
 
4.2.2. Materials and methods 
 
4.2.2.1. Materials 
 Adenosine-5’-triphosphate (ATP), adenosine-5’-diphosphate (ADP), adenosine-5’-
monophosphate (AMP), thymidine (dT) and uridine-5’-monophosphate (UMP), (E)-5-(2-
bromovinyl)-2'-deoxyuridine (BVDU) and thymidine-5’-monophosphate (TMP) from Sigma 
(Steinheim, Germany). Magnesium chloride and tris(hydroxymethyl)aminomethane (Trizma 
Base) were from Sigma (Taufkirchen, Germany). The dipotassium hydrogen phosphate for the 
CE buffer was obtained from Fluka (Neu-Ulm, Germany). Ganciclovir (GCV) was purchased 
from Roche, Mannheim, Germany.  
4.2.2.2. Expression and purification of TKHSV1  
TKHSV1 was expressed as gluthathione S-transferase fusion protein in competent Escherichia coli 
BL21 using the vector pGEX-6P-2-TK. The protein was purified by gluthathione-affinity 
chromatography followed by on-column PreScission protease cleavage. Purification was 
monitored by SDS-polyacrylamide gel electrophoresis and led to a >90% pure TKHSV1. Total 
protein concentration was measured using the Bio-Rad protein assay.  
Recombinant HSV-1 viral thymidine kinase was obtained from Prof. Dr. G. Folkers and Dr. L. 
Scapozza, Institute of Pharmaceutical Sciences, Department of Chemistry and Applied 
Biosciences, Swiss Federal Institute of Technology Zürich, Switzerland. 
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4.2.2.3. Capillary electrophoresis apparatus and conditions 
A P/ACE capillary electrophoresis (CE) system MDQ glycoprotein (Beckman Coulter 
Instruments, Fullerton, CA, USA) equipped with a UV detection system coupled with diode-array 
detector (DAD) was used in this study. The CE-instrument was fully controlled through a PC, 
which operated with the analysis software 32 KARAT obtained from Beckman Coulter. The 
evaluation of the electropherograms was done using the same software. The capillary temperature 
was kept constant at 25 °C. The temperature of the sample storing unit was adjusted to 25 °C. 
 
4.2.2.4. Fused silica capillary with pressure injection: Method A 
The electrophoretic separations were carried out using an eCAP fused-silica capillary [40 cm (30 
cm effective length) x 75 µm internal diameter (I.D) x 375 µm outside diameter (O.D) obtained 
from Beckman Coulter]. On-line UV detection was performed in the range of 190-350 nm. The 
runs were performed under the following conditions: T = 25 °C, λmax = 260 nm, current = 95 µA, 
running buffer 20 mM sodium phosphate buffer, pH 7.5. The capillary was washed with 0.1 N 
NaOH for 2 min, deionized water for 1 min, and running buffer for 1 min before each injection. 
Injections were made by applying 0.1 psi of pressure to the sample solution for 25 s. Sodium 
phosphate buffer (20 mM), pH 7.5, was used for the separations.  
 
4.2.2.5. Neutral capillary with electrokinetic injection: Method B 
The electrophoretic separations were carried out using an eCAP coated neutral capillary [(30 cm 
(20 cm effective length) x 50 µm internal diameter (I.D.) x 360 µm outside diameter (O.D.) and 
(30 cm (20 cm effective length) x 75 µm internal diameter (I.D.) x 360 µm outside diameter 
(O.D.), obtained from CS-Chromatographie (Langerwehe, Germany)]. 
An electrokinetic injection for 30 seconds was applied for introducing the sample into the 
capillary. The separation was performed using an applied current of -60 µA and a data acquisition 
rate of 8 Hz. Analytes were detected using direct UV absorbance at 210 nm. The capillary was 
conditioned by rinsing with water for 1 min and subsequently with buffer (phosphate 50 mM, pH 
6.5) for 1 min. Sample injections were made at the cathodic side of the capillary.   
 
4.2.2.6. Preparation of standard solutions for method validation 
10 mM stock solutions of nucleotides (TMP, UMP and GMP) were prepared by dissolving the 
compounds in deionized water. Then they were further diluted to get 1 mM stock solutions of 
 61
nucleotides in deionized water. The 1 mM stock solutions were further diluted for the standard 
calibration curves in reaction buffer containing 20 mM Tris-HCl buffer, pH 7.4, containing 5 mM 
MgCl2 and 1 mM ATP. A series of standards of nucleotides was obtained from the stock 
solutions by dilution with the same buffer over a concentration range from 0.01 to 50 µM. UMP 
(20 µM) was used as an internal standard for method validation of TMP, while cAMP was used 
as an internal standard for the method validation of GMP. Injections of standards were performed 
in triplicate. The calibration curve was obtained by plotting the corrected peak area of the TMP 
peak against its concentration.  
 
4.2.2.7. Investigation of the influence of reaction time on enzyme velocity  
A set of experiments was performed in order to investigate whether the reaction proceeds linearly 
with time for a fixed concentration of substrate, using method A. The reaction mixture for the 
determination of the enzymatic velocity over different intervals of time contained: 2 mM 
thymidine, 50 mM Tris-HCl buffer, pH 7.2, 5 mM ATP and 5 mM MgCl2. The reaction was 
started by adding 10 µl of thymidine kinase (4 µg). The reaction was carried out at 37 °C and 
after various time intervals; the reaction mixture was heated for 5 min at 99 °C to stop the 
reaction. Then 45 µl of the solution were transferred to a small CE vial containing 5 µl of an 
aqueous UMP solution (200 µM) as an internal standard. At each time interval three injections 
were made.  
 
4.2.2.8. Effects of Mg2+ on the activity of thymidine kinase 
Effects of different concentrations of Mg2+, 0.5, 1.0, 2.5, 5 and 10 mM of Mg2+ on the enzyme 
activity were monitored, using method B. The reaction mixture contained 1 mM ATP, 50 µM 
thymidine, 20 mM Tris-HCl buffer, pH 7.1, and different concentrations of Mg2+. The reaction 
was started by adding 10 µl of suitably diluted thymidine kinase (4 µg) and the mixture was 
incubated at 37 °C for 35 min, and then stopped by heating at 99 °C for 5 minutes. The TMP 
formed was measured in duplicate by capillary electrophoresis.  
 
4.2.2.9. Capillary electrophoresis method for determination of kinetic parameters of HSV-1 
thymidine kinase substrates  
Kinetic parameters of HSV-1 TK substrates were determined by a modification of the previously 
published protocol134, using method B. In the enzyme assay tube containing 100 µl of total 
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volume, the enzyme was preincubated at 37°C for 2 min in a reaction mixture containing 20 mM 
Tris-HCl buffer, pH 7.4, 5 mM MgCl2, 1 mM ATP and different concentrations of the substrates 
ranging from 15.625 to 1000 µM. The reactions were initiated by adding 10 µl of the HSV-1 
thymidine kinase to give a final amount of 2-4 µg and then allowed to proceed at 37°C for 15 
min. After incubation of the reaction mixture at 37°C for 15 min, it was immediately heated to 99 
°C for 5 min using an Eppendorf Thermomixer Comfort in order to inactivate the enzyme, 45 µl 
of the reaction mixture was transferred to the mini CE vials containing 5 µl of internal standard 
(UMP for dT, BVDU and cAMP for ACV, GCV). The final concentration of the internal 
standard in the assay was 20 µM. The absorbance at 210 nm was monitored continuously and the 
nucleotide concentrations were determined from the area under each absorbance peak. The 
experiments were repeated 3 times. Control experiments were performed in the absence of 
substrate and in the absence of enzyme in order to take into account the spontaneous hydrolysis 
of ATP under the experimental conditions.  
 
4.2.2.10. Capillary electrophoresis method for screening of potential inhibitors of herpes 
simplex virus -1 thymidine kinase  
HSV-1 TK inhibition assays were performed as described by a modification of the published 
protocol102, using method B. Thymidine phosphorylation was measured in the absence and 
presence of inhibitor (aciclovir) at three different concentrations (0.0625, 0.5 and 5 mM). In 
addition to the substrate and inhibitor, the reaction mixture contained 20 mM Tris buffer, pH 7.4, 
5 mM MgCl2 and 1 mM ATP in a final volume of 100 µl. Reactions were incubated at 37°C for 2 
min and then 4 µg of HSV-1 thymidine kinase was added in order to initiate the reaction, 
similarly as for the substrate assay (see above). The reaction was stopped after 15 min by heating 
to 99°C for 5 min.  
 
4.3. Results and discussion 
4.3.1. Optimization of nucleotide analysis by capillary electrophoresis  
Our initial studies were done using a fused silica capillary, however, with subsequent 
experiments we observed that in enzyme assays it is important to use a coated capillary to avoid 
adsorption of protein and analytes to the capillary wall. In case of an untreated fused silica 
capillary, a strong EOF in the direction from the anode to the cathode exists, which significantly 
increases the migration time of nucleotides and in some cases reverses the direction24. In 
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untreated fused silica capillary columns reproducibility was achieved by subsequent rinsing of 
the capillary with 0.1 N NaOH; such strong alkaline solution is required to remove the cations 
from the capillary wall to provide the same silica surface for each run34. Thymidine kinase is 
dependent on Mg2+ for its activity. In the fused silica capillary it was not possible to use 5 mM or 
even a higher concentration of Mg2+, whereas 5 mM Mg2+ was optimal for the enzyme assay. 
Higher concentrations of Mg2+ gave broad peak shapes and poor resolution. Therefore, we used a 
polyacrylamide-coated capillary in further investigations. Capillary electrophoretic separations 
can be optimized with respect to efficiency, selectivity, and running time. CE is still in 
development, therefore there is a lack of systematic approaches for optimizing experimental 
conditions. The separation and selectivity in CE depends on the buffer type, buffer ionic strength, 
buffer pH, column diameter, capillary length and operating voltage. In method B, for high 
resolution, sodium phosphate buffer pH 6.5 was used as a separation buffer because the 
nucleotides were relatively stable at higher pH, but readily hydrolyzed at low pH values27. 
Sodium phosphate buffer is the preferred buffer for the separation of nucleotides13, because it 
gives high efficiency and resolution in short analysis times. The resolution in CE is affected by 
the electroosmotic flow (EOF), which is due to the high buffer flow caused by the electrical 
double layer on the inner surface of the capillary. In the present study polyacrylamide-coated 
fused silica capillary columns were used to get high reproducibility and resolution. Ucon-coated 
and polyacrylamide-coated fused silica capillary columns have been used for the separation of 
nucleotides13,27,37. It was found that the electroosmotic flow of these columns was significantly 
reduced and coating was inert to biological samples13,30. Reproducibility of migration time of 
coated capillary columns is significantly higher than that of untreated fused silica capillary 
columns as shown in table 4.1. In coated capillaries rinse buffer has to be applied to prepare the 
capillary for the next run. A shorter capillary length (30 cm (20 cm effective length)) was used in 
order to reduce the analysis time (Figure 4.4) and for improving the rinsing cycles because in 
shorter capillary more rinsing solution could be passed through within the same period of time. 
The eluting sequence was triphosphates, diphosphates, and followed by monophosphates.  Due to 
the relatively high detection limits of CE because of a small internal diameter of 50-75 µm of the 
capillary this method lacked the sensitivity to perform assays for determining a full Michaelis-
Menten analysis137 of substrates having low Km values like dT. In such cases sample 
preconcentration could be used to increase the sensitivity. Special detectors, such as laser-
induced fluorescence and electrochemical detectors, are one solution for the problem of low 
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sensitivity of CE. However, another simple alternative is sample stacking. It is very convenient to 
utilize the electrical current not just for separation but also for sample concentration directly in 
the capillary138,139. The electrokinetic injection method was used to increase the sensitivity by on-
line preconcentration as compared to the hydrodynamic injection. Stacking by hydrodynamic 
injection requires a long time for sample transfer, which can exceed the separation time. Another 
approach is to increase the capillary internal diameter in order to increase the sensitivity. 
Therefore, a 75 µm internal diameter capillary was used. However, the precision of migration 
time was reduced with the larger internal diameter of the capillary (Table 4.1). In previous studies 
it was observed that by increasing the time for the electromigration to 60 s (at 5 kV) gives a 
concentration of about 120 times greater than that obtained by hydrodynamic injection under 
non-stacking conditions138. The limits of detection and quantitation by both electrokinetic 
injection and hydrodynamic injection methods are given in table 4.1. In the previous enzymatic 
studies13 a similar method was developed using a longer capillary length (60 cm (50 cm effective 
length)). 
 
Table 4.1. Method validation parameters: Limits of detection and quantitation, precision of 
migration time, peak area and linearity of the standard calibration curve. 
 
Compound  
 
dTMP 
50 µm NCa 
dTMP 
75 µm NC 
dTMP 
75 µm FCb 
UMP 
75 µm FC 
GMP 
50 µm NC 
Limit of detection (µM) ± SDc 0.36 ± 0.20 1.03 ± 1.4 2.60 ± 0.60 2.16 ± 0.38 0.86 ± 0.13
Limit of quantification (µM) ± 
SD 
1.08 ± 0.20 3.11 ± 1.4 6.80 ± 0.60 3.77 ± 0.38 3.31 ± 0.13
Coefficient of correlation; R2 1.000 0.990 0.970 0.998 0.999 
Mean value of migration time 
(min) ±  SD (n= 12) 
6.11 ± 0.01 7.96 ± 0.042 5.85 ± 0.15  6.08 ± 0.16 6.34 ± 0.02
 RSDd of migration time (%) 0.16 0.53 2.56 2.63 0.32 
aNC = neutral capillary 
bFC = fused silica capillary 
cSD = standard deviation 
dRSD =  relative SD 
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In the present study we used a shorter capillary length (30 cm (20 cm effective length)), and 
therefore, there was no need to dilute the sample prior to injection. The method was also 
optimized with regard to injection time and the applied voltage. Longer injection times give low 
reproducibility while very short injection times decrease the sensitivity. Different voltages and 
injection times like -10 kV for 5 sec, -6 kV for 15 sec and -6 kV for 30 sec were used with this 
shorter capillary length. The latter method was selected for the enzyme assays due to high 
sensitivity and reproducibility. The assay buffer concentration was optimized for electrokinetic 
injection, 20 and 50 mM Tris-HCl buffer, pH 7.4 was used; no difference in thymidine kinase 
activity was found. 20 mM Tris-HCl buffer, pH 7.4 was selected for the assay, because low 
concentration of the sample buffer improves the sensitivity in electrokinetic injection138-140. 
Chloride ions and other electrolytes in the buffer have faster mobility and thus, concentrate ahead 
of the analytes at the tip of the capillary thus decreasing the field strength and consequently 
decreasing the amount of the analyte being injected.  
 
4.3.2. The use of an internal standard 
The use of an internal standard (IS) has been generally accepted to be crucial for reproducibility 
in CE to compensate for injection errors and minor fluctuations of the migration times. The major 
source of imprecision remaining when using commercial CE instrumentation is injection volume 
variability. Therefore, the use of an IS will improve precision of quantification141. An ideal IS is 
water-soluble, and UV-detectable at 210 nm. Moreover, the migration time of the IS should differ 
from the migration times of the reaction compounds and not prolong the total analysis time. 
UMP, being UV-detectable at 210 nm, was chosen as an internal standard for the determination 
of kinetic parameters of thymidine and BVDU with a migration time of less than 8 min, while 
cAMP was used as an internal standard for ACV and GCV. As illustrated in table 4.1, with the 
use of the IS, the RSD of migration time after 12 runs was calculated to be 0.16, 0.53 and 2.56% 
for the coated capillary 50 µm ID, the coated capillary 75 µm ID and the untreated capillary 75 
µm ID for dTMP, respectively, and 2.63 % with the untreated capillary of 75 µm ID for UMP.  
 
4.3.3. Washing and re-equilibration 
Using a coated capillary the overall rinsing time is reduced. The capillary was conditioned every 
day by rinsing it with water for 20 minutes before starting measurements and then with separation 
buffer for 5 minutes. The standard rinsing periods consisted of rinsing with water for one minute 
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followed by rinsing with buffer for one minute. The capillary was stored in vials containing 
separation buffer inside the CE-instrument overnight after rinsing with water. For rinsing 
procedures we applied 40 p.s.i. of pressure for buffer and water. Under this standard rinsing 
method, the capillary could be used for several hundred runs. 
 
4.3.4. Validation of the capillary electrophoresis method 
4.3.4.1. Limits of detection, quantitation and linearity 
Three different capillary columns with different internal surfaces and diameters were used for the 
determination of limits of detection, quantitation and linearity of dTMP, while validation 
parameters for GMP were obtained with a neutral capillary of 50 µm ID. The concentrations of 
dTMP in this study were 0, 0.1, 0.5, 1, 5, 10 and 50 µM with the neutral capillary and 0, 2, 5, 10, 
20, 30 and 40 µM for the fused silica capillary. CE employing a neutral capillary with 
electrokinetic injection gave low detection limits as compared with a fused silica capillary with 
pressure injection, therefore, low concentrations were used with the neutral capillary. UMP (20 
µM) was used as an internal standard. The concentrations of GMP used in this study were 0, 1, 5, 
10, 20 and 50 µM. Each sample was measured four times. Each peak area for different 
concentrations was entered into a diagram as a function of concentration. The limit of detection 
and quantitation for dTMP with polyacrylamide-coated capillaries of 50 and 75 µm ID were 0.36 
and 1.03 µM, respectively which are low as compared to the fused silica capillary (2.60 µM). The 
75 µm (ID) polyacrylamide-coated capillary showed an unexpectedly high detection limit along 
with a higher standard deviation of migration time. It could be reasoned that with high ID 
electrokinetic injection could inject more buffer ions and other species into the capillary and thus 
resulted in a more unfavorable detection and quantitation limit. May be due to this reason many 
CE instrument companies (like Beckmann Coulter) do not produce 75 µm ID diameter coated 
capillaries. The regressive linearity coefficients with a 50 µm ID polyacrylamide-coated 
capillary, 75 µm ID polyacrylamide coated capillary and 75 µm ID untreated fused silica 
capillary for dTMP were 1.000, 0.990 and 0.970, respectively. Measurement with a 50 µm ID 
polyacrylamide-coated capillary proved to exhibit a good linearity of calibration curve in the 
range from its lowest determined concentration to the highest concentration in the enzyme assays. 
The linearity of calibration curve equation with a 50 µm ID polyacrylamide-coated capillary for 
the measurement of dTMP was determined as y = 40980 x - 8254 (R2 = 1.000) and the relative 
standard error of the slope was 2.02 %, whereas relatively poor linearity was observed in the 75 
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µm ID coated capillary. The limit of detection and quantitation for GMP with polyacrylamide-
coated capillaries, 50 µm ID, was 0.86 and 3.31 µM. The mean values and standard deviations 
were calculated as shown in table 4.1. 
 
4.3.4.2. Repeatability of migration time  
The repeatability of migration time was calculated by injecting dTMP and GMP solutions made 
in separation buffer for 12 times. A high repeatability was found with coated capillaries, while it 
was lower for untreated capillaries (Table 4.1). The reason for the good precision and 
reproducibility in migration times for neutral capillaries is due to the absence of an EOF. In 
addition, the coated capillary is very inert to biological samples, which increased the 
reproducibility of the analysis. 
 
4.3.5. Biological assays 
4.3.5.1. Michaelis-Menten analysis 
A typical single substrate based enzyme-catalyzed reaction can be expressed as: 
                K1/K-1                        Kcat 
E + S      ↔     ES     ↔    E + P   (1) 
 
where E is the enzyme, ES is the intermediate enzyme-substrate complex, S is the substrate and P 
is the product. When all of the enzyme is in the ES state the initial reaction velocity v reaches its 
maximum, Vmax. The relation between initial reaction velocity v and substrate concentration [S] 
can be described by the Michaelis-Menten equation:  
 
 
                       v  = 
   V max [S]                    
                         (2) 
    K m + [S]  
             
where v is the initial velocity of the reaction, Vmax is the maximum velocity, [S] is the substrate 
concentration and Km is the Michaelis constant, the substrate concentration at half of the 
maximum of the velocity. The Lineweaver-Burk plot is obtained by inversion of this equation 
and is far more accurate and convenient to use experimentally, because of its linear relation 
between 1/v and 1/[S]:  
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                     1/v  = 
    K m                      1           
                      +                  (3) 
V max + [S]             V max 
            
  
4.3.5.2. Determination of Km and Kcat values  
Binding affinity (Km) and catalytic constant (Kcat) of the substrate are both important parameters. 
The catalytic constant (Kcat) is the measure of the turnover rate of the enzyme. An increased (Kcat / 
Km) for the substrate toward the natural substrate dT correlates well with enhanced production of 
the active, phosphorylated drug within the cell111. Different concentrations of the substrates in the 
range of 15.625 –1000 µM were used in order to determine their kinetic parameters.  
 
The Kcat values were calculated directly from V max using the equation (4): 
 
 Kcat = V max / [E]        (4) 
 
where [E] is the final active enzyme concentration.  
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Table 4.2. Kinetic analysis of substrates of HSV-1 thymidine kinase 
 
       
NH
O
O N
O
OH
OH
CH3
N
NNH
N
O
OH
OH
O
NH2
N
NNH
N
OOH
O
NH2
Br
NH
O
O N
O
OH
OH
ACV GCVThymidine (dT) BVDU  
Substrate Capillary electrophoresisa Literature values 
 Km (µM) Kcat (S-1) Km (µM) Kcat (S-1) 
dT 
 
n.dd 0.016 ± 0.003 
 
0.2109b, 0.38142c, 0.9 ± 
0.08143c 
0.44111b, 
0.35 ± 0.004133b  
ACV 
 
238 ± 94 
 
0.011 ± 0.002 
 
200109b 103, 417142 0.02132c, 0.13111b 
 
GCV 
 
27.2 ± 18.6 
 
0.12 ± 0.05 
 
69±4143c, 47.6142c, 
48111b,  
0.1 ± 0.017133b, 
0.10111b 
BVDU 25.3 ± 13.4 
 
n.de 50109b  
a  n =  3 
b determined by standard spectrophotometric assays. 
c determined by standard radiometric assays.  
d n.d = could not be determined due to low Km value and the limited sensitivity of the assay. 
e n.d = could not be determined due to unavailability of isolated reaction product BVDUMP for 
measuring a calibration curve. 
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Figure 4.4. Typical electropherogram for the determination of Kcat of GCV. The concentration of 
thymidine kinase was 4 µg/µl of protein; GCV: 500 µM, ATP: 1 mM, cAMP (internal standard): 
20 µM. CE conditions: running buffer: 50 mM potassium phosphate, pH 6.5; constant current of 
-60 µA; detection at 210 nm, capillary cartridge temperature: 25 °C.  
 
The substrates were phosphorylated to the corresponding monophosphates by HSV-1 TK, as 
monitored by capillary electrophoresis.  
The Km and Kcat values were calculated by fitting the initial reaction rate for the formation of 
product (phosphorylated substrates) as a function of substrate concentration into the Michaelis-
Menten equation (3). An average value of 238 µM (n = 3, SD = 94) from three independent 
measurements was determined to be the Km of ACV for HSV-1 thymidine kinase (see Table 4.2). 
Figure 4.5 shows the Michaelis Menten plot of ACV at a HSV-1 TK concentration of 4 µg in the 
assay. The other Km values thus obtained were Km = 27.2 µM for GCV (n = 3, SD = 18.6) and Km 
= 25.3 µM for BVDU (n = 3, SD = 13.4) (Table 4.2). The Michaelis constant (Km) for HSV-1 TK 
substrates cannot be compared exactly with the Km values from other studies, as the latter ones 
employed different analysis methods and Km values can vary depending on the procedure for the 
purification of HSV-1 TK132. However, our results were in the same range as the reported values 
obtained by spectrophotometric and radiometric assays for ACV103,109,144, GCV80,132,144 and 
BVDU80,132,133.  
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The Kcat values were calculated using the equation Vmax = Kcat/[E], where [E] is the total enzyme 
concentration and is based on one active site per monomer. Calculating the Vmax values based on 
the product requires a calibration curve to convert the product peak areas of the reaction to the 
product concentration. Due to the unavailability of isolated reaction products, we could not obtain 
a product calibration curve directly. However, the Vmax values were calculated using the 
calibration curve of thymidine monophosphate for dT, while for ACV and GCV, GMP was used 
which has no significant difference in UV absorption as compared to the phosphorylated 
substrates of ACV and GCV. The Kcat values of dT, ACV and GCV were determined as 0.0160 
(n = 3, each concentration, SD = 0.003), 0.011 (n = 3, each concentration, SD = 0.002), and 0.12 
(n = 3, each concentration, SD = 0.05), respectively (Table 4.2). Due to the limited sensitivity of 
the assay, the Km value of dT could not be determined. The Kcat value of BVDU was not 
determined due to the unavailability of isolated reaction product for determining a calibration 
curve. However, Km could be determined from the added concentration of BVDU. 
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Figure 4.5. Michaelis-Menten plot of initial ACV concentration with respect to the reaction 
velocity (µmol of ACVMP produced in one second per mg of enzyme) for the determination of Km 
and Kcat  values by the capillary electrophoresis method. Assay was conducted at pH 7.4 using 1 
mM ATP, 5 mM MgCl2 and various concentrations of ACV. Data points represent means ± SD 
from three separate experiments each run in duplicate. 
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The activity of thymidine kinase as a function of various concentrations of MgCl2 had been 
examined45,95. Mg2+ was found as a co-substrate of this enzyme. Thymidine kinase showed 
maximal activity at a concentration of 5 mM of MgCl2. After increasing the concentration of 
MgCl2 above this limit, there was no further increase in the activity of thymidine kinase, whereas 
lower concentrations of MgCl2 resulted in reduced enzymatic activity (Figure 4.6). Thymidine 
kinase did not show any activity in the absence of magnesium, it showed an absolute requirement 
of magnesium. The dependence of the thymidine kinase activity on Mg2+ and ATP suggests that 
the ATP-Mg complex is the true substrate for the enzyme.  
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Figure 4.6. Effects of different MgCl2 concentrations on the activity of thymidine kinase at a fixed 
concentration of ATP, determined by capillary electrophoresis. Km was determined at pH 7.1 
using 1 mM ATP, 50 µM thymidine and various concentrations of MgCl2 (0.5 to 10 mM). The 
separation conditions were 50 mM phosphate buffer, pH 6.5, a neutral capillary, 30 cm length 
(20 cm to the detector), 50 µm I.D.; 60 µA; 25 °C; detection at 210 nm; electrokinetic injection 
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for 30 s at –6 kV. Data points represent means ± SD from three separate experiments each run in 
duplicate. 
 
4.3.6. Enzyme inhibition assay 
The assay results of HSV-1 TK with the competitive inhibitor ACV are presented in table 4.3 as  
percent inhibition of phosphorylated thymidine (dTMP). The reactions were performed with 
varying ACV concentrations while the substrate, thymidine, was held constant at 100 µM, and 
the preparation of the HSV-1 TK enzyme was 4 µg in a total assay volume of 100 µl. As the 
concentration of ACV increased, the percent formation of dTMP decreased, as shown in table 
4.3. 
 
 
Table 4.3. Percent phosphorylation inhibition of thymidine kinase by ACV determined by 
capillary electrophoresis (CE).  All values are means ± S.E.M of three separate experiments. 
 
No. Concentration of ACV 
(mM) 
Phosphorylation of dT (%)a 
(n = 3) b 
1 
2 
3 
4 
  0 (control) 
 0.0625 
 0.5 
 5.0 
100 ± 0 
97 ± 5.4 
71 ± 1.6 
62 ± 0.8 
 
aPercentage of phosphorylated product obtained without ACV was set at 100% 
bAll values are means ± S.E.M of three separate experiments 
 
In the presence of 0.5 and 5 mM of ACV the dTMP formation was reduced by 29 and 38 %, 
respectively.  
 
4.4. Summary 
We investigated and developed a very simple and robust method for the determination of 
substrates of HSV-1 TK which are used as antiviral drugs, and their binding affinity (Km) and 
catalytic constant (Kcat/Km). This CE method is also very useful for the investigation of novel 
potential inhibitors HSV-1 TK. The phosphorylated products of the substrates for the reaction of 
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HSV-1 TK could be separated successfully. Furthermore, enzymatic kinetics and inhibition 
assays were easily performed. Determination of Km and Kcat by the new capillary electrophoresis 
method has multiple advantages such as no need for expensive radiolabeled substrates and a 
minimal use of reagents. The assay is fully automated and can be carried out in less then 10 min. 
CE has particular advantage over other techniques in that both, loss of substrate as well as the 
increase in product(s), can be monitored simultaneously. With the development of combinatorial 
chemistry in drug discovery, a simple, non-radioactive and automated screening assay like this 
will be essential for the discovery process.  
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Chapter 5. Capillary electrophoresis assays of nucleoside 
triphosphate diphosphohydrolases 
 
5.1. Introduction 
Extracellular nucleotides such as ATP, ADP, UTP and UDP, and a variety of diadenosine 
polyphosphates (ApnA) act as extracellular signalling molecules in virtually all tissues and can be 
inactivated by hydrolysis via ectonucleotidases. In particular, extracellular ATP is involved in a 
large variety of physiological and pathological functions. These involve roles for ATP in the 
following areas: (1) as a neurotransmitter and neuromodulator in the central and peripheral 
nervous system; (2) as a key messenger in nociception; (3) as a tumour-inhibiting agent; (4) in 
the control of secretion from a variety of endocrine glands; (5) in the modulation of platelet 
aggregation by ADP; (6) in Cl- transport in the airway epithelia; (7) in renal function; and (8) in 
bone and cartilage disease145. Nucleotides are hydrolyzed by an extracellular hydrolysis cascade 
of surface-located enzymes that results in the formation of the respective nucleoside and free 
phosphate146. Nucleoside 5-tri- and –diphosphates may be hydrolyzed by members of the E-
NTPDase family (ectonucleoside triphosphate diphosphohydrolase family), the E-NPP family 
(ectonucleotide pyrophosphatase/phosphodiesterase family), and by alkaline phosphatases. 
Nucleoside 5-monophosphates are subject to hydrolysis by ecto-5-nucleotidase and also by all 
alkaline phosphatases. Members of the various ectonucleotidase families reveal overlapping 
substrate specificity and tissue distribution whose functional significance needs to be further 
elucidated146. 
 
5.1.1. The ecto-nucleoside triphosphate diphosphohydrolases family 
Members of ecto- nucleoside triphosphate diphosphohydrolases (E-NTPDase) family can 
hydrolyze nucleoside 5’-triphosphates and nucleoside 5’-diphosphates albeit with varying 
preference for the individual type of nucleotide. Therefore they represent ecto-nucleoside 5’-
triphosphate diphosphohydrolases147,148. All members of the family share five highly conserved 
sequence domains (pyrase conserved regions) that presumably are of major relevance for their 
catalytic activity147. All nucleotidases belonging to the E-NTPDase family contain the actin-hsp 
70-hexokinase β - and γ -phosphate binding motif148. Members of the E-NTPDase family may be 
separated into two groups according to their presumptive membrane topography (Figure 5.1). 
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Members of the first group include E-NTPDase1 to 4 and are predicted to have a transmembrane 
domain at the N- and at the C-terminus. Of the second group, including NTPDase5 and putative 
NTPDase6, NTPDase5 lacks the C-terminal hydrophobic domain. Its N-terminal hydrophobic 
leader sequence is cleaved, resulting in a soluble and secreted form of the enzyme. The enzymes 
hydrolyze not only ATP or ADP but have in common broad substrate specificity towards purine 
and pyrimidine nucleotides. They differ, however, regarding their preference for nucleotide 5’-
tri- and nucleotide 5’-diphosphates149,150. 
 
Table 5.1. Nomenclature of vertebrate members of the E-NTPDase (ecto-nucleoside triphosphate 
diphosphohydrolase) family151,152. 
 
Name Previously used names Human gene 
symbol 
Species (accession number) 
 NTPDase1 CD39, ecto-ATP 
diphosphohydrolase, 
ecto-apyrase 
ENTPD1 human (S73813, U87967, AJ133133); rat 
(U81295); mouse (AF037366); bovine 
(AF005940); porcine (AJ133746) 
 NTPDase2 CD39L1, ecto-ATPase ENTPD2 human (U91510, AF144748); rat 
(Y11835; AF276940); mouse 
(AF042811); chicken (U74467) 
 NTPDase3 CD39L3, HB6 ENTPD3 human (AF034840, AF039917); chicken 
(AF041355) 
 NTPDase4  UDPase (hLALP70v), 
hLALP70 
ENTPD4 human (AF016032, AJ131358) 
 NTPDase5 CD39L4, ER-UDPase ENTPD5 human (AF039918); mouse (AJ238636, 
AF006482) 
 NTPDase6  CD39L2 ENTPD6 human (AF039916); rat (AJ277748) 
 NTPDase7   ENTPD7 human (AAF90135) 
 NTPDase8   ENTPD8 mouse (AY364442); rat (AY536920) 
    
 
NTPDases 1, 2, 3, and 8 are oligomeric cell surface membrane proteins. NTPDases 4, 5, 6 and 7 
are intracellular membrane proteins.  
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Table 5.1. provides the new nomenclature for vertebrate NTPDases together with previously used 
names as well as the new human gene symbols and the accession numbers (including variants). 
Note that the family name is E-NTPDase and the name of individual enzymes NTPDase1 to 
NTPDase6. The accession numbers are given for the human enzymes as well as for the vertebrate 
species ortholog. The functional expression of NTPDase1 to NTPDase6 has been verified for at 
least one of the sequences listed.  
 
Apyrase 
conserved 
regions 
ATP → ADP + Pi 
ADP → AMP + Pi 
(ATP : ADP = 1 : 0.3) 
ATP → ADP + Pi  
ADP → AMP + Pi  
(ATP : ADP = 1 : 0.03) 
ATP → AMP + 2 Pi 
ADP → AMP + Pi 
(ATP : ADP = 1 : 0.8) 
out 
NTPDase3 NTPDase2 NTPDase1 
COOH NH2 COOH NH2 COOH 
NH2 
Plasma 
membrane 
in 
 
 
Figure 5.1. Membrane topography and catalytic properties of NTPDase1 to 3 of the E-NTPDase 
family. The apyrase conserved regions are situated in the N-terminal half of all sequences. The 
catalytic properties are not restricted to the examples given but include other purine and 
pyrimidine nucleoside 5’-tri- or -diphosphates. The ratios indicate the relative preference of the 
ecto-nucleotidases for ATP and ADP. 
 
5.1.2. General properties of nucleoside triphosphate diphosphohydrolases1-3  
Members of the ecto-nucleoside triphosphate diphosphohydrolase (E-NTPDase) family are 
dominant ectonucleotidases. These three closely related enzymes namely NTPDase1, NTPDase2 
and NTPDase3 are located at the surface of the plasma membrane and hydrolyze nucleotides in 
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the range of concentration that activate P2 receptors151. NTPDase1 (CD39, ecto-apyrase, ecto-
ATP diphosphohydrolase) hydrolyzes ATP and ADP at a molecular ratio of about 1:0.5 to 
1:0.9149. In contrast, NTPDase2 (CD39L1, ecto-ATPase) has a strong preference for ATP with 
molecular ratios of ATP : ADP of 1 : 0.03 or less. NTPDase3 (HB6) is a functional intermediate 
and reveals a molecular ratio of ATP : ADP of approximately 1:0.3. The activity of all three types 
of ecto-nucleotidases depends on millimolar concentrations of divalent cations such as Ca2+ or 
Mg2+ 148-150. Four out of the eight members of this family, namely NTPDases1, 2, 3 and 8 have 
two plasma membrane spanning domains with an active site facing the extracellular milieu151. 
 
 
 
Figure 5.2. Formation of the cognate agonist of the P2Y1 receptor by NTPDase2 and 
inactivation of P2Y1 receptor-activating nucleotides by NTPDase1. The scheme illustrates the 
release of cellular ATP and its conversion by NTPDase2 into the cognate agonist ADP for the 
P2Y1 receptor (top) and the release of cellular ATP and the conversion of ATP (and ADP) to 
AMP (bottom), which is not an agonist of the P2Y1 receptor. 
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Even though NTPDases 5 and 6 may be present at the surface of the plasma membrane and 
secreted as soluble enzymes following a proteolytic cleavage, their high Km values and low 
specific activities153 make it unlikely that these enzymes regulate P2 receptor signalling. E-
NTPDase activity is coupled with ecto-5'-nucleotidase activity to produce adenosine that exerts its 
effect through P1 receptors154. It can be concluded that NTPDase1 would hydrolyze nucleoside 
tri- and diphosphates equally well, resulting in the formation of nucleoside monophosphates and 
the inactivation of all P2 receptors agonists. NTPDase2 would selectively inactivate nucleoside 
triphosphates and act as an extracellular producer of nucleoside diphosphates. NTPDase2 
preferentially hydrolyzes nucleoside triphosphates, and the presence of NTPDase2 under either 
coexpression or coculture conditions did not change the activation of the P2Y1 receptor (Figure 
5.2)155. NTPDase3, with its intermediate properties, is expected to effectively hydrolyze 
nucleoside triphosphates, but the hydrolysis of nucleoside diphosphates may be delayed and 
therefore the nucleoside diphosphate may be more long-lasting151.  
 
5.1.3. Nucleoside triphosphate diphosphohydrolase inhibitors  
The analysis of nucleotide release or of the potency of externally applied ATP or its analogs 
requires the availability of inhibitors of ectonucleotidases that should preferably have no or only 
a small effect on P2 receptor activation151. It has been demonstrated that stable analogs of ATP 
can elicit tissue contractions up to a hundred times more effectively than ATP. This suggests that 
the effects of exogenously applied ATP on P2-receptors are limited by its enzymatic degradation. 
Inhibitors of ecto-nucleotidases could thus serve as drugs that increase the lifetime of 
extracellular ATP in situ. Regarding the diversity of enzyme families involved in extracellular 
nucleotide metabolism and the multiplicity of enzyme members, the task of developing specific 
inhibitors is demanding146. New molecules have been found to inhibit ecto-nucleotidases and 
particularly the E-NTPDases. These compounds can be grouped in to two categories: 1) 
nucleotides analogs, some of which are also P2 receptor agonists or antagonists (Figure 5.3) and 
2) other molecules, most of which are related to the suramin-Evans blue families of dyes (Figure 
5.4), also known as P2 receptor antagonists. 
 
5.1.3.1. Nucleotide analogs 
A large number of compounds have previously been investigated, representing nonhydrolyzable 
nucleotide analogs, as inhibitors of NTPDases. Until recently, the only compound that has been 
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shown to effectively inhibit hydrolysis of ATP in a variety of tissues (albeit with moderate 
potency) without significantly acting on purinoceptors was the structural analogue of ATP, ARL 
67156 (FPL 67156) (N6-diethyl-β,γ-dibromomethylene-ATP)23,156. ARL 67156 potentiates 
purinergic synaptic transmission, supporting the notion that endogenous ectonucleotidases reduce 
the effective concentrations of released ATP. Recently, 8-thioether-ATP derivatives, found 
inactive at P2Y- and P2X-receptors, and stable to NTPDase hydrolysis, were developed as 
specific and potent NTPDase inhibitors, and therefore hold promise as compounds that can 
inhibit ectonucleotidases without affecting P2 receptors. 8-Thiobutyladenosine-5'-triphosphate 
(compound 5.3), a nonhydrolyzable analogue of ATP, acts as a competitive inhibitor of ATP with 
an estimated Ki value of 10 µM at nucleoside triphosphate diphosphohydrolase (NTPDase)157,158.  
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Figure 5.3. Structures of nucleotide analogs as NTPDase inhibitors. 
 
Some 2-thioether-5'-mono-phosphoro-thioate adenosine derivatives (2-thioether-AMP-S) are 
inhibitors of E-NTPDase from pig pancreas. The monophosphate derivatives, 2-hexylthio-AMP-
 81
S, and 2-benzylthio-AMP-S, were not hydrolyzed by pig pancreas E-NTPDase. The rate of 
hydrolysis of 2-hexylthio-5'-O-(1-thiotriphosphate)adenosine (2-hexylthio-ATP-α-S) by E-
NTPDase was 28% of that of ATP. Hence, 2-hexylthio-AMP-S, 2-benzylthio-AMP-S and AMP-
S were competitive inhibitors of E-NTPDase159. The ideal NTPDase inhibitor should not be a P2 
receptor agonist and should not be dephosphorylated by the enzyme. 
 
5.1.3.2. Non-nucleotide analogs 
Inhibitors of P2-receptors antagonists such as suramin and related compounds21,160, Evans blue 
and Trypan blue161, Reactive red162,163, Reactive blue162,164, PPDAS (pyridoxal phosphate-6-
azophenly-2’,4’-disulphonic acid)165,166 or a variety of textile and protein dyes also attenuate 
hydrolysis of ATP. These compounds inhibit members of different enzyme families albeit with 
different potency. The development of effective ecto-nucleotidase inhibitors with weak or lacking 
P2 receptor antagonism would considerably facilitate the functional analysis of nucleotides in 
intact organ preparations. There is a possibility to develop inhibitors with differential potency on 
ecto-ATPase and P2 receptors. Evans Blue is a very effective inhibitor of ecto-apyrase, and 
suramin preferentially inhibited ecto-ATPase149.  
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Figure 5.4. Structures of sulfonate derivatives of the Suramin and Evans blue family that act as 
NTPDase inhibitors. 
 
These molecules share some common structural characteristics, including an aromatic core (e.g. 
naphthalene) substituted with sulfonate residues. From structure- activity relationship data 
obtained with P2 nucleotide receptors and ecto-nucleotidases, three structure-activity 
requirements have been found for these inhibitors: 1) the position of the sulfonate groups on the 
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naphthalene (or anthraquinone) core is important; 2) the amino-hydroxy-naphthalene disulfonate 
structures of these antagonists are involved in the binding to ectonucleotidases; 3) the inhibitory 
potencies and affinities of these antagonists at P2 purinoceptors increase with the size of the 
compounds161. BG0136 (1-naphthol-3,6-disulfonic acid disodium salt) exhibited inhibitory 
properties on E-NTPDase as well as antagonistic activity towards the P2Y2 receptor. From 
related derivatives of BG0136 it is clear that a hydroxyl group is essential for inhibition of E-
NTPDases. Substitution of the hydroxyl group by an amine caused a loss of the inhibitory 
property. Sulfonate groups (-SO3H) seem to play a role but do not appear to be essential for 
inhibition. Molecules with a sulfonate group in the meta position with respect to the hydroxyl 
group are more efficient. BG0136 exhibited a mixed type of inhibition on E-NTPDases with a Ki 
value of 380 µM167. Small aromatic isothiocyanatonaphthalene-sulfonates were found to be 
selective inhibitors of P2-purinoceptors, the isothiocyanato residue as well as the aromatic core 
being essential for P2-purinoceptor blockade. 2-Isothiocyanatonaphthalene-1-sulfonate was better 
because of relatively high P2X-selectivity versus both the P2Y-purinoceptor and ecto-
nucleotidases168.  
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5.2. A capillary electrophoresis method for the characterization of ecto-
nucleoside triphosphate diphosphohydrolases and the analysis of inhibitors by 
in-capillary enzymatic microreaction  
 
5.2.1. Introduction 
Extracellular nucleotides such as ATP, ADP, UTP, and UDP can act on a variety of nucleotide 
receptors (P2 receptors)18. The activation of P2 receptors is controlled by ecto-nucleotidases 
capable of hydrolyzing nucleoside tri- and diphosphates146. Inhibition of ecto-nucleotidases can 
result in a potentiation of purinergic signalling, supporting the notion that endogenous ecto-
nucleotidases reduce the effective concentration of the released nucleotide21,169,170. Similarly, 
metabolically stable analogs of ATP are considerably more effective in causing a biological 
response than ATP itself. Inhibitors of ecto-nucleotidases could thus represent valuable tools for 
amplifying the biological effects induced by extracellularly released nucleotides. In addition, 
inhibition of ecto-nucleotidases is mandatory for both, studies of nucleotide release and the 
analysis of the potency on P2 receptors of nucleotides or their hydrolyzable analogs.  
 
Inhibitors of ecto-nucleotidases should have no effect on P2 receptors and should not be 
dephosphorylated by ecto-nucleotidase. Ideally they would also reveal selectivity for individual 
E-NTPDase isoforms. Many inhibitors of P2 receptors also act as inhibitors of ecto-
nucleotidases. These include suramin, pyridoxalphosphate-6-azophenyl-2',4'-disulfonic acid 
(PPADS) and reactive blue 2 (Figure 5.4). To date only the ATP analog ARL67156 (FPL67156, 
N6-diethyl-β,γ-dibromomethylene-ATP, Figure 5.4)169,170 and 8-thiobutyladenosine 5´-
triphosphate (8-Bu-S-ATP)157 reveal enzyme inhibitory potential without significantly affecting 
nucleotide receptors. However, these compounds have not been tested on defined NTPDase 
isoforms. The development of novel inhibitors of ecto-nucleotidases requires fast and precise 
methods for analyzing catalytic activity.  
 
Capillary electrophoresis (CE) has recently emerged as a versatile technique for enzyme assays 
79,171. CE systems have been successfully applied for assaying enzyme activity5,82,141, including 
the determination of Michaelis-Menten constants (Km values)79, and inhibition constants (Ki 
values for enzyme inhibitors)80, exhibiting a number of advantages over conventional methods. 
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These include rapid separation of substrate and product, ultra-low sample volume requirements, 
and high throughput by automation. CE is particularly useful for investigating enzymatic 
reactions involving charged substrates or products, e.g. for the monitoring phosphorylation or 
dephosphorylation reactions30,84. Electrophoretically mediated microanalysis (EMMA), first 
described by Bao and Regnier85 has been successfully used for in-line enzyme assays86. In this 
technique, the capillary is used as a microbioreactor as well as for the separation of substrates and 
products. There are two major types of EMMA methods. In the first continuous format 85, the 
capillary is filled with an appropriate substrate solution and upon injection of a zone of enzyme, 
the product will continuously form during the electrophoretic mixing of enzyme and substrate. 
One drawback of this method is that the separation buffer has to allow the enzymatic reaction to 
proceed.  
 
In the second plug-plug technique87, substrate and enzyme are introduced into the capillary as 
distinct plugs. Upon application of an electric potential, these zones mix with each other due to 
differences in their electrophoretic mobilities. The reaction proceeds during the mixing process. 
The resultant product is transported to the detector separately from enzyme and educts under the 
influence of an applied voltage, where they are individually detected. Even double enzyme-
catalyzed reactions were studied by the latter method by injecting plugs of substrate and two 
different enzymes separately in reaction buffer. This technique was used to study the enzymatic 
reactions of hexokinase and apyrase as well as lactate dehydrogenase and glucose-6-phosphate 
dehydrogenase31,31,32.  
 
In the present study, a method for analyzing the enzymatic reactions of NTPDase1, 2 and 3, three 
surface-located members of the ecto-nucleoside triphosphate diphosphohydrolase family (EC 
3.6.1.5) 146 has been developed, performing the enzymatic reaction inside the capillary at the 
capillary inlet followed by electrophoretic separation of the reaction products. In the at-capillary 
inlet reaction technique, the plugs of enzyme, substrate and inhibitor are introduced into the 
capillary, where they are allowed to react by simple diffusion and not by voltage as in EMMA 
according to a previously described procedure for angiotensin-converting enzyme assays 172,173. 
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5.2.2. Materials and methods  
5.2.2.1. Reagents and chemicals  
Reactive blue 2, suramin, pyridoxalphosphate-6-azophenyl-2',4'-disulfonic acid (PPADS), 
dipyridamole and 4-(2-hydroxyethyl)piperazine-1-ethanesulfonic acid (HEPES) were obtained 
from Sigma, Steinheim, Germany. ARL-67156 was from Tocris Cookson, Bristol, UK. ATP, 
ADP, AMP, UMP, MgCl2·6H2O, and tris(hydroxymethyl)aminomethane (Trizma Base), were 
from Sigma (Taufkirchen, Germany). Culture medium was obtained from Invitrogen (Karlsruhe, 
Germany). Penicillin and streptomycin were purchased from Sigma-Aldrich (Deisenhofen, 
Germany). Leupeptin, pepstatin A, chymostatin, and antipain were from Calbiochem 
(Schwalbach, Germany).  
 
 
5.2.2.2. Cell transfection and preparation of membrane fractions containing nucleoside 
triphosphate diphosphohydrolases  
Chinese hamster ovary (CHO) cells were cultured in HAM’s F-12 medium containing 10% fetal 
calf serum, 100 U/ml penicillin and 100 µg/ml streptomycin. They were transfected by 
electroporation with plasmid-DNA containing rat NTPDase1 (GenBank Accession number 
U81295)174, NTPDase2 (Y11835)174, and NTPDase3 (AJ437217), all cloned into the pcDNA3 
plasmid. Transfection with the empty plasmid pcDNA3 served as a control. Transiently 
transfected CHO cells were used for preparation of membrane fractions 48 h after 
electroporation. 
After removal of culture medium, cells were washed twice with buffer A (in mM: 140 NaCl, 5 
KCl, 0.5 EDTA, 20 Hepes, pH 7.4) and scraped off with 5 ml of ice-cold buffer B (in mM: 140 
NaCl, 5 KCl, 20 Hepes, pH 7.4) containing protease inhibitors (in µg/ml: 2, chymostatin; 1, 
pepstatin A; 150 benzamidine; 2, antipain; 2, leupeptin) and iodoacetamide (2 mM). Cells were 
centrifuged at 300 g for 10 min at 4 °C. The cell pellet was resuspended in buffer B, 
homogenized using a Potter-Elvehjem homogenizer and sonicated. The homogenate was 
centrifuged for 10 min at 300 g at 4 °C and the resulting supernatant fraction was centrifuged at 
100,000 g for 1 h at 4 °C. The pellet fraction was resuspended in buffer C containing 50% (v/v) 
glycerol, 2 mM iodoacetamide, 20 mM Hepes (pH 7.4), and stored at –20 °C. ATPase activity of 
individual membrane fractions was determined by analysis of free phosphate formed according to 
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Lanzetta et al. 175. Protein was determined according to the method of Spector 176. The membrane 
preparations contained 4-6 µg of protein/µl. 
Cell transfections and preparations of membranes were performed by Prof. Dr. H. Zimmermann 
and coworkers, Institute of Zoology Department of Neurochemistry university of Frankfurt, 
Germany. 
 
5.2.2.3. Capillary electrophoresis instrumentation  
All experiments were carried out using a P/ACE MDQ capillary electrophoresis system 
(Beckman Instruments, Fullerton, CA, USA) equipped with a UV detection system coupled with 
a diode-array detector (DAD). Data collection and peak area analysis were performed by the 
P/ACE MDQ software 32 KARAT obtained from Beckman Coulter. The capillary temperature 
was kept constant at 37 °C. The temperature of the sample storing unit was adjusted to 10 °C. 
The electrophoretic separations were carried out using an eCAP polyacrylamide-coated fused-
silica capillary [(30 cm (20 cm effective length) x 50 µm internal diameter (I.D.) x 360 µm 
outside diameter (O.D.), obtained from CS-Chromatographie (Langerwehe, Germany)]. The 
separation was performed using an applied current of -60 µA and a data acquisition rate of 8 Hz. 
Analytes were detected using direct UV absorbance at 210 nm. The capillary was conditioned by 
rinsing with water for 2 min and subsequently with buffer (phosphate 50 mM, pH 6.5) for 1 min. 
Sample injections were made at the cathodic side of the capillary.  
 
5.2.2.4. Nucleoside triphosphate diphosphohydrolase inhibition assays outside the capillary 
The reaction mixture for the NTPDases inhibition assays contained 400 µM ATP in a phosphate-
free physiological saline solution (140 mM NaCl, 5 mM KCl, 1 mM MgCl2, 2 mM CaCl2, 10 mM 
Hepes, pH 7.4) and 10 µl of different concentrations of NTPDases inhibitors or test compounds 
were added over a range of 7 to 10 concentrations to determine the Ki values. Test compounds 
were first screened at 1 and 0.3 mM concentrations. The reaction was started by adding 10 µl of 
membrane preparation containing NTPDase enzyme. The reaction was carried out at 37 °C in a 
final volume of 100 µl for 10 min, then stopped by heating at 99 °C for 3 minutes. Then 50 µl 
were transferred to eppendorf tubes containing 50 µl of an aqueous UMP solution with a final 
concentration of 10 µM as an internal standard and 400 µl of deionized water. After mixing 50 µl 
of the reaction mixture was transferred to a small CE vial for measurement. The AMP or ADP 
formed was repeated three times in two separate experiments. The absorbance at 210 nm was 
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monitored continuously and the nucleotide concentrations were determined from the area under 
each absorbance peak. 
 
5.2.2.5. At-inlet reaction procedure and automation of analytical process  
The CE running buffer consisted of dipotassium hydrogen phosphate 50 mM, pH 6.5. The 
reaction buffer contained 140 mM NaCl, 5 mM KCl, 1 mM MgCl2, 2 mM CaCl2, and 10 mM 
Hepes, pH 7.4. Before use, a new capillary was washed with deionized water for 10 minutes. The 
automation cycle consisted of (i) washing with water for 2 minutes (40 p.s.i; 1 p.s.i = 6894.76 Pa) 
(ii) equilibration with the CE running buffer for 1 minute (40 p.s.i), (iii) injection of a plug of 
reaction solution containing 320 µM ATP (substrate) in reaction buffer and various 
concentrations of inhibitor stock solutions in reaction buffer, (iv) injection of a plug of suitably 
diluted enzyme, (v) injection of another plug of reaction solution as in (iii), (vi) and finally 
injection of a plug of water. The plugs were then allowed to react, while the capillary ends were 
dipped into water, for a predetermined waiting period of 5 min. Then, a current of -60 µA was 
applied and the reaction products moved towards the detector end of the capillary. After each 
analysis the capillary was rinsed with CE running buffer for 2 min followed by deionized water 
for 1 min.  
Each electropherogram was recorded over 7 min. The diluted membrane fractions containing 
enzyme were placed in the sample storage unit whose temperature was kept constant at 10 °C. At 
this temperature, enzyme activity remained unaffected during the approximately 24 h of 
instrument run. Substrate and buffers used in the enzyme reaction were also kept at 10 °C in the 
autosampler reservoir.  
 
5.2.2.6. Quantitative determination of AMP and ADP and method validation 
AMP and ADP were dissolved in enzyme assay buffer (140 mM NaCl, 5 mM KCl, 1 mM MgCl2, 
2 mM CaCl2, 10 mM Hepes, pH 7.4) to obtain 1 mM stock solutions. Standard calibration curves 
were obtained with final concentrations of 2, 5, 10, 20, 30, and 50 µM. For validating the method, 
20 µM of UMP was used as an internal standard. A polyacrylamide-coated capillary was used for 
the separation and quantitation of AMP and ADP. The procedure was as described above using 
enzyme preparations inactivated by heating to 99 °C for 3 min using an Eppendorf Thermomixer 
Comfort. Determinations were performed in triplicate. The calibration curves were obtained by 
plotting the corrected peak area of AMP or ADP, respectively, against their concentrations. 
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5.2.2.7. Investigation of standard nucleoside triphosphate diphosphohydrolase inhibitors by 
in-capillary reaction 
For the determination of the IC50 and Ki values of NTPDase inhibitors, 6-8 different 
concentrations of inhibitor spanning about three orders of magnitude were used (see Figure 5.8-
5.10), while a fixed substrate concentration of 320 µM of ATP was employed for all three 
NTPDases. Under the applied conditions less than 10 % of substrate was converted by the 
enzymes. Membrane preparations derived from transfected cells and containing NTPDase1, 
NTPDase2, or NTPDase3, were appropriately diluted with reaction buffer for the inhibition 
assays. Control experiments were performed using membrane preparations of cells transfected 
with the empty plasmid (pcDNA3). Substrate and inhibitors were dissolved in the reaction buffer 
containing 140 mM NaCl, 5 mM KCl, 1 mM MgCl2, 2 mM CaCl2, 10 mM Hepes, pH 7.4. The 
Cheng-Prusoff equation was used to calculate the Ki values from the IC50 values, determined by 
the non-linear curve fitting program PRISM 3.0 (GraphPad, San Diego, California, USA).  
 
             Ki   = 
                       IC50 
 
                      [ATP] 
      1  +      
                   Km (ATP) 
 
5.2.2.8. Michaelis-Menten constant (Km) and maximal velocity (Vmax) determination  
For the determination of the Michaelis-Menten constants (Km) and the maximum velocity (Vmax) 
eight different substrate concentrations of ATP were used, 10, 20, 30, 50, 100, 200, 250 and 1000 
µM of ATP for NTPDase1 dissolved in reaction buffer, while the following ATP concentrations 
were used for NTPDase2 and 3: 25, 50, 100, 150, 200, 250, 300, 500 and 1000 µM. The capillary 
inlet reaction method was used as described above. 
 
5.2.2.9. Investigation of Reactive blue 2 derivatives (anthraquinones), polyoxometalates and 
uridine nucleotide mimetics as potential inhibitors of nucleoside triphosphate 
diphosphohydrolases by capillary electrophoresis 
For the determination of the IC50 and Ki values of Reactive blue 2 derivatives and 
polyoxometalates (Table 5.5.)  as NTPDases inhibitors,  6-8 different concentrations of inhibitor 
spanning about three orders of magnitude were used, while a fixed substrate concentration of 400 
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µM of ATP was employed for all three NTPDases. Under the applied conditions less than 10 % 
of substrate was converted by the enzymes. Membrane preparations derived from transfected 
cells containing NTPDase1, NTPDase2, or NTPDase3, were appropriately diluted with reaction 
buffer for the inhibition assays. Control experiments were performed using membrane 
preparations of cells transfected with the empty plasmid (pcDNA3). Substrate and inhibitors were 
dissolved in the reaction buffer containing 140 mM NaCl, 5 mM KCl, 1 mM MgCl2, 2 mM 
CaCl2, 10 mM Hepes, pH 7.4.  
The anthraquinone derivatives related to RB-2 were synthesized by Dr. Stefanie Weyler 
Pharmaceutical Institute, University of Bonn. The polyoxometallates (Table 5.5.) were obtained 
from Dr. Holger Stephan, Forschungszentrum Rossendorf, Institut für Bioanorganische und 
Radiopharmazeutische Chemie, Dresden, Germany. The uridine nucleotide mimetics were 
synthesized by Andreas Brunschweiger, Pharmaceutical Institute, University of Bonn.  
 
 
5.3. Results  
5.3.1. Development of the on-capillary reaction technique  
The on-capillary reaction technique has previously been successfully applied for inside capillary 
enzymatic reactions using electrophoretically mediated microanalysis (EMMA)85,86,86. A related 
inside capillary enzymatic reaction methodology in which the enzymatic reaction was performed 
at the capillary inlet without electrophoretic mixing of enzyme and substrate had been applied for 
the determination of the Michaelis-Menten constant173 and for inhibition studies of the 
angiotensin-converting enzyme172. In the present study we developed a CE method for the 
monitoring of reactions of NTPDase1, 2 and 3 by a modification of the described at-capillary 
inlet enzymatic reaction172,173. Suitable conditions for the separation and quantitative 
determination of nucleotides and the monitoring of enzymatic nucleotide metabolism using CE 
had previously been developed in our group30. However in those studies, the enzymatic reaction 
was performed in a vial outside the capillary and the samples were injected into the capillary and 
subjected to CE analysis only after the enzymatic reaction had been stopped30. A modification of 
the developed separation protocols was now used after performing the enzymatic reaction 
directly in the capillary close to the capillary inlet. Thus, a small aliquot of substrate-bearing 
reaction buffer was hydrodynamically injected into the capillary followed by enzyme and then 
again substrate, effectively sandwiching an aliquot of enzyme on either side by substrate. After 
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the final plug of substrate a small plug of water was injected resulting in a stacking effect which 
improved the resolution of the peaks30. 
 
 
At-capillary inlet enzymatic reaction 
                                                      1. Injection of substrate (+ inhibitor) for 5 sec                                   
                                             2. Injection of enzyme for 5 sec 
Capillary                              3. Injection of substrate (+ inhibitor) for 5 sec            Capillary  
                                             4. Waiting period for 5 min (enzymatic reaction)  
                                             5. Electrophoretic separation for 6 min 
Vials                                                                                                                     
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Figure 5.5. Schematic illustration of microscale reaction of NTPDases at c
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since the rate of conversion of substrate to product was more than 10%. Figure 5.5 provides a 
schematic overview of the different steps of the capillary inlet reaction procedure. A reaction 
buffer containing 140 mM NaCl, 5 mM KCl, 1 mM MgCl2, 2 mM CaCl2 and 10 mM Hepes, pH 
7.4, was found suitable for the enzymatic reaction, which was allowed to take place for 5 min. 
The separation of substrate and product(s) was then initiated by applying a constant current of -60 
µA using a 50 mM phosphate buffer (pH 6.5) resulting in a voltage of 7 kV. The separation was 
completed within less than 6 min (see Figure 5.6). 
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Figure 5.6. Overlay of five electropherograms after NTPDase3 on-line reaction at the capillary 
inlet with different concentrations of reactive blue 2 (inhibitor) added to the substrate plug. The 
concentration of NTPDase3 was 0.05 µg/µl of protein, ATP: 320 µM, UMP (internal standard): 
40 µM. Waiting period (duration of enzymatic reaction): 5.0 min. CE conditions: running buffer: 
50 mM potassium phosphate, pH 6.5; constant current of -60 µA; detection at 210 nm, capillary 
cartridge temperature: 37 °C.  
Reactive blue 2 (RB2) concentrations: a) 20,  b) 6,  c) 2,  d) 0.6 and  e) 0.2 µM. The lowest 
concentration (0.2 µM), gave virtually the same electropherogram as the control without 
inhibitor. 
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A wavelength of 210 nm was chosen for the detection of the nucleotides due to the higher 
sensitivity that can be reached at this wavelength in comparison with higher wavelengths. The 
washing time and pressure had to be optimized for the enzyme assay, because inside the capillary 
there was a high concentration of salts, buffer ions, lipids and proteins. A period of 2 min of 
washing with buffer followed by 1 min with water at 40 p.s.i pressure was found to be sufficient 
for cleaning the capillary. In the method described for monitoring angiotensin converting enzyme 
172,173, van Dyck et al. had encountered some drawbacks, such as unpredictable migration time 
shifts and current breakdown. We believe that these problems were due to the adsorption of 
enzyme to the capillary wall because a fused silica capillary was used. In our study we used a 
polyacrylamide-coated capillary, which is not expected to show protein adsorption, thus we did 
observe neither current breakdown nor unpredicted migration time shifts. However, when we 
used a fused-silica capillary the method was not successful due to the high concentration of salts 
required in the reaction buffer and probably because of enzyme and lipid adsorption to the 
capillary wall resulting in peak broadening. Using a short, coated capillary, high precision of 
migration time and very good peak resolution was observed up to several hundreds of runs. 
 
5.3.2. Quantitative analysis of AMP and ADP 
The NTPDase activity and inhibition was determined by measuring the corrected peak area of 
AMP for NTPDase1, and ADP for NTPDase2 and 3, respectively. Validation of CE 
measurements of AMP and ADP were performed exactly the same way as for enzyme activity 
assays, i.e (1) injection of plugs of different concentrations of AMP or ADP in reaction buffer 
containing UMP (20 µM) as an internal standard, (2) a suspension of a membrane preparation 
containing inactived enzyme, followed by (3) another injection of AMP or ADP in reaction 
buffer containing UMP (20 µM) as an internal standard. An overview of the quantitative 
parameters of the method validation is provided in Table 5.1 A strictly linear correlation between 
AMP and ADP concentrations and the corrected peak area ratio was found: a correlation 
coefficient (R2) of 0.998 for AMP and 0.999 for ADP (n = 3) was calculated for a concentration 
range from 2.0 to 50.0 µM. The limit of quantification (LOQ) was found to be 2.95 µg/ml for 
AMP and 1.41 µg/ml for ADP. The limit of detection (LOD) of AMP was determined to be 0.80 
µg/ml for AMP and 0.36 µg/ml for ADP. Standard deviations of migration times were generally 
low (Table 5.1).  
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Table 5.1. Limits of detection, limits of quantification, migration times and linearity of 
calibration curve for AMP and ADP determination. 
 
Compound  
 
AMP ADP 
Limit of detection ± SDa 
(µg/ml)  
0.80 ± 0.20 0.36 ± 0.10 
Limit of quantification ± SD 
(µg/ml)  
2.95 ± 0.21 1.41 ± 0.13 
Coefficient of correlation; R2 0.998 0.999 
Mean value of migration time  
± SD (min) (n= 12) 
6.00 ± 0.03 4.77 ± 0.01  
RSDb of migration time (%) 0.50 0.21 
Regression equation y = 724.5x + 1.53, 
Sy,x= 775 
y = 432.2x + 0.70, 
Sy,x= 241 
 aSD = standard deviation 
 bRSD = relative standard deviation 
 
5.3.3. Determination of Michaelis-Menten constant (Km) and maximum velocity (Vmax)   
The newly developed method was subsequently used to characterize the catalytic properties of 
defined members of the E-NTPDase family. Using the optimized conditions, Michaelis-Menten 
constants (Km) and maximal velocity (Vmax) for NTPDases were determined. The enzyme 
velocity was determined by measuring the peak areas of the products of the enzymatic reaction. 
Km values were obtained by using different concentrations of the substrate ATP. Each substrate 
concentration was analyzed in triplicate. The Michaelis-Menten plots are depicted in Figure 5.7. 
Estimated Km values of 76, 203, and 311 µM were obtained for NTPDase1, 2 and 3, respectively. 
The initial reaction velocities were calculated from the amounts of product formed, AMP in the 
case of NTPDase1 and ADP in the case of NTPDase2 and 3. Vmax values were 0.023, 0.021 and 
0.010 µmol/min/mg of protein (membrane preparation) for NTPDase1, 2, and 3, respectively 
(Table 5.2).  
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Table 5.2. Kinetic parameters of NTPDases. The results are means ± SEM of three separate 
experiments each run in duplicate. 
 
 
 
NTPDase1 NTPDase2 NTPDase3 
Km  ± SEM [µM] 76 ± 12 203 ± 8  311 ± 4 
Vmax ± SEM 
[µmol/min/mg protein] 
 
0.023 ± 0.002 0.021 ± 0.002 0.010 ± 0.001 
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Figure 5.7. Michaelis-Menten plots for the enzymatic reaction of NTPDase1 (◆), NTPDase2 
(●) and NTPDase3 (■) of initial ATP concentrations with respect to the reaction velocity for the 
determination of Km and Vmax  values by using in-capillary reaction at capillary inlet. For enzyme 
activity assay see section 2.4 and for CE conditions see Figure 5.6. Data points represent means 
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± SD from three separate experiments each run in duplicate. For determined Km and Vmax values 
see table 5.2. 
 
5.3.4. Development of an enzyme inhibition assay  
Four selected NTPDase inhibitors were investigated: The nucleotide analog ARL67156 (Figure 
5.3), the anthraquinone dye Reactive blue 2, the pyridoxal phosphate derivative PPADS, and the 
symmetrical naphthalenesulfonic acid derivative suramin (Figure 5.4). While ARL67156 has 
been reported to be a weak but selective ectonucleotidase inhibitor without significant effects at 
P2 receptors, the other three compounds are also antagonists at certain P2 receptors 166,169.  
Inhibition of NTPDases 1, 2 and 3 was determined by a range of concentrations of inhibitors 
spanning 3 orders of magnitude. The compounds entered the capillary inlet together with the 
substrate by hydrodynamic injection and the injected plugs of substrate/inhibitor and enzyme 
were then allowed to react for 5 min. The compounds reacted inside the capillary without 
applying any voltage, unlike in EMMA, where compounds are mixed electrophoretically by 
applying voltage before the reaction takes place. After the reaction, a constant current of –60 µA 
with reverse polarity was applied to separate the reaction products. As an example, an overlay of 
six electropherograms of the NTPDase3 enzymatic reaction is shown in Figure 5.6, in which the 
inhibitor concentration (reactive blue 2) was varied from 0.2 to 20 µM and the concentration of 
ATP as a substrate was fixed at 320 µM. By increasing the concentration of the inhibitor reactive 
blue 2, the peak height for ADP was decreased. Using NTPDase1, NTPDase2 and NTPDase3 and 
the newly developed CE method, a concentration-dependent inhibition by the standard inhibitors 
was observed for each of the enzymes (Figure 5.8-5.10). This allows a direct comparison of the 
effects of these inhibitors on a variety of identified NTPDases. The Ki values derived are 
summarized in Table 5.3.  
The Ki values clearly show that the various NTPDases are differentially susceptible to the 
individual inhibitors. The values for reactive blue 2 were similar for NTPDase1 and 2, but lower 
by a factor of 20 for NTPDase3. Similarly, Ki values for PPADS were similar for NTPDase1 and 
NTPDase2 but 15-fold lower for NTPDse3. ARL67156 revealed the highest inhibitory potency 
for NTPDase1, was considerably less effective on NTPDase3 and essentially ineffective on 
NTPDase2. In contrast, suramin revealed the lowest Ki values for NTPDase3 and was less 
effective on NTPDase2 and NTPDase1. Dipyridamole was not an inhibitor of the E-NTPDases 
investigated.  
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Table 5.3. Ki values for NTPDase1, 2 and 3 obtained for Reactive blue 2, PPADS, suramin, and 
ARL67156, using the in-capillary electrophoresis method. The results are means ± SEM of three 
separate experiments each run in duplicate.  
 
Inhibitora Ki ± SEM [µM] 
 NTPDase1 NTPDase2 NTPDase3 
RB2 20.0 ± 0.003 24.2 ± 0.06 
 
1.10 ± 0.03 
 
PPADS 46.0 ± 0.01 44.2 ± 0.03 3.0 ± 0.001 
Suramin 300 ± 0.1 65.4 ± 0.01 12.7 ± 0.03 
ARL 67156 27.0 ± 0.004 ≥ 1,000b 
 
112.1 ± 0.05 
Dipyridamole 
 
> 1,000c > 1,000c 
 
> 1,000c 
 
 
                              a For structures see Figure 5.4 
                              b 50 % inhibition at 1 mM concentration 
                              c no inhibitory activity up to a concentration of 1 mM 
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Figure 5.8. Concentration-dependent inhibition of NTPDase1 by reactive blue 2 (), ARL67156 
(▼) suramin (●) and PPADS (◆) determined by capillary electrophoresis using in-capillary 
reaction at capillary inlet, using a substrate concentration of 320 µM ATP, a reaction buffer 
consisting of 140 mM NaCl, 5 mM KCl, 1 mM MgCl2, 2 mM CaCl2, and 10 mM Hepes, pH 7.4, 
and various concentrations of inhibitor. The separation conditions were 50 mM phosphate buffer, 
pH 6.5, neutral capillary, 30 cm length (20 cm to the detector), 50 µm I.D.; -60 µA, 7 kV; 
capillary cartridge temperature 37 °C; detection at 210 nm, pressure injection. Data points 
represent means ± SD from three separate experiments, each run in duplicate. 
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Figure 5.9. Concentration-dependent inhibition of NTPDase2 by reactive blue 2 (■) suramin (●) 
and PPADS (◆) determined by capillary electrophoresis using in-capillary reaction at capillary 
inlet. For CE and assay conditions see Figure 5.6. Data points represent means ± SD from three 
separate experiments, each run in duplicates. ARL67156 (not shown) exhibited only 50 % 
inhibition at a concentration of 1 mM. 
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Figure 5.10. Concentration-dependent inhibition of NTPDase3 by reactive blue 2 (■), 
ARL67156 (▼), suramin (●) and PPADS (◆) determined by capillary electrophoresis using in-
capillary reaction at capillary inlet. For CE and assay conditions see Figure 5.6. Data points 
represent means ± SD from three separate experiments each run in duplicate. 
 
5.3.5. Investigation of Reactive blue 2 derivatives and polyoxometalates as nucleoside 
triphosphate diphosphohydrolase inhibitors by capillary electrophoresis 
 Reactive blue 2 (RB-2) had been characterized as a relatively potent NTPDase inhibitor with 
some selectivity for NTPDase3 (see table 5.3.). In search for the pharmacophore and to analyze 
structure-activity relationships we investigated a series of truncated derivatives and analogs of 
RB-2. Anthraquinone dervatives 5.2.1-5.2.11 (see table 5.4) inhibited the NTPDases in a 
concentration-dependent manner.  
 
Table 5.4. Ki values for NTPDase1, 2 and 3 of anthraquinone derivatives determined by capillary 
electrophoresis. The results are means ± SEM of three separate experiments each run in 
duplicate; P2Y2 receptor inhibitory activity for assessing enzyme versus receptor selectivity is 
given. 
 
O
O
NH2
S
R
O
O
O Na 
+
 
Ki [µM] ±  SEM Inhibitor 
NTPDase1 NTPDase2 NTPDase3 
RB-2 (lead structure) 20.0 ± 0.003 24.2 ± 0.06 1.10 ± 0.03 
IC50 ± SEM
[µM], P2Y2-
Receptord 
No. R     
5.2.1 O
N
H
CH3NH
CH3
 
 > 1 mM (15 % a) 486 ± 18 343 ± 63 12 ± 4 
5.2.2 ClN
H  
15.7 ± 3.4 18.0 ± 2.0 16.4 ± 1.6 21 ± 7 
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5.2.3 N
H
CH3CH3
 
> 100 µMc 
1 mM (67 %a,c) 
22.7 ± 3.4 38.5± 5.0 14 ± 9 
5.2.4 
CH3NH
CH3
 
18.0 ± 3.5 15.6 ± 2.5 41.8 ± 5.5 10 ± 1 
5.2.5 
N
H
CH3  
> 1 mM (25 %a) 25.7 ± 5.1 23.0 ± 2.5 11 ± 2 
5.2.6 N
H
CH3
 
51.5 ± 0.4 12.8 ± 0.9 19.1 ± 6.0 22 ± 7 
5.2.7 
O
N
H
 
> 1 mM (17 %a) 40.8 ± 11.1 58.0 ± 12.7 18 ± 4 
5.2.8 NH
OCH3  
≈ 1 mM (57 %a) 53.8 ± 5.7 17.6 ± 6.6 10 ± 2 
5.2.9 N
H  
49.1 ± 5.1 35.8 ± 6.1 14.3 ± 1.5 11 ± 3 
5.2.10 
N
H
 
>>1 mM (0 %a) >>1 mM (0 
%a) 
1.5 ± 0.1 11 ± 1 
5.2.11 OMe
OMe
N
H
 
173 ± 6 54.1 ± 6.8 23.4 ± 0.4 n.db 
 
ainhibition at 1 mM. 
bnot determined. 
cA curve could not be determined. Inhibition was not concentration-dependent; there was no 
inhibition at 100 µM. 
dDissertation, S. Weyler, University of Bonn, 2004. 
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Figure 5.11. Structures of some anthraquinone derivatives and partial structures of suramin 
inactive as NTPDase1, 2 and 3 inhibitors. 
 
Structure-activity relationships 
Even though the investigated anthraquinone derivatives exhibited only a partial structure of RB-2 
and were much smaller than the parent compound, many of them were similar or even more 
active as NTPDase inhibitors. For example, compound 5.2.2 bearing a p-chlorophenylamino 
residue was a potent, non-selective NTPDase inhibitor (Ki 16-18µM). While NTPDase 2 and 3 
were quite tolerant with regard to the substituent R accepting a large variety of different 
substituted arylamino residues and even an arylethylamino residue, SARs of NTPDase 1 were 
more restricted: phenylamino (5.2.9), p-chlorophenylamino (5.2.2), m-methyl- (5.2.6) and o, p-
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dimethylphenylamino (5.2.4) were best tolerated, while monosubstitution in the ortho-position of 
the phenylamino residue (5.2.5, 5.2.7, 5.2.8) or replacement of the phenyl ring by 1-naphthyl 
(5.2.10) or a phenylethyl residue (5.2.11) were detrimental for NTPDase 1 inhibitory activity. 
Compound 5.2.10 was the most potent and selective inhibitor of NTPDase3 and not inhibitory to 
NTPDase1 and 2 even at high, millimolar concentrations. Anthraquinone derivatives with 
substitutions at the sulfonate and sulfanilamide groups were not inhibitors of NTPDases 
(compounds 5.2.12-5.2.19 and 5.2.32-5.2.35) (Figure 5.11). Thus, the sulfonate group appeared 
to be required for NTPDase inhibition. Other classes of non-anthraquinone derivatives related to 
suramin that were tested, compounds 5.2.20-5.2.35, were also inactive at NTPDases1-3 (Figure 
5.11 and 5.12). 
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Figure 5.12. Partial Structures of suramin  
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Polyoxometalates are anionic complexes that have relatively high thermodynamic and/or kinetic 
stability in aqueous solutions at biological pH. In addition to well-developed applications in 
catalysis, separations, analysis and as electron-dense imaging agents, these complexes have been 
shown to exhibit biological activity ranging from enzyme inhibition to antitumour/antiviral 
properties177. All of the polyoxometalates tested, PV1 to PV6, were potent inhibitors of the 
NTPDases, with Ki values between 0.14 and 29 µM (Table 5.5). Compound PV1 and PV3 were 
selective inhibitors, they showed low Ki values for NTPDase1 and 2 but higher ones for 
NTPDase3, while PV2, PV4 and PV5 were equally potent inhibitors for all three NTPDases. PV6 
was not an inhibitor of NTPDase1 but a potent inhibitor of NTPDase2 and 3. Previously, 
[(O3POPO3)4W12O36]16- (polyoxometalate I) and [(O3PCH2PO3)4W12O36]16- (polyoxometalate II)  
which are structurally related, have been used successfully against HIV-1 infected cells. It was 
found that these compounds inhibit the DNA polymerases, with IC50 values ranging from 2 to 10 
µM177. The cesium and tetramethylammonium (TMA) salts of polyoxotungstate anions with 
covalently attached organosilyl groups were found to be active against HIV-1 with EC50 values in 
the range of 3.3 to 50 µM178. The anti-HIV-1 activity of polyoxotungstates in human 
lymphocytes was tested and EC50 values were found to be around 1 µM179. But in our study the 
Ki values are even lower for NTPDase inhibition, with Ki values as low as 140 nM (PV4, 
NTPDase 1).  
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Table 5.5. Ki values for polyoxometalate inhibitors of NTPDase1, 2 and 3 obtained by a capillary 
electrophoresis method. The results are means ± SEM of three separate experiments each run in 
duplicate. Formulae, molecular mass and stability of polyoxometalates tested as NTPDase     
inhibitors. 
 
Inhibitor General informations Ki [µM] ± SEM 
 
Formula Stability 
at pH 7.4
Mr 
 g/mole 
NTPDase1 NTPDase2 NTPDase3 
PV1 
PV2 
PV3 
PV4 
PV5 
 
PV6 
Na6[W12O39] x H2O 
H3[PW12O40] x H2O 
K7[Ti2W10PO40] K6H2 
[CoW11TiO40] x 12H2O 
K10[Co4(H2O)2(PW9O34)2] 
x 22H2O 
(NH4)18[NaSb9W21O86] 
stable 
< 1 h 
stable 
3 h 
24 h 
 
10 h 
2986.1 
2880.2 
2878.9 
3221.9 
5518.3 
 
6680.2 
2.58 ± 0.30 
3.49 ± 0.23 
2.00 ± 0.34 
0.140 ± 0.021 
0.480 ± 0.010 
 
> 1 mM (15 %)a 
28.8 ± 0.2 
6.17 ± 0.15 
37.4 ± 1.3 
0.910 ± 0.041 
1.53 ± 0.20 
 
3.94 ± 0.78 
3.26 ± 0.18 
8.72 ± 1.81 
4.00 ± 0.26 
0.563 ± 0.113 
2.61 ± 0.97 
 
3.77 ± 0.52 
a Percent inhibition at 1 mM 
 
5.3.6. Investigations of uridine-derived nucleotide mimetics as nucleoside triphosphate 
diphosphohydrolase1 inhibitors by capillary electrophoresis 
Several different uridine-derived nucleotide mimetics (for structures see Figure 5.13) were tested 
at NTPDase1 using similar assay conditions as for P2 receptor antagonists but with 1.0 mM 
concentration of test compounds. But none of them was inhibitory at the tested 1.0 mM 
concentration. 
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Figure 5.13. Structures of uridine nucleotide mimetics 
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5.4. Discussion 
The ecto-nucleoside triphosphate diphosphohydrolases (EC 3.6.1.5) represent a major and 
ubiquitous family of ecto-nucleotidases. They catalyze the sequential hydrolysis of the γ- and β-
phosphate residues of nucleoside tri- and diphosphates, producing the corresponding nucleoside 
monophosphate derivatives146. To date four different cell surface-located isoforms of the enzyme 
family have been cloned and functionally characterized (NTPDase1, 2 and 3, and very recently 
NTPDase8)151,180,181. The four enzymes differ in substrate specificity and in the pattern of product 
formation. Whereas NTPDase1 hydrolyzes ATP and ADP about equally well, NTPDase2 has a 
high preference for the hydrolysis of ATP over ADP. NTPDase3 and NTPDase8 are functional 
intermediates. NTPDase1 hydrolyzes ATP directly to AMP, ADP is the preferential product of 
ATP hydrolysis by NTPDase2, and NTPDase3 and NTPDase8 hydrolyze ADP formed from ATP 
efficiently to AMP.   
 
In previous studies, a variety of compounds have been tested regarding their potency for 
inhibiting ecto-nucleotidases, often in intact tissues or on cells with undefined enzyme species. 
Only few studies have used recombinant enzymes to clearly identify the isoform investigated 
149,165. In addition, several methods have been used for the determination of Michaelis-Menten 
constants (Km values), and inhibition constants (Ki values for enzyme inhibitors) of NTPDases, 
including radioisotopic166, HPLC148,182,182 and spectrophotometric assays183. All of these methods 
are time-consuming. Radiometric assays are very sensitive, but require tedious procedures and 
the use of radiolabeled substrates166. High performance liquid chromatography suffers from 
relatively high prices for columns, buffers and solvents; in addition, sample pretreatment to 
remove proteins and lipids is required. Spectrophotometric methods 157,183 require large amounts 
of material and are prone to interference from other biological matrices. In addition, the analysis 
of the total of free phosphate formed confuses the additive contribution of the ATPase and 
ADPase activity of the identical enzyme, if the nucleoside triphosphate is applied. Our newly 
developed in-capillary electrophoresis method represents an easy, fast and convenient method for 
analyzing ecto-nucleotidase activity, including substrate analysis, enzyme kinetics, and the 
screening for novel inhibitors.  
The validity of the method is underpinned by a comparison with previously obtained Km values. 
Reported Km values vary between species and investigators. Since in many cases the identity of 
the enzyme species was not determined, the values cannot easily be related to our data. However, 
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the Km  values we have obtained for the rat orthologs of the enzymes are in very good agreement 
with values obtained for the recombinant enzymes from other species. Reported Km-values (ATP, 
µM) are 17 for human NTPDase1180 and 12 for mouse NTPDase1180; 70, 210 and 394, 
respectively for human NTPDase2184,185 and 37 for mouse NTPDase2; 75 and 128, respectively 
for human NTPDase3186 and 11 for mouse NTPDase3 187. Interestingly, the value obtained for rat 
NTPDase1 in our study (76 µM) is in excellent agreement with a previously reported value for 
recombinant rat NTPDase1 (75 µM187). The Km values for NTPDase8, the most recently cloned 
member of the enzyme family are within the same range (13 µM for mouse and 46 µM for rat 
NTPDase8)181.  
Using identified enzyme species we can clearly show that NTPDase1, 2 and 3 reveal a 
differential susceptibility to inhibitors. An inhibitory effect of suramin20,21,23,160,166,188-191, of 
PPADS166, of Reactive blue 223,166,190, or of ARL6715623,156,169 on the hydrolysis of ATP by 
mammalian ecto-nucleotidases has previously been reported for various cellular systems. 
However, these studies did not identify the NTPDase isoform(s) expressed nor did they exclude a 
contribution to ATP hydrolysis by other types of ecto-nucleotidases.  
In our study, Reactive blue 2, PPADS and suramin inhibited NTPDase3 15- to 25-fold more 
effectively than NTPDase1. NTPDase2 was inhibited by Reactive blue 2 and PPADS to a similar 
extent as NTPDase1 but the Ki value for suramin was five fold higher for NTPDase1. An analysis 
of detergent-solubilized NTPDase1 and NTPDase2 purified from porcine brain, revealed Ki 
values (ATP) for suramin of 1.8 mM and 2.1 mM, respectively82,147. These values are much 
higher than those obtained for the membrane-bound rat enzymes reported in this study. In 
contrast to the other compounds tested, ARL67156 revealed the highest inhibitory potency for 
NTPDase1. It was considerably less effective on NTPDase3 and essentially ineffective on 
NTPDase2. Since ARL67156 is a widely used inhibitor of “ecto-ATPase” activity, this 
observation is a caveat for experiments in which this inhibitor is used without previous 
identification of the NTPDase involved. Dipyridamole was not an inhibitor of the NTPDases 
investigated but in a previous study it was found to be an effective inhibitor of ATP hydrolysis in 
rat superior cervical ganglionic cells at 10 µM concentration192. The compound has been found to 
be inactive in other systems [e.g.13]. 
The P2 receptors are currently under intense investigation in order to understand the 
pharmacology of these receptors and the physiological processes they mediate162. To determine 
the structural requirements for inhibition of NTPDases by Reactive blue 2 and suramin, we tested 
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a series of analogs. Several anthraquinone derivatives related to Reactive blue 2 were active 
(5.2.1-5.2.11). Compound (5.2.1) is more active at NTPDase1 than NTPDase2 and 3 but 
equipotent at P2Y receptors. It seems that amino-hydroxy-naphthalene-sulfonate structures are 
responsible for the binding with P2 receptors and NTPDases.  
The position of sulfonate group is important for the activity in case of P2Y receptors and 
NTPDases. Within the anthraquinone derivatives the individual compounds are about equipotent, 
indicating that the position of the substituents has little effect on potency (5.2.2-5.2.9). 
Compound 5.2.10 was a selective inhibitor of NTPDase3 with Ki value of 1.5 µM, while being 
inactive at NTPDase1 and 2. Several- fold lower activity (IC50 = 11 µM) was observed at P2Y2 
receptors, compared to NTPDase3 inhibitory activity. It contains a naphthalene ring side chain. It 
is noteworthy that all of the inhibitors used in this study share two common structural feature- 
multiple negative charges (sulfonates) and hydrophobic fused rings- suggesting that these are key 
determinants for the binding specificity of both the purinoceptors and the NTPDases. 
Anthraquinone derivatives with substitution at the sulfonate group were not inhibitors of 
NTPDases (compounds 5.2.12-5.2.25). The presence of an unsubstituted sulfonate group on the 
anthraquinone core is important for both P2Y2 receptors and NTPDase inhibition of the analogs. 
Effects of Reactive blue 2 and related analogs had been studied on ecto-nucleotidases and P2 
receptors but no structure-activity relationships were established164, similar studies had been 
conducted with suramin and Reactive red analogs193. 
 
5.5. Summary  
A capillary electrophoresis (CE) method for the characterization of recombinant NTPDases 1, 2, 
and 3, and for assaying NTPDase inhibitors has been developed performing the enzymatic 
reaction within the capillary. After hydrodynamic injection of plugs of substrate solution with or 
without inhibitor in reaction buffer, followed by a suspension of an enzyme-containing 
membrane preparation, and subsequent injection of another plug of substrate solution with or 
without inhibitor, the reaction took place close to the capillary inlet. After 5 min, the 
electrophoretic separation of the reaction products was initiated by applying a constant current of 
–60 µA. The method employing a polyacrylamide-coated capillary and reverse polarity mode 
provided baseline resolution of substrates and products within a short separation time of less than 
7 min. A 50 mM phosphate buffer (pH 6.5) was used for the separations and the products were 
detected by their UV absorbance at 210 nm. In order to define the properties of individual 
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isoforms, we determined the Km-values of heterologously expressed NTPDase1, NTPDase2 and 
NTPDase3 and the Ki values for selected inhibitors. The Michaelis-Menten constants (Km) for the 
recombinant rat NTPDases 1, 2, and 3 obtained with this method were consistent with previously 
reported data. The inhibition studies revealed pronounced differences in the potency of reactive 
blue 2, pyridoxalphosphate-6-azophenyl-2',4'-disulfonic acid (PPADS), suramin, and N6-diethyl-
β,γ-dibromomethylene-ATP (ARL67156) towards the NTPDase isoforms. Notably, ARL67156 
does not inhibit all NTPDases, having only a minor inhibitory effect on NTPDase2. 
Dipyridamole is not an inhibitor of the NTPDase isoforms investigated. To determine the 
structural requirements for inhibition of NTPDases by suramin and Reactive blue 2, we also 
tested a series of analogs. Compound 5.2.10 was identified as a selective inhibitor of NTPDase3 
with a Ki value of 1.5 µM, while being inactive at NTPDase1 and 2.  
The scale of the enzymatic reaction could be dramatically reduced to the nanoliter scale as 
compared to off-line analysis of the reaction carried out in a microcentrifuge tube. Moreover, 
since the capillary is used as a reaction vessel, all the assay steps (mixing, reaction, separation, 
and quantitation) are combined in a fully automated assay. This process was carried out using a 
temperature-controlled autosampler in order to eliminate routine handling and to speed-up the 
process. The new method is fast and accurate, requires no sample pretreatment and can be fully 
automated; thus it is clearly superior to the current standard methods. 
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Chapter 6. Investigation of the extracellular metabolism of 
nucleotides in neuroblastoma x glioma NG108-15 cells determined 
by at-capillary inlet reaction 
 
6.1. Introduction 
Extracellular purine and pyrimidine nucleotides, such as ATP, ADP, UTP and UDP, are 
physiological signalling molecules which bind to membrane receptors termed P2 receptors and 
produce a wide range of physiological responses18. Nucleotides released into the extracellular 
space are rapidly degraded by ecto-nucleotidases145. Such metabolism is quite important in 
control of nucleotide-mediated cellular responses, not only terminating the activation of P2 
receptors but also generating another signalling molecule, adenosine. Since P2 receptors usually 
co-exist with P1 adenosine receptors, extracellular adenine nucleotide metabolism converts the 
signal input derived from P2 receptors to P1 receptors. A major problem in pharmacological 
studies at P2 receptors using nucleotides is their fast enzymatic degradation. Some P2 receptor 
antagonists make the studies even more complicated by inhibiting the ecto-nucleotidases. 
Extracellular adenine nucleotide metabolism to adenosine proceeds by a cascade of several ecto-
enzymes, such as ecto-ATPase, ecto-apyrase, ecto-nucleotide pyrophosphatase and ecto-5'-
nucleotidase (CD73). These enzyme activities largely affect P2 receptor-mediated physiological 
responses. A group of enzymes was previously identified to metabolize nucleotides on NG108-15 
cells based on degradation and inhibition studies: (1) ecto-alkaline phosphatase (E-ALP) 
responsible for AMP and UMP hydrolysis. In addition, the enzyme plays an important role in the 
breakdown of UDP, and to a lesser extent of ADP and UTP, while exhibiting only a minor effect 
on ATP degradation; (2) ecto-adenylate kinase, which leads to the phosphorylation of ADP to 
ATP; and (3) E-NTPDase which is mainly responsible for the beakdown of ATP and UTP13. 
Capillary electrophoresis (CE) appears to be well-suited to the study of whole, intact cells. It is 
possible to analyze samples with volumes ranging from nanoliters to picoliters with CE. It also 
provides fast and highly efficient separations of diverse analytes. It has recently been used for the 
screening of specific ligands of endothelin receptors by immobilizing whole cells on the capillary 
surface194. But this approach may encounter a problem that receptors or enzymes may lose their 
activity upon fixation to the capillary column. Also, coating of the capillary column with cells is 
very difficult and a non-reproducible method. Therefore, we developed an electrophoretically 
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mediated microanalysis (EMMA) method for studying the extracellular adenine nucleotide 
metabolism of intact live NG108-15 cells. 
In this study, a simple and fast method for analyzing the extracellular enzymatic degradation of 
nucleotides has been developed, performing the reaction inside the capillary at the capillary inlet 
followed by electrophoretic separation of the reaction products. In the at-capillary inlet reaction 
technique, plugs of live NG108-15 cells and substrate are introduced into the capillary, where 
they are allowed to react by simple diffusion173. After that the products are separated by 
application of the voltage. 
 
6.1.1. Experimental 
6.1.1.1. Apparatus 
The experiments were performed on a P/ACE capillary electrophoresis (CE) system MDQ 
glycoprotein (Beckman Coulter Instruments, Fullerton, CA, USA) equipped with a UV detection 
system. The electrophoretic separations were carried out using an eCAP polyacrylamide-coated 
fused-silica capillary [(30 cm (20 cm effective length) x 50 µm internal diameter (I.D.) x 360 µm 
outside diameter (O.D.), obtained from CS-Chromatographie (Langerwehe, Germany)]. An 
electrokinetic injection for 30 seconds was applied for introducing the sample. The separation 
was performed using an applied current of -60 µA and a data acquisition rate of 8 Hz. Analytes 
were detected using direct UV absorbance at 210 nm. The capillary was conditioned by rinsing 
with 10 mM HCl, 0.5 % SDS for 1 min, with water for 0.5 min and subsequently with buffer 
(phosphate 50 mM, pH 7.4) for 1 min. Sample injections were made at the cathodic side of the 
capillary. The CE-instrument was fully controlled through a PC, which operated with the analysis 
software 32 KARAT obtained from Beckman Coulter. The evaluation of the electropherograms 
was done using the same software. The capillary temperature was kept constant at 37 °C. The 
temperature of the sample storing partition was adjusted to 37 °C. 
 
6.1.1.2. Chemicals 
The nucleotides adenosine-5’-diphosphate, adenosine-5’-triphosphate, uridine-5’monophosphate, 
uridine-5’-diphosphate, uridine-5’-triphosphate were obtained from Sigma (Taufkirchen, 
Germany). Stock solutions of nucleotides were prepared in Hepes (N-[2-
hydroxyethyl]piperazine-N’-[2-ethanesulfonic acid]) buffer with nucleotide concentrations 
ranging from 1 to 10 mM. The dipotassium hydrogen phosphate for the CE buffer was purchased 
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from Fluka (Neu-Ulm, Germany). Sodium chloride, potassium chloride, potassium dihydrogen 
phosphate, sodium bicarbonate, anhydrous D-glucose, Hepes (free acid), calcium chloride and 
magnesium sulfate (constituents of Krebs-Hepes buffer), Dulbecco's modified eagle's medium 
(DMEM), penicillin-streptomycin and fetal bovine serum for cell culture were obtained from 
Sigma. HAT (hypoxanthine, aminopterin, thymidine) supplement was from Gibco Life 
Technologies (Karlsruhe, Germany).  
 
6.1.1.3. Biological experiments and sample preparation  
Cells were cultured in DMEM containing 10% fetal bovine serum, HAT-supplement and 
penicillin-streptomycin until cells were 80% confluent. After rinsing off the cells from the culture 
flasks they were washed three times with Krebs-Hepes buffer at 37 °C. Then the pellet was 
suspended in buffer at a cell concentration of 105 cells per mL (final concentration in the assay). 
The Krebs-Hepes buffer consisted of sodium chloride (118.6 mM), potassium chloride (4.7 mM), 
potassium dihydrogen phosphate (1.2 mM), sodium bicarbonate (4.2 mM), anhydrous D-glucose 
(22 mM), Hepes (free acid, 10 mM), calcium chloride (1.3 mM) and magnesium sulfate (2.7 
mM).  
 
6.1.1.4. Sample preparation procedure  
Nucleotides were first dissolved in Krebs-Hepes buffer to obtain 10.0 mM stock solutions. These 
were further diluted with the necessary amount of the same buffer to obtain a physiological 
concentration of nucleotides for the in-capillary NG108-15 cell metabolism studies. NG108-15 
cell suspension (105 cells/mL) was placed in mini CE vials inside the instrument.  
 
6.1.1.5. At-inlet reaction procedure and automation of analytical process  
The CE running buffer consisted of dipotassium hydrogen phosphate 50 mM, pH 7.4. The 
reaction buffer (Krebs-Hepes buffer) consisted of sodium chloride (118.6 mM), potassium 
chloride (4.7 mM), potassium dihydrogen phosphate (1.2 mM), sodium bicarbonate (4.2 mM), 
anhydrous D-glucose (22 mM), Hepes (free acid, 10 mM), calcium chloride (1.3 mM) and 
magnesium sulfate (2.7 mM). Before use, a new capillary was washed with deionized water for 
10 minutes. The automation cycle consisted of (i) washing with 10 mM HCl, 0.5 % SDS for 1 
min (40 p.s.i; 1 p.s.i = 6894.76 Pa) (ii) with water for 0.5 minutes (ii) equilibration with the CE 
running buffer for 1 minute (40 p.s.i), (iii) injection of a plug of reaction buffer containing 
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NG108-15 cells, (iv) injection of a plug of reaction buffer containing ATP, 200 µM, (v) injection 
of another plug of reaction solution as in (iii), (vi) and finally injection of a plug of water. The 
plugs were then allowed to react, while the capillary ends were dipped into water, for a 
predetermined waiting period of 5 min. Then, a current of -60 µA was applied and the reaction 
products moved towards the detector end of the capillary. After each analysis the capillary was 
rinsed with 10 mM HCl, 0.5 % SDS for 2 min, CE running buffer for 1 min followed by 
deionized water for 0.5 min.  
Each electropherogram was recorded over 7 min. The NG108-15 cells were placed in the sample 
storage unit whose temperature was kept constant at 37 °C. At this temperature, the cells’ activity 
remained unaffected during the approximately 12 h of instrument run. Substrate and buffers used 
in the reaction were also kept at 37 °C in the autosampler reservoir.  
 
 
6.2. Results and discussion 
6.2.1.  Optimization of washing procedure 
In our previous studies13,30 we performed enzymatic reactions outside the capillary and diluted 
the samples before injection into the capillary, which produced reproducible migration times and 
sharp peaks with simple washing procedures using water and separation buffer. Later on using an 
in-capillary enzymatic reaction procedure, there was a need to increase the rinsing time to get 
reproducible migration times, since with shorter rinsing times the capillary was blocked after 
several runs. However, in this study, investigating the nucleotide metabolism by NG108-15 cells 
by performing the reaction directly inside the capillary, we observed the adsorption of materials 
on the coated capillary. The accumulation of proteins at the capillary wall is probably caused by 
precipitation of proteins/lipids by the freely moving non-cross-linked polyacrylamide chains 
attached at a high ligand density to the capillary wall (free polymers are known to precipitate 
proteins)195. Therefore, previously established procedures of washing were not enough for 
reproducible results, which generated zone broadening after few runs. To prevent such 
distortions, the efficacy of different conditioning procedures was evaluated. Washing procedures 
applying 5 M and 2 M HCl for 2 min and 5 min, respectively, were tried followed by 
conditioning for 2 min with separation buffer, 50 mM phosphate, pH 7.4. However, this 
procedure was not efficient enough to remove the proteins accumulated at the capillary wall. 
Also, polyacrylamide coating did not withstand such strongly acidic conditions. It has previously 
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been reported that for polyacrylamide-coated capillaries washing with 2 M HCl between the runs 
and storage in water over night, is a prerequisite for their high performance. But in our case the 
capillary coating was found to be not stable under strongly acidic conditions196. Wätzig et al. 
investigated the use of washing solutions containing sodium dodecyl sulfate (SDS) in the 
analyses of both small molecules and proteins. It was observed that after the SDS wash, the 
electroosmotic flow was restored to values close to normal in a capillary which had previously 
been coated with plasma proteins, even when applying a reduced washing procedure (1 min)197. 
SDS binds to the proteins, denatures them and gives them a net negative charge which 
considerably reduces their tendency to adhere to the walls of the capillary. Plasma protein 
samples were analyzed by the direct injection method and subsequent washing with SDS gave 
reproducible results198. Capillary zone electrophoresis using polyacrylamide-coated capillaries 
had been used to study metallothionein isoforms (cysteine-rich metal-binding proteins), using 
sodium phosphate buffer for separation. 0.01 M HCl containing 0.5 % SDS was used as a 
washing procedure between each run199. We observed that the use of 0.01 M HCl containing 0.5 
% SDS, pH 3.0, was a good separation buffer for obtaining reproducible migration times in a 
polyacrylamide-coated capillary. 
 
 6.2.2. Biological applications 
6.2.2.1. Nucleotide metabolism by NG108-15 cells 
Nucleotide metabolism is usually detected by HPLC or radioactive methods which are sensitive 
but costly and complicated. HPLC separations require large amounts of biological material and 
involve time-consuming procedures. In comparison to this, capillary electrophoresis offers a 
simple and cost-effective alternative. It allows short analysis times and requires only very samll 
amounts (nanoliters) of samples. Another major advantage of CE is the fact that it does not 
require sample pretreatment. The degradation of the nucleotides ATP and UTP by intact, live 
mammalian NG108-15 cells (mouse neuroblastoma x rat glioma hybrid cell line) was 
investigated using the developed CE method. As an example, electropherograms of ATP and 
UTP degradation by the cells are shown in Figure 6.1A and 6.1B. An electropherogram of 
NG108-15 cells without nucleotide added is shown in Figure 6.1 C. Plugs of assay buffer 
containing 105 cells/mL were injected and in between two plugs, a single plug of assay buffer 
containing 500 µM of nucleotide were injected by hydrodynamic injection into the capillary and 
then allowed to react for different time intervals. Subsequently, after electrophoretic separation, 
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the concentrations of nucleoside tri-, di-, and monophosphates were determined. The degradation 
of substrates (ATP and UTP) inside the capillary occurred without applying any voltage, unlike 
in EMMA, where compounds are mixed electrophoretically by applying voltage before the 
reaction takes place. After the reaction, a constant current of –60 µA with reverse polarity was 
applied to separate the reaction products. A time-dependent degradation of ATP and UTP was 
observed. On increasing the incubation time inside the capillary the formation of ADP, UDP and 
AMP and UMP was increased (Figure 6.2). Degradation of ATP to ADP was faster than that of 
ADP to AMP and UTP degradation was faster than that of UDP. Degradation of UTP was slower 
than that of ATP. This is the first time that the nucleotide metabolism by intact whole cells has 
been studied by capillary electrophoresis performing the enzymatic reaction directly inside the 
capillary.  
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Figure 6.1. A. Typical electropherogram of NG108-15 cell metabolism at capillary inlet using 
intact, live cells and performing the enzymatic reaction within the capillary. Concentration of 
NG108-15 cells was 105 cells/mL and 500 µM ATP was used as a substrate, in Krebs-Hepes 
buffer. The plugs of cells and substrates were allowed to stand during a predetermined period of 
5 min and subsequently a –60 µA current was applied and the reaction products migrated to the 
detector. The separation conditions were 50 mM phosphate, pH 7.4, polyacrylamide coated 
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capillary, 30 cm length (20 cm to the detector), 50 µm I.D.; -60 µA; 37 °C; detection at 210 nm; 
pressure injection; reverse polarity. 
B. Typical electropherogram of NG108-15 cell metabolism at capillary inlet. Concentration of 
NG108-15 cell was 105 cells/mL and 500 µM UTP was used as a substrate, in Krebs-Hepes 
buffer.  
C. Typical electropherogram of NG108-15 cell metabolism at capillary inlet. Concentration of 
NG108-15 cell were 105 cells/mL without nucleotide added, in Krebs-Hepes buffer.  
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Figure 6.2. Time-dependent degradation of ATP by NG108-15 cells (105 cells/ml). Determined 
by in-line CE assay using live cells. The initial ATP concentration was 500 µM. 
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6.3. Summary  
Capillary electrophoresis can be a valuable tool for the on-line monitoring of bioprocesses. The 
metabolism of extracellular nucleotides on intact NG108-15 cells, a neuroblastoma x glioma 
hybrid cell line, was studied by means of capillary zone electrophoresis (CZE) using an in-
capillary enzyme-catalyzed microreaction technique. The CZE method employing a neutral-
bonded capillary and reversed polarity mode provided a good resolution and short analysis time 
of less than 7 min. Plugs of cells and nucleotides were injected hydrodynamically and allowed to 
react inside the capillary for a predetermined period of time, after that degraded products were 
detected by their UV absorbance at 210 nm. Constant current (–60 µA) was applied, and a 
phosphate buffer, pH 7.4, was used. Ecto-nucleotidases and ectophosphatases present on the 
extracellular surface of the cells hydrolyzed nucleotides, such as ATP, ADP, UTP, UDP, UMP 
and AMP. The cells were stable in the presence of the applied electric current. This could be 
confirmed by injecting the cells into the capillary and allowing them to stand for 10 min; after 
electrophoretic separation we did not see any nucleotide peak. Which inticates that interacellular 
nucleotides, present in high concentration, are not released. In a separate experiment, the cells 
were destroyed by heating at 99 °C for 10 min to detect the nucleotides released from inside the 
cells. Under such conditions a high quantity of nucleotides was released from the cells. By these 
experiments it was confirmed that cells had remained intact during incubation inside the capillary 
and also by applying a current to separate the nucleotides. The method is superior to the other 
methods in which the cells were incubated outside the capillary. No sample preparation at all was 
required.  
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Chapter 7. Development of a capillary electrophoresis method for 
the investigation of ester hydrolysis products  
 
7.1. Introduction 
Marine ascidians are known to be a rich source of chemically diverse secondary metabolites with 
often remarkable biological activities. In many cases these compounds are simple amino acid 
derivatives or more complex alkaloids. Especially, ascidians of the family Didemnidae have been 
investigated intensively because of their unusual, cytotoxic metabolites.  
In the present study a CE-based assay was developed for the investigation of the chemical and 
enzymatic stability of a 5'-deoxy-5'-methylthioadenosine-2',3'-diester, a natural product isolated 
from a scidians200 that had been collected at  Heron Island’s, Wistari Reef, the Great Barrier Reef, 
Australia. 5'-deoxy-5'-methylthioadenosine-2',3'-diester was investigated in radioligand binding 
assays in order to determine its affinity for AR subtypes. To make sure that the measured effects 
were actually due to intact 5'-deoxy-5'-methylthioadenosine-2',3'-diester, we examined a possible 
hydrolysis of compound 5'-deoxy-5'-methylthioadenosine-2',3'-diester by rat brain cortical 
membrane preparations as a potential source of esterase activity. To examine the enzymatic 
hydrolysis of compound 5'-deoxy-5'-methylthioadenosine-2',3'-diester, it was incubated with 
carboxylesterase.  
 
7.2. Experimental 
7.2.1. Materials and methods 
7.2.1.1. Capillary electrophoresis instrumentation 
CE separations were carried out using a P/PACE system MDQ glycoprotein (Beckman Coulter 
Instruments, Fullerton, CA, USA) equipped with a DAD detection system. The electrophoretic 
separations were carried out using an eCAP fused-silica capillary [40 cm (30 cm effective length) 
x 75 µm internal diameter (I.D) x 375 µm outside diameter (O.D) obtained from Beckman 
Coulter]. On-line UV detection was performed in the range of 190-350 nm. The runs were 
performed under the following conditions: T = 25 °C, λmax = 260 nm, current = 95 µA, running 
buffer 25 mM sodium tetraborate buffer, 100 mM SDS, pH 8.5. The capillary was washed with 
0.1 N NaOH for 2 min, deionised water for 1 min, and 25 mM sodium tetraborate buffer, 100 
mM SDS, pH 8.5, for 1 min before each injection. Injections were made by applying 0.1 psi of 
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pressure to the sample solution for 25 s. The CE instrument was fully controlled through a 
personal computer, which operated with the analysis software 32 KARAT obtained from 
Beckman Coulter. The evaluation of the electropherograms was done using the same software. 
The temperature was kept constant at 25°C and the samples were also stored at the same 
temperature.  
 
7.2.1.2. Chemicals 
Tris(hydroxymethyl)aminomethane was obtained from Acros Organics, Geel, Belgium. Sodium 
tetraborate, boric acid and sodium dodecyl sulphate (SDS) were obtained from Sigma Aldrich, 
Germany. All other reagents were obtained from Sigma Aldrich, Germany. 
 
7.2.2. Determination of ester hydrolysis by capillary electrophoresis 
Ester hydrolysis of 5'-deoxy-5'-methylthioadenosine-2',3'-diester was performed with 
carboxylesterase from porcine liver (EC 3.1.1.1; 1840 I.U./mL) obtained from Sigma Aldrich, 
Germany. A 1 mM stock solution of 5'-deoxy-5'-methylthioadenosine-2',3'-diester in DMSO 
(12.5 µL) was diluted with Tris-HCl buffer, 5 or 50 mM, pH 8.0 (concentration of 5'-deoxy-5'-
methylthioadenosine-2',3'-diester : 25 µM) and 2 µL of carboxylesterase were added. Incubation 
was carried out at 25°C for 60 min. A sample of 12.5 µL of a 1 mM stock solution of 5'-deoxy-5'-
methylthioadenosine-2',3'-diester in DMSO was diluted with Tris-HCl buffer 50 mM, pH 7.4 
(concentration of 5'-deoxy-5'-methylthioadenosine-2',3'-diester: 25 µM) and incubated with rat 
brain cortex (protein concentration ca. 70 µg/mL) at room temperature (23°C) for 90 min.  
Incubation was terminated by heating the sample at 99°C for 10 min. The samples were 
centrifuged at 10,000 g for 5 min at room temperature (23°C) and the resulting supernatants were 
used for subsequent analysis by capillary electrophoresis (CE).  
 
7.3. Results and discussion 
7.3.1. Investigation of ester hydrolysis products by capillary electrophoresis 
Micellar electrokinetic capillary chromatography (MECC) was used for the separation of 
hydrolyzed products of a natural product, a 5'-deoxy-5'-methylthioadenosine-2',3'-diester (for 
structure see Table 7.1). 5'-deoxy-5'-methylthioadenosine-2',3'-diester consists of a nucleoside 
moiety (adenosine) with a methylthio group at the 5'-position of the ribose moiety instead of a 
hydroxyl group. The ribose is esterified with 3-(4-hydroxyphenyl)-2-methoxyacrylic acid at the 
 122
2'-position and with urocanic acid at the 3'-position. A standard solution of 5'-deoxy-5'-
methylthioadenosine-2',3'-diester (25 µM) was injected into the capillary and the migration time 
was found to be 17.72 min with a wavelength of maximum absorption at 295 nm using borate 
buffer (25 mM) with 50 mM SDS. Then 5'-deoxy-5'-methylthioadenosine-2',3'-diester was 
incubated with esterase to examine the hydrolysis of 5'-deoxy-5'-methylthioadenosine-2',3'-
diester (see Figure 7.1). Under these conditions, the 5'-deoxy-5'-methylthioadenosine-2',3'-diester 
was hydrolyzed to three products and peaks appeared at 4.77, 5.80, 6.28 and 17.72 min 
respectively, the last peak appeared with the same migration time as the standard, which could 
therefore be detected as the intact compound. Further detection of the hydrolyzed products was 
done by visualising their UV spectra. Each peak showed a different UV spectrum, wavelengths of 
maximum absorption with their characteristic UV band are collected in Table 7.1. By hydrolysis 
of 5'-deoxy-5'-methylthioadenosine-2',3'-diester the number of chromophores was changed, so 
that different UV spectra were obtained by photodiode array detection, which represented a key 
method to identify the hydrolyzed products.  
To examine the hydrolysis of the 5'-deoxy-5'-methylthioadenosine-2',3'-diester by rat brain 
cortical membranes, as a possible source of esterase activity, the 5'-deoxy-5'-
methylthioadenosine-2',3'-diester was incubated with rat brain cortex as described above. The 
resulting electropherogram showed only one peak that could be identified as the non-hydrolzsed 
intact 5'-deoxy-5'-methylthioadenosine-2',3'-diester (see Figure 7.2). In comparison to Figure 7.1 
no additional peaks could be found within the migration time of the three peaks derived from 
hydrolysis products. Therefore it could be confirmed that no hydrolysis of 5'-deoxy-5'-
methylthioadenosine-2',3'-diester occurred when incubating it with rat brain cortex. Further the 
stability of 5'-deoxy-5'-methylthioadenosine-2',3'-diester was examined by heating the 25 µM 
standard solution of the compound at 99°C for 10 min. When this solution was injected into CE 
no degradation products could be found, which confirmed that this compound was stable at high 
temperature. Therefore no degradation was caused in the termination process of the incubation by 
heating the samples at 99°C. In the sample preparation for ester hydrolysis two different buffer 
concentrations (5 and 50 mM) were used to dilute the 5'-deoxy-5'-methylthioadenosine-2',3'-
diester. CE analyses showed that no differences in the peak area of the hydrolyzed products could 
be observed and that both buffer concentrations can be used for the ester hydrolysis experiments. 
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Table 7.1. CE measurements of hydrolysis products of 5'-deoxy-5'-methylthioadenosine-2',3'-
diester after incubation with esterase a 
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5'-deoxy-5'-methylthioadenosine-2',3'-diester  
 
Peak 
no. 
Mean migration 
time ± SEM (min) 
Structures of products λmax in UV-
spectrum 
 
A 17.72 ± 0.31 5'-deoxy-5'-methylthioadenosine-
2',3'-diester b 
295 nm 
B 4.77 ± 0.06 O N N
N
N NH2
OHOH
S
MTA  
260 nm 
C 5.80 ± 0.07 
OH
OOH
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283 nm 
D 6.28 ± 0.08 
N
H
N
OH
O
 
275 nm 
a for incubation conditions see Figure 7.1 and Experimental Section 
b 85 % of 5'-deoxy-5'-methylthioadenosine-2',3'-diester were unhydrolyzed 
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7.4. Summary 
A capillary electrophoresis (CE) method was developed for the investigation of ester hydrolysis 
products of a marine natural product, 5'-deoxy-5'-methylthioadenosine-2',3'-diester. The method 
employing a fused-silica capillary and normal polarity mode provided good resolution of the 
products of the enzymatic reaction. After stopping the enzymatic reaction by heating, the samples 
were injected by pressure and detected by their UV absorbance at 260 nm. A constant current (95 
µA) was applied, and a sodium tetraborate buffer containing 100 mM SDS, pH 8.5 was used for 
the separations. The stability of the 5'-deoxy-5'-methylthioadenosine-2',3'-diester was examined 
by heating a 25 µM standard solution of the compound at 99 °C for 10 min. It was shown that the 
compound is chemically stable at high temperature. Similarly, incubation of the ester with rat 
brain cortex for 90 min showed no hydrolysis. However, incubation with carboxylesterase 
resulted in slow hydrolysis of the compound.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 126
Chapter 8. Development of a capillary electrophoresis method for 
the purity determination of [3H]PSB-298, a new radioligand for 
adenosine A2B receptors 
 
8.1. Introduction  
Adenosine receptors (ARs) are investigated as potential drug targets in many therapeutic areas. 
Adenosine has been suggested to play a role in asthma, possibly via activation of A2B adenosine 
receptors on mast cells and other pulmonary cells. New A2B receptor antagonists (1,8-
disubstituted xanthine derivatives) were synthesized in our group to obtain highly potent and 
selective A2B antagonists possessing good water solubility. For the development of a radioligand 
binding assay for A2B ARs, a tritium-labeled adenosine receptor antagonist, [3H]PSB-298 (see 
Fig.8.1) was prepared. In order to determine the purity of [3H]PSB-298, we had to develop a 
capillary electrophoresis method. 
 
8.2. Experimental 
8.2.1. Materials and methods 
8.2.1.1. Capillary electrophoresis instrumentation 
Capillary electrophoresis was performed on a P/PACE System 5500 (Beckman Coulter 
Instruments, Fullerton, CA, USA) equipped with a photodiode array detection system. The 
instrument was controlled by P/ACE station software (Beckman instruments). The runs were 
performed under the following conditions: T = 25 °C, λ = 321 nm, V = 10 kV, in 150 mM Tris-
HCl buffer containing 100 mM SDS, pH 9.1. The electrophoretic separations were carried out 
using an eCAP fused silica capillary (75.0 µm internal diameter (I.D.) x 375 µm outside diameter 
(O.D.), 37.0 cm length (30 cm to the detector). The capillary was washed with 0.1 N aqueous 
NaOH solution for 2 min, followed by deionized water for 1 min, and 150 mM Tris-HCl buffer 
containing 100 mM SDS, pH 9.1, for 1 min before each injection. Injections were made by 
applying a slight pressure (0.5 psi) for 5 s delivering approximately 5 nL of the sample solution. 
 
8.2.1.2. Chemicals 
(8-{4-[2-(2-Hydroxyethylamino)-2-oxoethoxy]phenyl}-1-propylxanthine (PSB-298) and 1-
propargyl derivative (8-{4-[2-(2-hydroxyethylamino)-2-oxoethoxy]-phenyl}-1-propargylxanthine 
 127
(PSB-297) were synthesized in our laboratory201 and PSB-297 was custom-labeled via catalytic 
hydrogenation using tritium gas by Nycomed Amersham, Buckinghamshire, UK through 
Amersham Pharmacia Biotech Europe GmbH, Freiburg, Germany, to obtain [3H] PSB-298. The 
specific activity of [3H] PSB-298 was 124 Ci (4.59 TBq)/mmol. 
Tris(hydroxymethyl)aminomethane was obtained from Acros Organics (Leverkusen, Germany). 
Dimethylsulfoxide (DMSO) was from Fluka (Switzerland), sodium dodecyl sulfate (SDS) was 
from Sigma, Germany; HCl was from Merck, Germany. 
 
8.2.1.3. Preparation of standard solutions of PSB-298  and PSB-297 
Stock solutions of the unlabeled compounds 8-[4-(2-hydroxyethylamino)-2-oxoethoxy)phenyl-1-
propylxanthine (PSB-298) and 8-[4-(2-hydroxyethylamino)-2-oxoethoxy)phenyl-1-
propargylxanthine (PSB-297) were prepared in DMSO at a concentration of 1.0 mg/mL which 
were then diluted with a mixture of DMSO and deionized water (1 : 1) to obtain a range of 
different concentrations. The radioactive compound [3H]PSB-298 was dissolved in DMSO at a 
concentration of 4.4 mg/mL and then diluted 1 : 1 with deionized water. For the determination of 
linearity and the limit of detection and quantitation, solutions of PSB-298 and PSB-297 were run 
in the concentrations 0.002, 0.005, 0.01, 0.02, 0.06, 0.08 and 0.1 mg/mL.  
 
8.3. Results and discussion 
The compound [3H]PSB-298 was synthesized from PSB-297 (see Figure 8.1); therefore, a CE 
method had to be developed for the determination of potential contamination of [3H]PSB-298 by 
its precursor PSB-297. 
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Figure 8.1. Preparation of [3H]PSB-298 from the propargyl precursor PSB-297 by catalytic 
hydrogenation (* denotes position of radiolabel). 
 
A Tris-HCl buffer with a high pH (pH 9.1) was chosen because at this pH the majority of the 
silanol groups were negatively charged. Hence, interactions between sample components, which 
have a negative charge in micelles, and the wall, should be reduced resulting in a shorter 
migration time. Additionally, the ionic strength of the selected buffer was rather high (150 mM). 
This is beneficial for the separation efficiency but at the same time limits the possibility of 
applying higher voltages. Thus, a moderate value of 10 kV was chosen. The use of SDS as a 
micelle-forming agent had two advantages; firstly, the compound-SDS aggregates are negatively 
charged and interaction with the negatively charged wall is reduced. Secondly, it separated the 
two compounds, which were very similar in molecular weight by additional partition 
chromatography because SDS micelles act as peudostationary phase.  
8.3.1. Method validation 
8.3.1.1. Linearity and limit of detection and quantitation 
Figure 8.2 shows a plot of PSB 298 peak areas vs. concentrations, which was used to determine 
the concentration of [3H]PSB-298. Linear relationships between peak areas and concentrations of 
compounds were found within the concentration range of the standards. 
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Figure 8.2. Linearity of calibration curve was determined for the concentration range of 0.002-
0.1 mg/mL of PSB-298). Regression equation;  y = 5260000x + 8290 and R2 = 0.996 
 
The determination of the compouds exhibited a high degree of linearity of calibration cuver in the 
range from their limit of quantitation (LOQ; calculated at a signal-to-noise ratio equal to 10, 
within the linear range) to the highest measured concentration at 0.1 mg/mL. 
Figure 8.3. Electropherogram of [3H]PSB-298 in the presence of PSB-297 as an internal 
standard. The separation conditions were 150 mM Tris-HCl, 100 mM SDS, pH 9.1, fused silica 
capillary, 37 cm length (30 cm to the detector), 75 µm I.D.; 10 kV; 25 °C; detection at 321 nm; 
pressure injection (0.5 psi,  5 s). 
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The coefficient of correlation for PSB-298 and PSB-297 were 0.996 and 0.993, respectively. The 
LOQs for PSB-298 and PSB-297 were 0.04 ± 0.001 (SEM) (n = 3) and 0.05 ± 0.002 (SEM) (n = 
3) mg/mL, respectively. The limit of detection (LOD) was defined as a signal-to-noise ratio of 3. 
The LOD value for PSB-298 and PSB-297 was 0.002 mg/mL. Each sample was measured 3-4 
times. 
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8.3.1.2. Purity determination of [3H]PSB-298 by capillary electrophoresis 
The concentration of the solution of [3H]PSB-298 in DMSO was determined by using capillary 
electrophoresis.  Peaks were identified by two means: (i) by comparing the migration times of the 
observed peak with that of the nonradioactive PSB-298 eluted under the same conditions, and (ii) 
by spiking the radioactive sample with non-radioactive PSB-298 standard. Under the same 
conditions the peak for the precursor compound PSB-297 appeared at 6.31 ± 0.07 min and that 
for PSB-298 (radioactive and non-radioactive) at 9.54 ± 0.13 min. Concentration in the original 
radioactive sample of PSB-298 was found to be 4.4 µg ± 0.0054 /50µl (SEM) (n = 3). The 
solution of the radioactive compound gave only a single peak, no peak of the starting compound 
was found indicating high purity (>95%). Therefore, quantitative determination could be 
performed in the presence of PSB-297 (0.1 mg/mL) as an internal standard. A typical 
electropherogram of [3H]PSB-298 in the presence of its precursor PSB-297 used as internal 
standard is shown in Figure 8.3.  
 
8.4. Summary  
A micellar electrokinetic chromatographic (MECC) method has been developed for determining 
the purity of a newly synthesized antagonist radioligand for A2B adenosine receptors [3H]PSB-
298 ((8-{4-[2-(2-hydroxyethylamino)-2-oxoethoxy]phenyl}-1-propylxanthine). MECC 
separation of [3H]PSB-298 ((8-{4-[2-(2-hydroxyethylamino)-2-oxoethoxy]phenyl}-1-
propylxanthine) and its precursor, the 1-propargyl analog (8-{4-[2-(2-hydroxyethylamino)-2-
oxoethoxy]-phenyl}-1-propargylxanthine (PSB-297) was performed with the use of an untreated 
fused-silica capillary of 30 cm of effective length and 75 µm I.D., and a positive voltage of 10 kV 
in 150 mM Tris-HCl buffer containing 100 mM SDS, pH 9.1. The CE method was successfully 
validated: linearity of calibration curve, limit of quantitation, limit of detection and accuracy were 
evaluated.  
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